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1 Summary	  
Various	   different	   tumors	   are	   characterized	   by	   oncogenic	   addiction	   to	   transcription	  factors,	  which	  are	   frequently	  mutated	  and	  aberrantly	  expressed.	  These	   transcription	  factors	   represent	   ideal	   therapeutic	   targets	   supposing	   that	   specific	   inhibition	   might	  improve	   therapeutic	   outcome	   and	   minimize	   treatment	   related	   side	   effects.	   While	  direct	   targeting	   of	   transcription	   factors	   remains	   a	   pharmaceutical	   challenge	   due	   to	  unfavorable	   structure,	  we	   developed	   an	   efficient	   strategy	   to	   impair	   their	   activity	   in	  fusion	  positive	  alveolar	  rhabdomyosarcoma	  (aRMS).	  This	  aggressive	  pediatric	   tumor	  is	  mainly	   driven	   and	  maintained	  by	   the	   tumor-­‐specific	   chimeric	   transcription	   factor	  PAX3-­‐FOXO1.	  As	  the	  PAX3-­‐FOXO1-­‐underlaying	  translocation	  is	  often	  the	  sole	  genetic	  alteration	   detected	   in	   aRMS	   biopsies,	   this	   tumor	   is	   highly	   addicted	   to	   the	   emerging	  oncogenic	   transcription	   factor	   and	   consequently	   its	   depletion	   induces	   apoptosis	   of	  cancer	   cells.	   Hence,	  we	   believe	   that	   establishing	   a	   targeting	   approach	   to	   antagonize	  activating	   posttranslational	   modifications	   of	   the	   PAX3-­‐FOXO1	   fusion	   protein	   might	  improve	  aRMS	  treatment	  to	  overcome	  resistance	  to	  conventional	  therapy.	  	  In	   fact,	   utilizing	  mass	   spectrometric	   analysis,	  we	   detected	  multiple	   phosphorylation	  sites	   in	   PAX3-­‐FOXO1.	   Having	   established	   a	   two-­‐armed	   activity	   reporter	   system	   to	  screen	  for	  druggable	  upstream	  regulatory	  kinases	  in	  aRMS	  cells,	  we	  applied	  a	  kinome	  siRNA	   library	   as	   well	   as	   a	   small-­‐molecule	   library	   and	   identified	   polo-­‐like	   kinase	   1	  (PLK1)	  and	  casein	  kinase	  1α	  (CK1α)	  as	  modulators	  of	  PAX3-­‐FOXO1.	  We	  could	  further	  demonstrate	   binding	   of	   PLK1,	   likely	   induced	   by	   CDK1	   priming,	   and	   cooperation	   of	  PLK1	  and	  CK1α	   in	  direct	  phosphorylation	  of	  PAX3-­‐FOXO1	  at	   the	  novel	  phospho-­‐site	  S503,	   respectively	   in	   phosphorylation	   within	   the	   previously	   characterized	  octapeptide.	   Phosphorylation	   of	   S503	   led	   to	   protein	   stabilization,	   whereas	  phosphorylation	  of	  the	  octapeptide	  mediated	  fusion	  protein	  transactivation.	  	  With	  promising	  PLK1	   inhibitors	   in	  clinical	   studies,	   such	  as	  BI	  2536	  and	  BI	  6727,	  we	  first	   of	   all	   focused	   on	   antagonizing	   PLK1.	   PLK1	   inhibition	   resulted	   in	   ubiquitination	  and	   proteasomal	   degradation	   of	   the	   fusion	   protein,	   subsequent	   reduction	   of	   target	  gene	   expression	   and	   induction	   of	   apoptosis.	   We	   believe	   that	   objective	   responses	  observed	   in	   aRMS	   xenograft	   mouse	   models	   are	   the	   result	   of	   different	   mechanisms	  induced	  by	  PLK1	   inhibition,	  with	  a	  central,	  dominant	  role	  of	   the	  novel	  PLK1	  -­‐	  PAX3-­‐FOXO1	   axis.	   In	   addition,	   mechanistic	   data	   imply,	   next	   to	   PAX3-­‐FOXO1	   and	   NMYC	  oncogene	   reduction,	   a	   cell	   cycle	   arrest	   that	   potentiates	   PAX3-­‐FOXO1	   degradation.	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Moreover,	   tissue	  microarray	   analysis	   of	   human	   aRMS	   tumor	   biopsies	   showed	   PLK1	  overexpression	  and	  multivariate	  analysis	  offered	  prognostic	   significance	  of	  PLK1	   for	  event-­‐free	   and	   overall	   survival	   of	   aRMS	   patients.	   As	   one	   of	   the	   first	  markers	   at	   all,	  PLK1	   might	   therefore	   be	   used	   for	   prognosis	   of	   fusion	   positive	   RMS	   and	   thus	   have	  major	  implications	  on	  risk	  stratification	  and	  treatment	  options.	  	  However,	   monotherapy	   with	   kinase	   inhibitors	   can	   induce	   escape	   mechanisms	   and	  cause	  drug	   resistance	  as	  observed	   in	  our	   in	  vivo	   studies.	  Thus,	  we	  propose	  different	  rational	   combinations	   with	   PLK1	   inhibitors	   based	   on	   our	   screening	   results.	   Our	  findings	   highlighted	   phosphatidylinositol	   and	   MAPK	   signaling	   as	   well	   as	   cell	   cycle	  regulation	   to	   exert	   impact	   on	   PAX3-­‐FOXO1	   activity.	   Moreover,	   we	   discovered	  cooperating	   functions	   of	   PLK1,	   PLK4	   and	   CK1α,	   which	   might	   be	   relevant	   for	  prevention	   of	   resistance	   to	   PLK1	   inhibition.	   Especially,	   overexpression	   of	   PLK4	   in	  fusion	  positive	  tumors	  suggests	  synergistic	  cytotoxicity	  by	  simultaneous	  inhibition	  of	  PLK1	  and	  PLK4.	  Tumor	  specific	  treatment	  combination	  could	  furthermore	  enable	  the	  generation	   of	   a	   favorable	   therapeutic	   window,	   which	   is	   indispensable	   considering	  potential	  adverse	  effects	  of	  PLK1	  inhibition.	  In	   summary,	   we	   established	   a	   promising	   strategy	   to	   target	   oncogenic	   transcription	  factors.	   Our	   preclinical	   studies	   validated	   the	   PLK1	   -­‐	   PAX3-­‐FOXO1	   axis	   as	   a	   highly	  relevant	   target	   in	  alveolar	   rhabdomyosarcoma	  and	  our	  data	   suggest	   translation	   into	  clinical	  practice.	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2 Zusammenfassung	  
Eine	   Vielfalt	   von	   Tumoren	   ist	   durch	   onkogene	   Abhängigkeit	   von	  Transkriptionsfaktoren	   charakterisiert,	   welche	   häufig	   mutiert	   sind	   und	   anomal	  exprimiert	   werden.	   Da	   sich	   diese	   Transkriptionsfaktoren	   deshalb	   ideal	   als	  therapeutische	   Angriffspunkte	   eignen,	   könnte	   deren	   spezifische	   Inhibition	  Therapieergebnisse	   verbessern	   und	   behandlungsbedingte	   Nebenwirkungen	  minimieren.	   Während	   die	   direkte	   Inhibition	   von	   Transkriptionsfaktoren	   aufgrund	  unvorteilhafter	   Struktur	  weiterhin	   eine	   pharmazeutische	   Herausforderung	   darstellt,	  haben	  wir	  eine	  effiziente	  Strategie	  zur	  Hemmung	  ihrer	  Aktivität	  im	  Fusions-­‐positiven	  alveolären	   Rhabdomyosarkom	   (aRMS)	   entwickelt.	   Diese	   aggressive,	   pädiatrische	  Krebsart	   wird	   hauptsächlich	   durch	   den	   tumorspezifischen,	   chimären	  Transkriptionsfaktor	   PAX3-­‐FOXO1	   hervorgerufen,	   welchem	   eine	  Chromosomentranslokation	   zugrunde	   liegt	   und	   welcher	   das	   Überleben	   von	  Tumorzellen	   sichert.	   Somit	   ist	   aRMS	   von	   PAX3-­‐FOXO1	   hochgradig	   abhängig	   und	  folglich	   induziert	   die	   Schwächung	   von	   PAX3-­‐FOXO1	  Apoptose	   in	   Krebszellen.	   Daher	  glauben	   wir,	   dass	   die	   Etablierung	   eines	   gezielten	   Ansatzes	   zur	   Hemmung	  aktivierender	   posttranslationaler	   Modifikationen	   die	   Behandlungsaussichten	   für	  aRMS	   verbessern	   würde	   und	   so	   aRMS-­‐Resistenzen	   gegenüber	   konventionellen	  Therapien	  überwunden	  werden	  könnten.	  Tatsächlich	   haben	   wir	   durch	   massenspektrometrische	   Analyse	   mehrere	  Phosphorylierungsstellen	   detektiert.	   Nach	   der	   Entwicklung	   und	   Etablierung	   eines	  zweiarmiges	   Aktivitäts-­‐Reportersystems,	   welches	   darauf	   abzielt,	   systematisch	   nach	  medikamentös	   behandelbaren,	   regulatorischen	   Kinasen	   zu	   suchen,	   setzten	   wir	   eine	  Kinom-­‐siRNA-­‐Bibliothek	  und	  eine	  Bibliothek	  sogenannter	  „kleiner	  Moleküle“	  ein	  und	  identifizierten	   Polo-­‐like	   Kinase	   1	   (PLK1)	   und	   Casein	   Kinase	   1α	   (CK1α)	   als	  Modulatoren	  von	  PAX3-­‐FOXO1.	  Wir	  konnten	  die	  Bindung	  von	  PLK1	  -­‐	  wahrscheinlich	  eingeleitet	  durch	  sogenanntes	  „CDK1	  priming”	  -­‐	  sowie	  die	  Kooperation	  von	  PLK1	  und	  CK1α	   in	   direkter	   Phosphorylierung	   von	   PAX3-­‐FOXO1	   an	   der	   neuen	  Phosphorylierungsstelle	  S503,	   respektive	   innerhalb	  des	   im	  Vorfeld	  charakterisierten	  Oktapeptids	   nachweisen.	   Die	   Phosphorylierung	   von	   S503	   führte	   dabei	   zu	  Proteinstabilisierung,	   während	   Phosphorylierung	   des	   Oktapeptids	   Transaktivierung	  des	  Fusionsproteins	  verursachte.	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Aufgrund	   vielversprechender	   Studienresultate	   in	   Bezug	   auf	   PLK1	   Inhibitoren	   wie	  etwa	   BI	   2536	   und	   BI	   6727,	   konzentrierten	   wir	   uns	   in	   der	   Folge	   darauf,	   PLK1	   zu	  hemmen.	   PLK1	   Inhibierung	   verursachte	   Ubiquitinierung	   und	   proteasomale	  Degradierung	   des	   Fusionsproteins,	   anschließende	   Verringerung	   der	   Zielgen-­‐Expression	   sowie	  die	  Einleitung	  von	  apoptotischen	  Mechanismen.	  Wir	  glauben,	  dass	  der	   erzielte	   Behandlungseffekt	   in	   Xenograft-­‐Mausmodellen	   das	   Resultat	  verschiedener,	  durch	  PLK1	  Inhibierung	  induzierter	  Mechanismen	  mit	  einer	  zentralen,	  dominanten	   Rolle	   der	   neuentdeckte	   PLK1	   -­‐	   PAX3-­‐FOXO1	   Achse	   ist.	   Mechanistische	  Daten	   implizieren	  neben	  der	  Abnahme	  der	  Onkogene	  PAX3-­‐FOXO1	  und	  NMYC	  einen	  Zellzyklusarrest,	   welcher	   die	   PAX3-­‐FOXO1	   Degradierung	   verstärkt.	   Darüberhinaus	  zeigten	   Gewebeschnitts-­‐Analysen	   von	   humanen	   Tumorbiopsien	   eine	   PLK1-­‐Überexprimierung.	   Schlussendlich	   demonstrierten	   multivariate	   Analysen	   den	  signifikanten	   prognostischen	   Wert	   von	   PLK1	   im	   Hinblick	   auf	   ereignisfreie	   und	  gesamte	  Überlebensraten	  von	  aRMS	  Patienten.	  Als	  einer	  der	  ersten	  Marker	  überhaupt	  könnte	  PLK1	  deshalb	  für	  Prognosen	  von	  Fusions-­‐positiven	  RMS	  Tumoren	  verwendet	  werden	  und	  somit	  zukünftig	  bedeutende	  Auswirkungen	  auf	  die	  Risiko-­‐Stratifizierung	  und	  auf	  Behandlungsoptionen	  haben.	  Dennoch	   kann	   entsprechend	   unserer	   Beobachtungen	   in	   in	   vivo	   Studien	   eine	  Monotherapie	   mit	   Kinase-­‐Inhibitoren	   Ausweichmechanismen	   erzeugen	   und	  Medikamentenresistenz	   bewirken.	   Basierend	   auf	   unseren	   Screening-­‐Resultaten	  schlagen	   wir	   deshalb	   konsequenterweise	   verschiedene	   Kombinationen	   mit	   PLK1	  Inhibitoren	   vor.	   Unsere	   Ergebnisse	   zeigen	   auf,	   dass	   insbesondere	  Phosphatidylinositol-­‐	   und	   MAPK-­‐Signaltransduktion	   bedeutenden	   Einfluss	   auf	   die	  Aktivität	   von	   PAX3-­‐FOXO1	   ausüben.	   Zudem	   haben	  wir	   eine	   Kooperation	   von	   PLK1,	  PLK4	  und	  CK1α	  entdeckt,	  welche	  relevant	  für	  Resistenzen	  gegenüber	  PLK1	  Hemmung	  sein	   könnte.	   Insbesondere	   die	   Überexprimierung	   von	   PLK4	   in	   Fusions-­‐positiven	  Tumoren	   lässt	   synergistische	  Zytotoxizität	  durch	  gleichzeitige	   Inhibierung	  von	  PLK1	  und	   PLK4	   vermuten.	   Tumorspezifische	   Kombinationsbehandlung	   ermöglicht	   des	  Weiteren	   die	   Bildung	   eines	   bevorzugten	   therapeutischen	   Fensters,	   welches	   in	  Anbetracht	  potentieller	  Nebenwirkungen	  der	  PLK1	  Hemmung,	  unabdingbar	  ist.	  Zusammenfassend	   haben	   wir	   eine	   erfolgsversprechende	   Strategie	   zur	   gezielten	  Hemmung	   onkogener	   Transkriptionsfaktoren	   erarbeitet.	   Unsere	   präklinischen	  Studien	  konnten	  die	  PLK1	  -­‐	  PAX3-­‐FOXO1	  Achse	  als	  hochrelevantes	  Ziel	  im	  alveolären	  Rhabdomyosarkom	   validieren	   und	   unsere	   Daten	   legen	   eine	   Übertragung	   in	   die	  klinische	  Praxis	  nahe.	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3 Abbreviations	  
14-­‐3-­‐3γ	   Tyrosine	  3-­‐monooxygenase/tryptophan	  5-­‐monooxygenase	  	  activation	  protein,	  gamma	  	  ABCB1	   ATP-­‐binding	  cassette	  sub-­‐family	  B	  member	  1	  ABCG2	   ATP-­‐binding	  cassette	  sub-­‐family	  G	  member	  2	  ACN	   Acetonitrile	  ADAM	   Metalloproteinase;	  ADAM	  =	  	  a	  disintegrin	  and	  metalloproteinase	  	  AKT	   v-­‐Akt	  murine	  thymoma	  viral	  oncogene	  homolog	  ALK	   Anaplastic	  lymphoma	  kinase	  ALL	   Acute	  lymphoblastic	  leukemia	  AmBIC	   Ammonium	  bicarbonate	  AML	   Acute	  myeloid	  leukemia	  AP2β	   Transcription	  factor	  AP2	  beta	  APC	   Anaphase	  promoting	  complex	  ARF	   Alternate	  reading	  frame	  aRMS	   Alveolar	  rhabdomyosarcoma	  ATP	   Adenosine	  triphosphate	  BALB/c	   Albino	  laboratory-­‐bred	  strain	  of	  mus	  musculus	  BCL-­‐XL	   BCL2-­‐like	  1	  BCL2	   B-­‐cell	  CLL/lymphoma	  2	  BCOR	   BCL6	  co-­‐repressor	  BET	   Bromo	  and	  extra	  terminal	  family	  BORA	   Aurora	  kinase	  A	  activator	  	  BRD4	   Bromodomain	  containing	  4	  	  BSA	   Bovine	  serum	  albumin	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BUB1B	   BUB1	  mitotic	  checkpoint	  serine/threonine	  kinase	  B	  CARD11	   Caspase	  recruitment	  domain	  family,	  member	  11	  CCND	   Cyclin	  D	  CD44v6	   CD44	  molecule	  variant	  6	  CDC25	   Cell	  division	  cycle	  25	  CDE	   Cycle-­‐dependent	  element	  CDH3	   P-­‐cadherin	  CDK	   Cyclin-­‐dependent	  kinase	  	  CDKN2A	   Cyclin-­‐dependent	  kinase	  inhibitor	  2A	  cDNA	   Complementary	  deoxyribonucleic	  acid	  CHR	   Cell	  cycle	  gene	  homology	  region	  CHX	   Cycloheximide	  CI	   Confidence	  interval	  CIAP	   Calf	  intestinal	  alkaline	  phosphatase	  CID	   Collision-­‐induced	  dissociation	  CK1	   Casein	  kinase	  1	  CML	   Chronic	  myeloid	  leukemia	  CNR1	   Cannabinoid	  receptor	  type	  1	  CNS	   Central	  nervous	  system	  CSNK1A1	   Casein	  kinase	  1,	  alpha	  1	  CTNNB1	   Beta-­‐catenin	  CXCR4	   CXC	  chemokine	  receptor	  type	  4	  DAPI	   4’,6-­‐Diamidino-­‐2-­‐phenylindole	  DMEM	   Dulbecco’s	  minimum	  essential	  medium	  DMSO	   Dimethyl	  sulfoxide	  Dpn1	   Restriction	  endonuclease	  to	  digest	  methylated	  GATC	  sites	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DTT	   Dithiothreitole	  E2F1	   Transcription	  factor	  E2F1	  ECT2	   Epithelial	  cell	  transforming	  2	  EDTA	   Ethylene	  diamine	  tetraacetic	  acid	  EFS	   Event-­‐free	  survival	  EGR1	   Early	  growth	  response	  1	  EMI1	   Metazoan	  protein	  early	  mitotic	  inhibitor	  1	  ERK	   Extracellular	  signal	  regulated	  kinase	  eRMS	   Embryonal	  rhabdomyosarcoma	  EZH2	   Enhancer	  of	  zeste	  2	  polycomb	  repressive	  complex	  2	  subunit	  FACS	   Fluorescence	  activated	  cell	  sorting	  FBS	   Fetal	  bovine	  serum	  FBXW7	   F-­‐box/WD	  repeat-­‐containing	  protein	  7	  FGFR4	   Fibroblast	  growth	  factor	  receptor	  4	  Fig.	   Figure	  FLAG	   Octapeptide	  DYKDDDDK	  FOXM	   Forkhead	  box	  M	  FOXO	   Forkhead	  box	  O	  FRS2	   Fibroblast	  growth	  factor	  receptor	  substrate	  2	  GAPDH	   Glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  GFP	   Green	  fluorescent	  protein	  GSK3β	   Glycogen	  synthase	  kinase	  3	  beta	  GTP	   Guanosine	  triphosphate	  GTSE1	   G2	  and	  S-­‐phase	  expressed	  1	  H2afx	   H2A	  histone	  family,	  member	  X	  HBSS	   Hank’s	  balanced	  salt	  solution	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HEPES	   4-­‐(2-­‐Hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  HER2	   v-­‐ERB-­‐B2	  erythroblastic	  leukemia	  viral	  oncogene	  homolog	  2	  HPLC	   High	  pressure	  liquid	  chromatography	  HRAS	   Harvey	  rat	  sarcoma	  viral	  oncogene	  homolog	  HRP	   Horseradish	  peroxidase	  HsCYK4	   Rac	  GTPase	  activating	  protein	  1	  HSP90	   Heat	  shock	  protein	  90	  IAM	   Iodoacetamide	  IGF1R	   Insulin-­‐like	  growth	  factor	  1	  receptor	  IGF2	   Insulin-­‐like	  growth	  factor	  2	  IGFBP2	   Insulin-­‐like	  growth	  factor	  binding	  protein	  2	  IgG	   Immunoglobulin	  G	  	  Il2rg	  	   Interleukin	  2	  receptor,	  gamma	  chain	  INK4	   Inhibitor	  of	  cyclin-­‐dependent	  kinase	  4	  INO80D	   INO80	  complex	  subunit	  D	  IP	   Immunoprecipitation	  IRES	   Internal	  ribosomal	  entry	  site	  JARID2	   Jumonji,	  AT	  rich	  interactive	  domain	  2	  KEGG	   Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes	  pathway	  analysis	  KIF11	   Kinesin	  family	  member	  11	  KMT1A	   Histone	  lysine	  N-­‐methyltransferase	  KRAS	   Kirsten	  rat	  sarcoma	  viral	  oncogene	  homolog	  LDS	   Lithium	  dodecyl	  sulfate	  LF/V	   Luciferase	  activity	  /	  cell	  viability	  LOH	   Loss	  of	  heterozygosity	  MAPK	   Mitogen-­‐activated	  protein	  kinase	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MCL1	   Myeloid	  cell	  leukemia	  1	  MCU/MICU1	   Mitochondrial	  calcium	  uniporter/mitochondrial	  calcium	  uptake	  1	  MDM2	   Mouse	  double	  minute	  2	  homolog	  MEF	   Mouse	  embryonic	  fibroblast	  MEK	   Dual	  specificity	  mitogen-­‐activated	  protein	  kinase	  (MAPK)	  kinase	  MET	   Mesenchymal-­‐epithelial	  transition	  factor	  MIB1	   Proliferation	  marker,	  antibody	  directed	  against	  Ki-­‐67	  MIR-­‐17-­‐92/	  MIR17HG	   Polycystronic	  microRNA	  encoding	  cluster	  miRNA	   Micro	  ribonucleic	  acid	  MKLP2	   Mitotic	  kinesin-­‐like	  protein	  2	  MMP	   Matrix	  metalloproteinase	  mRNA	   Messenger	  ribonucleic	  acid	  MS	   Mass	  spectrometry	  MSC	   Mesenchymal	  stem	  cell	  mTOR	   Mammalian	  target	  of	  rapamycine	  mTORC1/2	   mTOR	  complex	  1	  and	  2	  MYC	   v-­‐Myc	  avian	  myelocytomatosis	  viral	  oncogene	  homolog	  MYF	   Myogenic	  factor	  MYL1	   Myosin	  light	  chain	  1	  MYOD1	   Myogenic	  differentiation	  1	  MYT1	   Myelin	  transcription	  factor	  1	  NCOA1	   Nuclear	  receptor	  and	  coactivator	  1	  NEK2	   NIMA	  (never	  in	  mitosis	  gene	  a)-­‐related	  kinase	  2	  NF1	   Neurofibromin	  1	  NLP	   Ninein-­‐like	  protein	  NMYC/MYCN	   Neuroblastoma	  v-­‐Myc	  avian	  myelocytomatosis	  viral	  oncogene	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NOD	   Non-­‐obese	  diabetic	  NRAS	   Neuroblastoma	  rat	  sarcoma	  viral	  oncogene	  homolog	  ORC2	   Origin	  recognition	  complex,	  subunit	  2	  	  OS	   Overall	  survival	  p21	   Cyclin-­‐dependent	  kinase	  inhibitor	  1A	  (p21,	  Cip1)	  P3F	   PAX3-­‐FOXO1	  p53	   Tumor	  protein	  p53	  p57KIP2	   Cyclin-­‐dependent	  kinase	  inhibitor	  p57	  PARP	   Poly	  (ADP-­‐ribose)	  polymerase	  PAX	   Paired	  box	  protein	  PBD	   Polo-­‐box	  binding	  domain	  PBS	   Phosphate	  buffered	  saline	  PDGFRα	   Platelet-­‐derived	  growth	  factor	  receptor	  alpha	  PDK1	   3-­‐Phosphoinositide	  dependent	  protein	  kinase	  1	  pGL4	   Luciferase	  reporter	  vector	  PI	   Propidium	  iodide	  PI3K	   Phosphoinositide-­‐3-­‐kinase	  PIK3CA	   Phosphatidylinositol-­‐4,5-­‐bisphosphate	  3-­‐kinase	  alpha	  PIPOX	   Pipecolic	  acid	  oxidase	  PKC	   Protein	  kinase	  C	  PKC412	   Midostaurin	  PKCA	   Protein	  kinase	  C,	  alpha	  PLK	   Polo-­‐like	  kinase	  POU4F1	   POU	  domain,	  class	  4,	  transcription	  factor	  1	  PP	   Protein	  phosphatase	  PRC1	   Protein	  regulator	  of	  cytokinesis	  1	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PRC2	   Polycomb	  repressive	  complex	  2	  PRKAR2B	   cAMP-­‐dependent	  protein	  kinase	  type	  2	  beta	  PTEN	   Phosphatase	  and	  tensin	  homolog	  qRT-­‐PCR	   Quantitative	  real-­‐time	  polymerase	  chain	  reaction	  RAF	   RAF	  proto-­‐oncogene	  serine/threonine	  protein	  kinase	  RARA	   Retinoic	  acid	  receptor,	  alpha	  RAS	   RAS	  GTPase;	  rat	  sarcoma	  viral	  oncogene	  homolog	  RB	   Retinoblastoma	  protein	  RNAi	   RNA	  interference	  ROS	   Reactive	  oxygen	  species	  SCC1	   Sister	  chromatid	  cohesin	  protein	  1	  SCID	   Severe	  combined	  immunodeficiency	  SD	   Standard	  deviation	  SDS	  	   Sodium	  dodecyl	  sulfate	  siPF2	   PAX3-­‐FOXO1	  directed	  siRNA	  siRNA	   Small	  interfering	  RNA	  SRC	   SRC	  proto-­‐oncogene	  tyrosine	  kinase	  STAT	   Signal	  transducer	  and	  activator	  of	  transcription	  STR	   Short	  tandem	  repeat	  TBS	   Tris	  buffered	  saline	  TERT	   Telomerase	  reverse	  transcriptase	  TET	   Tetracycline	  TFA	   Trifluoroacetic	  acid	  	  TMA	   Tissue	  microarray	  Tris	   Tris(hydroxymethyl)-­‐aminomethane	  VSV-­‐G	   Vesicular	  stomatitis	  virus	  glycoprotein	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WEE1	   M	  phase	  inhibitor	  protein	  kinase	  	  Wnt	   Wingless	  type	  integration	  site	  wt	   Wild	  type	  YES1	   Yamaguchi	  sarcoma	  viral	  oncogene	  homolog	  1	  γ-­‐TuRC	   Gamma-­‐tubulin	  ring	  complex	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4 Introduction	  
4.1 Cancer	  
Cancer	   is	   a	   very	   complex	   disease	  with	  more	   than	  100	  different	   types,	  which	   can	   be	  further	  divided	   into	  different	   subtypes,	   again	   showing	  great	  heterogeneity.	  They	  are	  classified	   depending	   on	   the	   various	   kinds	   of	   normal	   tissue	   they	   arise	   from.	  Most	   of	  them	  develop	   from	  epithelial	   tissue	   and	   are	   called	   carcinomas.	  Non-­‐epithelial	   tissue	  includes	  mesenchymal	  tissue	  giving	  rise	  to	  sarcomas,	  the	  hematopoietic	  system	  giving	  rise	   to	   leukemias	   or	   lymphomas,	   and	   the	   nervous	   system	   as	   tissue	   of	   origin.	  Furthermore,	  also	  atypical	  and	  mixed	  multi-­‐lineage	  forms	  exist.	  Nevertheless,	  not	  only	  the	   tissue	   but	   also	   the	   age	   of	   onset	   of	   cancer	   development	   is	   used	   to	   distinguish	  between	  adult	  and	  pediatric	  cancer.	  The	   development	   of	   cancer	   is	   a	   multi-­‐step	   process	   reflecting	   genetic	   alterations	  leading	   to	   the	   transformation	   of	   a	   healthy	   to	   a	   malignant	   cell.	   These	   alterations	  include	   mainly	   point	   mutations,	   but	   also	   deletions,	   insertions,	   inversions,	  translocations	   and	   changes	   in	   chromosome	   numbers,	   which	   can	   result	   in	   the	  activation	  of	  oncogenes	  or	  the	  inactivation	  of	  tumor	  suppressor	  genes.	  	  Despite	  complexity	  and	  heterogeneity	  between	  patients	  as	  well	  as	  between	  and	  even	  within	   metastatic	   lesions,	   underlying	   principles	   of	   transformation	   are	   common	   to	  probably	  most	  or	  all	   the	  different	   forms	  of	  cancer	  and	  have	  been	  summarized	  as	  the	  hallmarks	   of	   cancer	   by	   Hanahan	   and	   Weinberg	   (2000,	   2011).	   These	   hallmarks	  describe	   transforming	   cells	   to	   sustain	   proliferative	   signaling,	   to	   evade	   growth	  suppression,	   to	   avoid	   immune	   destruction,	   to	   enable	   replicative	   immortality,	   to	  promote	  inflammation,	  to	  activate	  invasion	  and	  metastasis,	  to	  induce	  angiogenesis,	  to	  destabilize	  the	  genome,	  to	  resist	  cell	  death,	  and	  to	  deregulate	  cellular	  energetics	  (Fig.	  1).	   Still,	   tumor	   progression	   is	   highly	   variable	   and	   cells	   take	   alternative	   pathways	  acquiring	   all	   the	   different	   capabilities	   as	   proven	   by	   exome	   and	   whole	   genome	  sequencing	   approaches	   allowing	   the	   generation	   of	   genomic	   landscapes	   to	   visualize	  genetic	   alterations	   for	   many	   of	   the	   most	   common	   cancer	   types.	   However,	   it	   is	  important	   to	   distinguish	   between	   driver	   and	   passenger	   alterations	   and	   also	   to	  consider	  epigenetic	  regulation,	  which	  can	  cause	  aberrant	  expression	  of	  driver	  genes.	  	  In	   total,	   Vogelstein	   and	   colleagues	   (2013)	   described	   138	   driver	   genes	   that	   lead	   to	  selective	   growth	   advantage.	   They	   can	   be	   summarized	   in	   12	   signaling	   pathways	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spanning	   the	  core	  cellular	  processes	  cell	   survival,	   cell	   fate	  and	  genome	  maintenance	  (Fig.	  2)	  (Vogelstein	  et	  al.,	  2013).	  
	  
Fig.	   1.	   Hallmarks	   of	   cancer.	   Cancer	   hallmark	   capabilities	   acquired	   during	   tumor	   development	   and	  progression	  are	  illustrated.	  Adapted	  from	  (Hanahan	  and	  Weinberg,	  2011).	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Fig.	   2.	   Cancer	   cell	   signaling	   pathways	   and	   core	   processes.	   138	   driver	   genes	   identified	   in	   genetic	  landscapes	  of	  tumors	  have	  been	  classified	  into	  twelve	  pathways,	  which	  in	  turn	  mediate	  the	  regulation	  of	  the	  three	  core	  cellular	  processes	  cell	  survival,	  cell	  fate	  and	  genomic	  maintenance	  (Vogelstein	  et	  al.,	  2013).	  
4.2 Childhood	  cancer	  
Usually	  tumor	  evolution	  is	  a	  long-­‐term	  process	  that	  needs	  time	  to	  acquire	  a	  series	  of	  mutations	   and	   thus	   the	   different	   cancer	   capabilities,	   meaning	   that	   the	   number	   of	  mutations	   is	  correlated	  with	   long-­‐time	  exposure	   to	  potent	  mutagens	   like	  UV	   light	  or	  cigarette	   smoke,	   and	   also	   to	   age	   (Tomasetti	   et	   al.,	   2013).	   Consequently,	   pediatric	  tumors	   harbor	   fewer	  mutations	   than	   adult	   tumors	   (Fig.	   3)	   (Vogelstein	   et	   al.,	   2013).	  Pediatric	  cancers	  often	  originate	  from	  non-­‐self-­‐renewing	  tissue	  or	  precursor	  cells	  with	  a	   shorter	   history	   of	   self-­‐renewal	   in	   children	   than	   in	   adults,	   which	   reduces	   the	  probability	   for	   random	  mutations	   (Vogelstein	   et	   al.,	   2013).	   However,	   that	   does	   not	  mean	   that	   pediatric	   tumors	   do	   not	   fulfill	   all	   hallmarks	   of	   cancer.	   More	   likely,	   one	  single	   genetic	   event	  might	   simultaneously	   cause	   the	   acquisition	   of	   several	   different	  properties	   (Hanahan	   and	   Weinberg,	   2000).	   Furthermore,	   pediatric	   cancers	   show	   a	  high	  frequency	  of	  mutations	  in	  genes	  encoding	  epigenetic	  regulators,	  which	  can	  affect	  transformation	  in	  multiple	  manners	  (Huether	  et	  al.,	  2014).	  
to designing uniformly effective treatments for
cancer. Efforts to individualize treatments based
on knowledge of the genomes of cancer pa-
tients are largely based on an appreciation of
this heterogeneity.
Signaling Pathways in Tumors
The immense complexity of cancer genomes
that could be inferred from the data described
above is somewhat misleading. After all, even
advanced tumors are not completely out of
control, as evidenced by the dramatic responses
to agents that target mutant BRAF in mela-
nomas (108) or mutant ALK in lung cancers
(109). Albeit transient, these responses mean
that interference with even a single mutant gene
product is sufficient to stop cancer in its tracks,
at least transiently. How can the genomic com-
plexity of cancer be reconciled with these clin-
ical observations?
Two concepts bear on this point. The first,
mentioned above, is that >99.9% of the altera-
tions in tumors (including point mutations, copy-
number alterations, translocations, and epigenetic
changes distributed throughout the genome,
not just in the coding regions) are immaterial to
neoplasia. They are simply passenger changes
that mark the time that has elapsed between
successive clonal expansions. Normal cells also
undergo genetic alterations as they divide, both
at the nucleotide and chromosomal levels. How-
ever, normal cells are programmed to undergo
cell death in response to such alterations, per-
haps as a protective mechanism against cancer.
In contrast, cancer cells have evolved to tolerate
genome complexity by acquiring mutations in
genes such as TP53 (110). Thus, genomic com-
plexity is, in part, the result of cancer, rather than
the cause.
To appreciate the second concept, one must
take the 30,000-foot view. A jungle might look
chaotic at ground level, but the aerial view shows
a clear order, with all the animals gathering at
the streams at certain points in the day, and all
the streams converging at a river. There is order
in cancer, too. Mutations in all of the 138 driver
genes listed in table S2 do one thing: cause a
selective growth advantage, either directly or
indirectly. Moreover, there appears to be only a
limited number of cellular signaling pathways
through which a growth advantage can be in-
curred (Fig. 7 and table S5).
All of the known driver genes can be classi-
fied into one or more of 12 pathways (Fig. 7).
The discovery of the molecular components of
these pathways is one of the greatest achievements
of biomedical research, a tribute to investigators
working in fields that encompass biochemistry,
cell biology, and development, as well as cancer.
These pathways can themselves be further or-
ganized into three core cellular processes:
1) Cell fate: Numerous studies have demon-
strated the opposing relationship between cell
division and differentiation, the arbiters of cell
fate. Dividing cells that are re-
sponsible for populating normal
tissues (stem cells) do not differ-
entiate, and vice versa. Regen-
erative medicine is based on this
distinction, predicated on ways
to get differentiated cells to de-
differentiate into stem cells, then
forcing the stem cells to differ-
entiate into useful cell types for
transplantation back into the pa-
tient. Many of the genetic alter-
ations in cancer abrogate the
precise balance between differ-
entiation and division, favoring
the latter. This causes a selective
growth advantage, because dif-
ferentiating cells eventually die
or become quiescent. Pathways
that function through this process
include APC, HH, and NOTCH,
all of which are well known to
control cell fate in organisms
ranging from worms to mammals
(111). Genes encoding chromatin-
modifying enzymes can also be
included in this category. In nor-
mal development, the heritable
witch from division to differen-
tiation is not determined bymuta-
tion, as it is in cancer, but rather
by epigenetic alterations affecting DNA and chro-
matin proteins. What better way to subvert this
normal mechanism for controlling tissue archi-
tecture than to debilitate the epigenetic modifying
apparatus itself?
2) Cell survival: Though cancer cells di-
vide abnormally because of cell-autonomous al-
terations, such as those controlling cell fate, their
surrounding stromal cells are perfectly normal
and do not keep pace. The most obvious ram-
ification of this asymmetry is the abnormal vas-
culature of tumors. As opposed to the well-ordered
network of arteries, veins, and lymphatics that
control nutrient concentrations in normal tissues,
the vascular system in cancers is tortuous and
lacks uniformity of structure (112, 113). Normal
cells are always within 100 mm of a capillary,
but this is not true for cancer cells (114). As a
result, a cancer cell acquiring a mutation that
allows it to proliferate under limiting nutrient
concentrations will have a selective growth ad-
vantage, thriving in environments in which its
sister cells cannot. Mutations of this sort occur,
for example, in the EGFR,HER2, FGFR2, PDGFR,
TGFbR2, MET, KIT, RAS, RAF, PIK3CA, and
PTEN genes (table S2A). Some of these genes
encode receptors for the growth factors them-
selves, whereas others relay the signal from the
growth factor to the interior of the cell, stim-
ulating growth when activated (115, 116). For
instance, mutations in KRAS or BRAF genes
confer on cancer cells the ability to grow in glu-
cose concentrations that are lower than those
required for the growth of normal cells or of
cancer cells that do not have mutations in these
genes (117, 118). Progression through the cell
cycle (and its antithesis, apoptosis) can be di-
rectly controlled by intracellular metabolites,
and driver genes that directly regulate the cell
cycle or apoptosis, such as CDKN2A, MYC, and
BCL2, are often mutated in cancers. Another
gene whose mutations enhance cell survival is
VHL, the product of which stimulates angiogen-
esis through the secretion of vascular endothelial
growth factor. What better way to provision
growth factors to a rogue tumor than to lure the
unsuspecting vasculature to its hideout?
3) Genome maintenance: As a result of the
exotic microenvironments in which they re-
side, cancer cells are exposed to a variety of
toxic substances, such as reactive oxygen spe-
cies. Even without microenvironmental poi-
sons, cells make mistakes while replicating their
DNA or during division (119, 120), and check-
points exist to either slow down such cells or
make them commit suicide (apoptosis) under
such circumstances (110, 121, 122). Although it
is good for the organism to remove these dam-
aged cells, tumor cells that can survive the dam-
age will, by definition, have a selective growth
advantage. Therefore, it is not surprising that
genes whose mutations abrogate these checkpoints,








































Fig. 7. Cancer cell signaling pathways and the cellular pro-
cesses they regulate. All of the driver genes listed in table S2
can be classified into one or more of 12 pathways (middle ring)
that confer a selective growth advantage (inner circle; see main text).
These pathways can themselves be further organized into three core
cellular processes (outer ring). The publications on which this figure
is based are provided in table S5.
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Fig.	  3.	  Number	  of	   somatic	  mutations	   found	   in	  different	   cancer	   types.	   Indicated	  pediatric	  and	  adult	  cancers	   have	   been	   analyzed	   in	   genome-­‐wide	   sequencing	   studies.	   Median	   numbers	   of	   mutations	   per	  tumor	  are	  shown	  in	  parenthesis	  in	  (A)	  and	  as	  graphic	  illustration	  in	  (B).	  Horizontal	  bars	  indicate	  the	  25	  and	   75%	   quartiles.	  MSI,	  microsatellite	   instability;	   SCLC,	   small	   cell	   lung	   cancers;	   NSCLC,	   non-­‐small	   cell	  lung	   cancers;	   ESCC,	   esophageal	   squamous	   cell	   carcinomas;	  MSS,	  microsatellite	   stable;	   EAC,	   esophageal	  adenocarcinomas	  (Vogelstein	  et	  al.,	  2013).	  
For	   these	   reasons	   and	   since	   pediatric	   cancers	   arise	  mainly	   in	   developing	   tissue,	   the	  spectrum	  of	  cancer	  types	  arising	  in	  childhood	  is	  very	  different	  from	  the	  one	  observed	  in	   the	   adult	   population.	  The	  most	   common	   types	   of	   childhood	   cancer	   are	   leukemias	  followed	  by	  CNS	  tumors	  and	  lymphomas.	  Carcinomas	  are	  very	  frequent	  in	  adults	  but	  not	   in	   the	   pediatric	   population,	   whereas	   many	   brain	   and	   solid	   tumors	   including	  medulloblastoma,	  neuroblastoma,	  rhabdomyosarcoma,	  Ewing	  sarcoma,	  osteosarcoma	  and	  Wilms	   tumor	  are	  almost	  exclusively	   found	   in	  children.	  Also,	  pediatric	   leukemias	  substantially	  differ	  from	  adult	  leukemias	  (Fig.	  4)	  (Downing	  et	  al.,	  2012).	  	  
divergence time. The number of mutations has
been measured in tumors representing progressive
stages of colorectal and pancreatic cancers (11, 16).
Applying the evolutionary clock model to these
data leads to two unambiguous conclusions: First,
it takes decades to develop a full-blown, meta-
static cancer. Second, virtually all of themutations
in metastatic lesions were already present in a
large number of cells in the primary tumors.
The timing of mutations is relevant to our
understanding of metastasis, which is responsible
for the death of most patients with cancer. The
primary tumor can be surgically removed, but the
residual metastatic lesions—often undetectable and
widespread—remain and eventually enlarge, com-
promising the function of the lungs, liver, or other
organs. From a genetics perspective, it would
seem that there must be mutations that convert a
primary cancer to a metastatic one, just as there
are mutations that convert a normal cell to a be-
nign tumor, or a benign tumor to a malignant one
(Fig. 2). Despite intensive effort, however, con-
sistent genetic alterations that distinguish cancers
that metastasize from cancers that have not yet
metastasized remain to be identified.
One potential explanation invokes mutations
or epigenetic changes that are difficult to iden-
tify with current technologies (see section on “dark
matter” below). Another explanation is that meta-
static lesions have not yet been studied in suf-
ficient detail to identify these genetic alterations,
particularly if the mutations are heterogeneous
in nature. But another possible explanation is
that there are no metastasis genes. A malignant
primary tumor can take many years to metasta-
size, but this process is, in principle, explicable
by stochastic processes alone (17, 18). Advanced
tumors release millions of cells into the circula-
tion each day, but these cells have short half-lives,
and only a miniscule fraction establish metastatic
lesions (19). Conceivably, these circulating cells
may, in a nondeterministic manner, infrequently
and randomly lodge in a capillary bed in an organ
that provides a favorable microenvironment for
growth. The bigger the primary tumor mass, the
more likely that this process will occur. In this
scenario, the continual evolution of the primary
tumor would reflect local selective advantages
rather than future selective advantages. The idea
that growth at metastatic sites is not dependent on
additional genetic alterations is also supported by
recent results showing that even normal cells,
when placed in suitable environments such as
lymph nodes, can grow into organoids, complete
with a functioning vasculature (20).
Other Types of Genetic Alterations in Tumors
Though the rate of point mutations in tumors is
similar to that of normal cells, the rate of chro-
mosomal changes in cancer is elevated (21).
Therefore, most solid tumors display widespread
changes in chromosome number (aneuploidy),



























































































































































































































































































Adult solid tumors Liquid  Pediatric 
Fig. 1. Number of somatic mutations in representative human cancers, detected by genome-
wide sequencing studies. (A) The genomes of a diverse group of adult (right) and pediatric (left)
cancers have been analyzed. Numbers in parentheses indicate the median number of nonsynonymous
utations per tumor. (B) The median number of nonsynonymous mutations per tumor in a variety of
tumor types. Horizontal bars indicate the 25 and 75% quartiles. MSI, microsatellite instability; SCLC,
small cell lung cancers; NSCLC, non–small cell lung cancers; ESCC, esophageal squamous cell carcinomas;
MSS, microsatellite stable; EAC, esophageal adenocarcinomas. The published data on which this figure is
based are provided in table S1C.
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Fig.	   4.	   Frequency	   of	   pediatric	   and	   adult	   cancer	   types.	   Graphics	   are	   based	   on	   2012	   Surveillance,	  Epidemiology	  and	  End	  Results	  (SEER)	  data.	  Adapted	  from	  (Downing	  et	  al.,	  2012).	  
Representing	   about	   1%	   of	   all	   malignancies	   and	   an	   incidence	   rate	   of	   about	   140	   per	  million	   children	   aged	   younger	   than	   14,	   childhood	   cancers	   are	   quite	   rare.	   However,	  incidence	   rates	   are	   increasing	   (Kaatsch,	   2010;	   Ward	   et	   al.,	   2014).	   About	   175,000	  children	  younger	  than	  15	  years	  are	  annually	  diagnosed	  with	  cancer	  worldwide	  and	  in	  developed	   countries,	   cancer	   is	   actually	   the	   second	  most	   common	   cause	   of	   death	   in	  childhood	  (Ward	  et	  al.,	  2014).	  Although	  5-­‐year	  survival	  rates	  have	  improved	  with	  the	  discovery	   of	   cytotoxic	   chemotherapeutic	   agents	   and	   currently	   range	   at	   about	   80%,	  aggressive	   pediatric	   tumors	   like	   rhabdomyosarcoma,	   Ewing	   sarcoma	   and	  osteosarcoma	  display	  resistance	  to	  conventional	  chemo-­‐	  and	  radiotherapy	  leading	  to	  a	  5-­‐year	   survival	   rate	   of	   60-­‐65%	   (Linabery	   and	   Ross,	   2008).	   Unfortunately,	   and	   in	  contrast	   to	   other	   pediatric	   malignancies,	   there	   has	   been	   no	   major	   improvement	   in	  mortality	  rates	   for	   these	  bone	  and	  soft	   tissue	  sarcomas	  during	   the	   last	  decades	   (Fig.	  5).	   Despite	   a	   satisfying	   overall	   outcome	   and	   superior	   response	   rates	   to	   therapy	   in	  comparison	   to	   adults,	   future	   goals	   include	   development	   of	   innovative	   treatment	   of	  solid	  tumors	  as	  well	  as	  reduction	  of	  treatment	  side	  effects	  aiming	  at	  improvement	  in	  quality	  of	  life	  for	  long-­‐term	  survivors	  (Smith	  et	  al.,	  2010).	  
PERSPECT IVE
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specific tumor subtypes, as shown (Fig. 2). In the initial 3 years of our proj-
ect, we plan on interrogating approximately an equal number of genomes 
from childhood leukemias, solid tumors and brain tumors.
Lessons learned
Several important findings have emerged from our initial studies. 
Foremost was the importance of using the WGS approach to identify 
mutations in pediatric cancers. Analysis of an aggressive subtype of pedi-
atric ALL known as early T-cell precursor leukemia identified complex 
structural variations, focal deletions and sequence mutations of genes 
encoding key hematopoietic regulators that act as driver lesions in these 
leukemias5. The exceedingly complex nature of some of these structural 
alterations would make it impossible to accurately identify them using 
more targeted sequencing approaches, such as exome or transcriptome 
sequencing. This observation has important implications for the applica-
tion of next-generation sequencing–based assays in the clinic. The inabil-
ity of targeted sequencing approaches to accurately and comprehensively 
maturation. The unique biology of these developing tissues suggests that 
the spectrum of mutations that lead to malignant transformation will also 
differ between pediatric and adult cancers. Thus, a focused project to char-
acterize the landscape of mutations in pediatric canc rs is necessary to 
achieve the goal of advancing cures for pediatric cancers.
So, what tumors should be sequenced first? Although statistical 
arguments suggest that 500 tumors of an individual subtype need to 
be sequenced to accurately identify all mutations occurring at a 5% or 
greater frequency, the relative rarity of pediatric cancers coupled with the 
heterogeneity of tumor subtypes makes this approach unfeasible in the 
short term. In fact, obtaining sufficient tumor sa ples has been a major 
limitation in the adult cancer genome sequencing projects. We therefore 
took the approach of sequencing the pediatric cancer subtypes for which 
outcome (cure) with current treatment is poor and/or where there is a 
conspicuous lack of knowledge regarding the genetic basis of the disease. 
To date, we have completed primary data acquisition and initial analyses 
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Figure 1  Frequency of cancer diagnoses and leukemia subtypes in children and adults. (a) The frequency of cancer types in children (left) and adults (right) 
on the basis of 2012 Surveillance, Epidemiology and End Results (SEER) data. Each chart is organized with cancers listed from the most common to the 
least common in a clockwise fashion. (b) The frequency of T-cell lineage (blue text) and B-cell lineage (black text) subtypes of acute lymphoblastic leukemia 
(ALL) in children (left) and adults (right). Each chart is organized with ALL subtypes listed from the most common to the least common in a clockwise 
fashion. iAMP21, intrachromosomal amplification of chromosome 21.
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Fig.	  5.	  Mortality	  rates	   for	  different	  pediatric	  cancer	   types.	  Children	  aged	  0-­‐19	  years	  are	  included	  in	  the	  statistics	  from	  1975	  to	  2010.	  Joinpoint	  fitted	  trends	  are	  shown.	  ONS,	  other	  nerve	  system	  (Ward	  et	  al.,	  2014).	  
4.3 Rhabdomyosarcoma	  
Rhabdomyosarcoma	  (RMS)	  accounts	  for	  4-­‐8%	  of	  all	  pediatric	  cancers	  and	  is	  the	  most	  common	  soft	   tissue	   sarcoma	  with	  an	   incidence	   rate	  of	  4.3	  per	  million	  and	  year.	  The	  two	  main	  subtypes	  embryonal	  (eRMS)	  and	  alveolar	  (aRMS)	  rhabdomyosarcoma	  share	  features	   of	   skeletal	   myogenesis	   and	   express	   embryonic	   or	   adult	   myogenic	   lineage	  markers	   but	   block	   terminal	   muscle	   differentiation.	   Both	   subtypes	   are	   first	   in	   line	  diagnosed	   by	   MYOD1	   and	   myogenin	   expression	   controlling	   differentiation	   (De	  Giovanni	   et	   al.,	   2009).	   However,	   the	   origin	   of	   the	   two	   subtypes	   is	   probably	   not	   the	  same	   und	   is	   still	   under	   debate	   (Hettmer	   and	   Wagers,	   2010).	   It	   was	   first	   of	   all	  suggested	   that	  RMS	  could	  originate	   from	   the	  myogenic	   lineage.	   eRMS	  might	   arise	   in	  myoblasts	  (Rubin	  et	  al.,	  2011),	  while	  aRMS	  could	  be	  experimentally	   induced	  in	  Myf6	  expressing	  maturing	  muscle	   cells	   hypothesizing	   that	   dedifferentiation	   underlies	   the	  tumor	  formation	  (Fig.	  6)	  (Keller	  and	  Capecchi,	  2005).	  However,	  RMS	  can	  also	  occur	  in	  non-­‐skeletal	   muscle	   sites	   like	   the	   biliary	   and	   the	   genitourinary	   tract.	   Furthermore,	  infiltration	  of	  bone	  marrow,	  which	  is	  reminiscent	  of	  acute	  leukemia,	  and	  cases	  without	  any	  detectably	  primary	  tumor	  have	  been	  reported	  (Lisboa	  et	  al.,	  2008).	  Hence,	   it	  has	  been	  suggested	  that	  aRMS	  could	  also	  originate	  from	  mesenchymal	  progenitors,	  which	  
Mortality declines were observed for all major sites shown
in Figure 3, with the steepest declines noted in HL, NHL,
and ALL. Between 1975 and 2009, there were substantial
improvements in 5-year survival rates for many types of
childhood cancer due to improved treat ent and supportive
care (Table 3). Although children who survive 5 years after
the diagnosis of their first cancer continue to be at an
increased risk of morbidity and mortality related to the can-
cer and its treatment, an analysis of 5-year 10-year, and 15-
year survival among childhood and adolescent cancer
patients diagnosed between 1991 and 2000 found that for
the most part children who survived 5 years after the diag-
nosis of their primary tumor had a high probability of subse-
quent survival (Table 4). The cancers with the greatest
declines in survival between 5 and 15 years after diagnosis,
reflecting continued mortality related to the disease or its
treatment, were medulloblastoma (12%), ependymoma
(9%), osteosarcoma (7%), and Ewing sarcoma (ES) (7%)
(Table 4).
Prevention and Early Detection
In contrast to cancers in adults, only a relatively small per-
centage of all childhood cancers have known preventable
causes. Ionizing radiation exposure is a well-recognized risk
factor for cancer in children and adolescents based on
studies of medical and environmental radiation exposure.
The association between low doses of ionizing radiation
received by the fetus in utero from diagnostic radiography
and the subsequent risk of leukemia and other childhood
cancers was demonstrated in the 1950s.26 As a result, pre-
cautions have been taken to minimize radiation exposure
during pregnancy. Radiation exposure from diagnostic com-
puted tomography scans is higher a more variable han
exposures from conventional x-rays, and studies suggest that
radiation exposure early in life increases the long-term risk
of leukemia and brain cancer.27,28 Health care providers are
encouraged to limit the use of computed tomography scans
in children and pregnant women to those situations in
which there is a definite clinical indication and to optimize
scans by using the lowest possible radiation dose.29
In recent years, a number of studies have demonstrated
associations between accelerated fetal growth and/or high
birth weight and pediatric cancers, including ALL, CNS
tumors, Wilms tumor (WT), NHL, and embryonal rhabdo-
myosarcoma, while low birth weight has been associated
with acute myeloid leukemia (AML) and some CNS tumor
subt pes.30-37 Although numerous epidemiologic studies
have investigated potential environmental causes of child-
hood cancers, few strong or consistent associations have
been found. The International Agency for Research on
FIGURE 3. Trends in Pediatric Cancer Mortality Rates by Site, Ages Birth to 19 Years, 1975 to 2010.
ONS indicates other nervous system. Note: Lines represent joinpoint fitted trends. The average annual percent change for cancers with significant trends dur-
ing the most recent period: acute lymphocytic leukemia (23.1* during 1988-2010), brain (21.1* during 1975-2010), non-Hodgkin lymphoma (24.1* during
1975-2010), soft tissue (21.0* during 1979-2010), kidney (21.2* during 1992-2010), and Hodgkin lymphoma (24.9* during 1975-2010). Source: National
Center for Health Statistics, Centers for Disease Control and Prevention.
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are	  not	  committed	  to	   the	  myogenic	   lineage	  and	  can	  circulate	   to	  different	  organs	  and	  also	  be	  found	  in	  bone	  marrow	  (Hettmer	  and	  Wagers,	  2010).	  Along	  these	  lines,	  also	  the	  adipogenic	  lineage	  or	  a	  non-­‐myogenic	  neural	  crest-­‐derived	  stem	  cell	  compartment	  are	  discussed	  as	  potential	  origins	  of	  eRMS	  (Hatley	  et	  al.,	  2012;	  Vogel	  et	  al.,	  1999).	  	  	  
	  
Fig.	   6.	   Potential	   cellular	   origins	   of	   rhabdomyosarcoma	   subtypes	   during	   skeletal	   myogenesis.	  Expression	  of	  myogenic	  transcription	  factors	  PAX3,	  PAX7,	  MyoD,	  myogenin	  and	  Myf6,	  crucial	  for	  muscle	  specification,	  is	  indicated.	  Muscle	  progenitor	  cells	  are	  responsible	  for	  postnatal	  muscle	  maintenance	  and	  regeneration.	   Uncommitted	   MSCs	   could	   give	   rise	   to	   ARMS	   (aRMS)	   and	   undifferentiated	   sarcomas.	   A	  second	  hypothesis	  describes	  maturing	  muscles	   as	   the	  origin	  of	  ARMS.	  Myoblasts	  might	   generate	  ERMS	  (eRMS)	  and	  undifferentiated	  sarcomas.	  NOS,	  not	  otherwise	  specified	  (Hettmer	  and	  Wagers,	  2010).	  
4.3.1 Clinical	  classification:	  Clinical	  features	  and	  therapy	  
eRMS	  and	  aRMS	  need	  to	  be	  distinguished	  not	  just	  in	  terms	  of	  origin	  but	  also	  regarding	  histology,	   incidence,	   age	   of	   onset,	   primary	   tumor	   localization,	   predestination	   of	  metastasis	   and	   outcome.	   With	   60-­‐70%,	   the	   majority	   of	   diagnosed	   RMS	   tumors	  compose	   the	   subgroup	   of	   embryonal	   RMS,	   which	   presents	   histologic	   features	   of	  immature	  skeletal	  muscle.	  eRMS	  predominately	  occurs	  in	  the	  head	  and	  neck	  as	  well	  as	  the	  genitourinary	  region	  of	  mainly	  0-­‐5	  years	  old	  children.	  The	  5-­‐year	  overall	  survival	  is	  about	  73%	  (Ognjanovic	  et	  al.,	  2009).	  20%	  of	  RMS	  tumors	  are	  diagnosed	  as	  alveolar	  RMS,	  which	  gained	  its	  name	  due	  to	  the	  histological	   appearance	   resembling	   lung	   alveoli.	   aRMS	  mainly	   localizes	   to	   the	   trunk	  and	  the	  extremities	  and	  is	  more	  common	  in	  adolescents	  than	  in	  young	  children.	  	  It	  is	  more	   aggressive	   than	   eRMS,	   with	   a	   high	   tendency	   to	   metastasize,	   usually	   to	   lungs,	  bone	   marrow,	   lymph	   nodes	   and	   bones	   (Breneman	   et	   al.,	   2003).	   Thus,	   the	   5-­‐year	  overall	  survival	  of	  48%	  is	  lower	  than	  in	  eRMS	  (Ognjanovic	  et	  al.,	  2009)	  and	  can	  even	  fall	  below	  30%	  in	  metastatic	  cases	  (Malempati	  and	  Hawkins,	  2012).	  
B E T W E E N  B E D S I D E  A N D  B E N C H
sarcoma tissue lacks any traces of neural dif-
ferentiation, expression of PAX3, PAX7 and 
MRFs has been interpreted as indicating a 
skeletal muscle ori in of rhabdomyosarcoma. 
Consistent with such an origin, our ongoing 
work demonstrates that embryonal rhab-
domyosarcomas in mice contain a subset of 
cells that phenotypically resemble skeletal 
muscle stem cells, present within the normal 
muscle satellite cell pool5. This population 
of stem cells is substantially overrepresented 
in many mouse rhabdomyosarcoma tumors, 
implicating primitive muscle precursor cells in 
the tumorigenic process. Likewise, Langenau et 
al.7 recently identified a serially transplantable 
cell population in K-ras–induced embryonal 
rhabdomyosarcomas in zebrafish that harbors 
a transcriptional signature similar to that of 
activated satellite cells7.
Together, these data support the notion that 
rhabdomyosarcoma represents an aberrant 
stage of normal muscle development and sug-
gest that embryonal rhabdomyosarcoma may 
arise from muscle progenitor cells. However, 
such conclusions, mad  on the basis of corre-
lated expression of genes, proteins or both in 
tumor cells and normal muscle, provide only 
indirect clues about tumor-initiating events, 
particularly because the tumors themselves 
must b  considered a final stage of the onco-
genic process. Expression of muscle lineage 
markers in rhabdomyosarcoma tissue could 
instead arise as a byproduct of transforma-
tion, especially given that ectopic expression 
of MRFs is well known to convert several non-
myogenic cell types to the muscle lineage8. 
A reasonable alternative hypothesis has been 
proposed in which rhabdomyosarcoma arises 
from mesenchymal progenitor cells9, which are 
mesodermal in origin but are not committed 
to the myogenic lineage (contributing instead 
by these various rhabdomyosarcoma subtypes, 
additional experimental evidence suggests that 
individual rhabdomyosarcoma subtypes may 
originate from dis inct cellular sources, pos-
sibly including circulating mesenchymal pro-
genitor cells, which can be found in the bone 
marrow stroma. Although it is conceivable that 
miniscule primary rhabdomyosarcoma tumors 
(too small to be detected clinically) spread to 
the bone marrow, rhabdomyosarcoma forma-
tion originating from progenitor cells already 
in the marrow could explain the ‘leukemic’ 
variants of rhabdomyosarcoma described by 
Lisboa et al.2 and Shi koda et al.3.
As it has long been proposed that rhab-
domyosarcoma results from aberrant skeletal 
muscle differentiation, insights into normal 
muscle development have been used to identify 
candidate populations of rhabdomyosarcoma-
initiating cells. In the embryo, mesodermal cells 
generate myogenic (muscle-forming) cells, the 
majority of which differentiate to produce skel-
etal muscle fibers under the control of myo-
genic transcription factors such as PAX3 and 
PAX7 (Fig. 1). Howeve , a subset of these myo-
genic cells escapes terminal differentiation in 
the embryo and instead forms a unique popu-
lation of mononuclear ‘satellite cells’, which are 
retained beneath the basal lamina of mature 
mu cle fibers. Satellite cells act as myogeni  
precursors to support muscle maintenance and 
growth after birth5. When activated by muscle 
injury, these cells proliferate, terminally differ-
entiate and fuse into multinucleated myofibers 
through a highly regulated process orchestrated 
by sequentially expressed myogenic regulatory 
factors (MRFs; Fig. 1)6.
Like normal muscle precursors, rhabdomyo-
sarcoma cells express PAX3, PAX7 and MRFs1. 
PAX3 and PAX7 mark both muscle-forming 
and neural crest cells, but, as rhabdomyo-
the two m jor rhabdomyosarcoma subtypes, 
in which the individuals presented with wide-
spread tumor infiltration in the bone marrow, 
reminiscent of ac te leuk mia, and an absen e 
of any detectable primary tumor. 
These two reports spotlight an ongoing chal-
lenge for conquering this disease: researchers 
have yet to clearly answer the fundamental 
question of which cells in the body give rise to 
rhabdomyosarcoma. Identifying the cell (or 
cells) of origin for rhabdomyosarcomas would 
yield vital insights into the contextual require-
ments of oncogenic mutations associated with 
these tumors, possibly enabling treatments to 
be tailored to the particular cellular and genetic 
requirements of distinct tumor subtypes. Such 
improved therapies are urgently needed, par-
ticularly given the dismal outcomes associ-
ated with this disease (only ~27% event-free 
survival at three years for all individuals with 
metastatic rhabdomyosarcoma).
An initial appreciation of the complications 
surrounding the origin of rhabdomyosarcoma 
can be gleaned from the observation that even 
canonically present g rhabdomyosarcoma 
manifests in distinct subtypes with consider-
able variability. Its two main histopathologic 
subtypes, embryonal and alveolar, reflect 
distinct clinical and molecular entities that 
may arise through distinct biological mecha-
nisms. Embryonal rhabdomyosarcoma typi-
cally occurs in young children, mainly in the 
head, neck or genitourinary tract1. Alveolar 
rhabdomyosarcoma presents throughout 
childhood1, in the trunk and extremities, and 
harbors distinguishing chromosomal trans-
locations. These occur at t(2;13) and t(1;13) 
and generate the diagnostic paired box (PAX)-
forkhead (FKHR) fusion oncoproteins PAX3-
FKHR and PAX7-FKHR, respectively1.
Compounding the complexity introduced 
Figure 1  Model of skeletal myogenesis, with possible cellular origins of rhabdomyosarcoma as suggested experimentally. Muscle specification from 
the mesoderm depends on myogenic transcription factors (such as PAX3, PAX7, MyoD, Myf5, myogenin and Myf6). Postnatal muscle maintenance 
and regeneration invokes quiescent muscle precursor cells within the satellite cell pool that proliferate, terminally differentiate and fuse to generate 
multinucleated myotubes. Depending on the set of oncogenes used and the developmental age of the cells, low-passage MSCs can generate alveolar 
rhabdomyosarcomas and undifferentiated sarcomas, whereas low-passage myoblasts can form embryonal rhabdomyosarcomas and undifferentiated 
sarcomas. Alternatively, it has been suggested that alveolar rhabdomyosarcomas arise from maturing muscle. ARMS, alveolar rhabdomyosarcoma;  
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The	  very	  rare	  group	  of	  pleomorphic	  RMS	  tumors	  affects	  mainly	  adults	  with	  a	  5-­‐year	  overall	  survival	  rate	  of	  only	  27%	  (Sultan	  et	  al.,	  2009).	  Before	   therapy	  starts,	  patients	  are	  classified	   into	  different	   risk	  groups	  depending	  on	  clinical	   parameters	   and	   pathological	   features	   including	   histology,	   site,	   size,	  involvement	   of	   lymph	   nodes	   and	   metastases	   to	   receive	   risk-­‐based	   multimodal	  treatment	  of	  different	  intensities	  (Malempati	  and	  Hawkins,	  2012).	  Although	  protocols	  slightly	   differ	   in	   Europe	   and	   the	   United	   States,	   all	   patients	   undergo	   chemotherapy	  with	   standard	   regimens	   including	   vincristine,	   actinomycin-­‐D	   and	   ifosfamide	   or	  cyclophosphamide.	   Topotecan	   and	   irinotecan	   are	   additionally	   used	   for	   intermediate	  and	   high-­‐risk	   groups	   in	   US	   protocols.	   Furthermore,	   surgical	   intervention	   aims	   at	  complete	   resection	   of	   the	   primary	   tumor.	   Depending	   on	   group	   classification,	  radiotherapy	   is	   optionally	   applied	   for	   local	   control	   of	   the	   tumor	   (Van	   Gaal	   et	   al.,	  2012a).	   During	   the	   last	   decades,	   progress	   in	   treatment	   strategies	   led	   to	   improved	  outcomes	   of	   low	   and	   intermediate	   risk	   patients.	   Unfortunately,	   children	   with	  advanced	  RMS	  could	  not	  benefit	  so	  far,	  and	  clinical	  and	  pathologic	  features	  might	  not	  be	   sufficient	   to	   assign	   patients	   to	   different	   treatment	   protocols	   within	   the	  intermediate	  risk	  group	  (Chen	  et	  al.,	  2013;	  Dasgupta	  and	  Rodeberg,	  2012).	  
4.3.2 Molecular	   classification:	   Genetic	   landscapes	   and	   aberrant	   signaling	   of	  
rhabdomyosarcoma	  
Molecular	   classification	   and	   better	   understanding	   of	   RMS	   biology	   might	   help	   to	  develop	  novel	   targeted	   therapies,	  especially	   for	   the	  advanced	  RMS	  cases.	   	  At	  genetic	  level,	   the	  most	  prominent	  difference	  of	  eRMS	  and	  aRMS	   is	   the	  occurrence	  of	  specific	  chromosomal	   translocations.	   In	   about	   70%-­‐80%	   of	   aRMS,	   translocation	   of	   PAX3	  (60%-­‐70%)	  or	  PAX7	  (10%)	  to	  FOXO1	  ((2;13)(q35;q14)	  or	  (1;13)(p36;q14))	  results	  in	  the	  generation	  of	  a	  fusion	  protein.	  	  It	  consists	  of	  the	  PAX3/7	  N-­‐terminal	  paired	  domain	  and	   homeodomain	   encompassing	   the	   octapeptide	   motif,	   and	   the	   FOXO1	   C-­‐terminal	  transactivation	  domain	  (Fig.	  7).	  In	  very	  rare	  cases	  translocations	  of	  PAX3	  to	  different	  genes	   like	  NCOA1	   or	   INO80D	   have	   been	   detected	   (Shern	   et	   al.,	   2014;	  Wachtel	   et	   al.,	  2004).	  Translocation	  leads	  to	  higher	  expression,	  exclusive	  nuclear	  localization	  and	  enhanced	  activity	  of	  the	  emerging	  chimeric	  transcription	  factor	  compared	  to	  wild	  type	  PAX3	  and	  FOXO1	   (Olanich	   and	   Barr,	   2013).	   Importantly,	   the	   fusion	   protein	   is	   also	   a	   highly	  relevant	   prognostic	   factor,	   especially	   comparing	   PAX3-­‐FOXO1	   expressing	   to	   fusion	  negative	   tumors	   (De	   Giovanni	   et	   al.,	   2009;	  Williamson	   et	   al.,	   2010).	   Sorensen	   et	   al.	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(2009)	  reported	  a	  4-­‐year	  overall	  survival	  of	  only	  8%	  for	  PAX3-­‐FOXO1	  positive	  tumors	  within	  the	  cohort	  of	  metastatic	  aRMS	  patients.	  
	  
Fig.	   7.	   Chromosomal	   translocations	   generating	   the	   chimeric	   fusion	   proteins	   PAX3-­‐FOXO1	   and	  
PAX7-­‐FOXO1.	   Translocation	   occurs	   between	   chromosome	   2	   and	   chromosome	   13,	   respectively	  chromosome	   1	   and	   chromosome	   13.	   Fusion	   proteins	   harbor	   complete	   paired	   domains	   and	  homeodomains	   of	   PAX3/7	   and	   a	   complete	   transactivation	   domain	   of	   FOXO1.	   PB,	   paired	   domain;	   HD,	  homeodomain;	  FD,	  forkhead	  domain;	  DBD,	  DNA	  binding	  domain;	  TAD,	  transcriptional	  activation	  domain	  (Olanich	  and	  Barr,	  2013).	  
The	   crucial	   role	   of	   determination	   of	   fusion	   protein	   status	   for	   classification	   of	   RMS	  types	   becomes	   further	   evident	   comparing	   genetic	   landscapes	   as	   well	   as	   gene	  expression	   analyses	   and	   regulation	   of	   differentiation	   of	   translocation	   positive	   and	  negative	  tumors.	  	  Sequencing	  approaches	  revealed	  that	  translocation	  negative	  tumors,	  including	   eRMS	   tumors,	   are	   characterized	   by	   a	   higher	   number	   of	   mutations	   and	  structural	   and	   copy	   number	   alterations	   than	   translocation	   positive	   RMS.	   Sequence	  analyses	  have	   identified	  mutations	   in	   the	  eight	   cancer	   consensus	  genes	  NRAS,	  KRAS,	  
TP53,	   NF1,	   RARA,	   CTNNB1,	   CARD11	   and	   PIK3CA	   as	   well	   as	   recurrent	   alterations	   in	  
HRAS,	   FGFR4,	   FBXW7	   and	   BCOR	   in	   patient-­‐derived	   fusion	   negative	   tumors	   (Fig.	   8)	  (Chen	  et	  al.,	  2013;	  Shern	  et	  al.,	  2014).	  Additionally,	  lesions	  could	  be	  detected	  in	  genes	  regulating	   cell	   cycle	   checkpoints	   (BUB1B,	   FOXM1,	   CCND1	   and	   CCND2).	   Apart	   from	  these	   mutations,	   eRMS	   tumors	   are	   characterized	   by	   a	   high	   frequency	   in	   loss	   of	  heterozygosity	   in	   11p15.5	   including	   IGF2.	   Also	   loss	   of	   imprinting	   at	   IGF2	   or	  
a member of the subfamily of Forkhead box O transcription
factors [18,19,32]. FOXO1 contains a Forkhead DNA binding
domain at its N terminus and a transcriptional activation
domain at its C terminus [6].
The 2;13 and 1;13 translocations break within the seventh
intron of PAX3 or PAX7 and within the first intron of
FOXO1 [32]. Chimeric genes are, thereby, generated and encode
chimeric proteins consisting of the PAX3 or PAX7 N-
terminal DNA binding domain fused to the FOXO1 C-termi-
nal transactivation domain (Figure 1) [20,32]. PAX3/PAX7 and
FOXO1 coding sequences are fused in-frame, creating
functional -- albeit aberrant -- transcription factors. PAX--FOXO1
fusion proteins are discussed in greater detail below.
Molecular pathology studies of the chimeric products reveal
that ~ 60% of ARMS tumors are PAX3-FOXO1-positive,
~ 20% are PAX7-FOXO1-positive and ~ 20% are fusion-
negative [45,47]. These studies, thus, confirm that there is a subset
of histologically defined ARMS tumors that are negative for the
hallmark translocations generating PAX3-FOXO1 or PAX7-
FOXO1 [33]. In rare cases, alternative translocations, such as
t(2;2)(p23;q35) and t(2;8)(q35;q13), result in fusion of PAX3
to nuclear receptor coactivator genes, NCOA1 and NCOA2,
respectively [48]. Most cases in this PAX3-FOXO1 and
PAX7--FOXO1-negative subset show no detectable rearrange-
ments involving PAX3, PAX7 or FOXO1, providing evidence
for bona fide fusion-negative ARMS cases [49]. Interestingly,
fusion-negative ARMS demonstrates genetic changes character-
istic of ERMS, which is consiste t with the similar expression
patterns [50] and clinical outcomes [51] of fusion-negative
ARMS and ERMS cases.
2.2 PAX--FOXO1 oncogenicity
The PAX--FOXO1 fusion products have altered expression,
subcellular localization and function, compared to wild-
type PAX3, PAX7 or FOXO1. PAX--FOXO1 fusion proteins
are expressed at higher levels than their wild-type PAX coun-
terparts; PAX7--FOXO1 overexpression results from gene
amplification, while PAX3-FOXO1 overexpression occurs via
copy number-independent enhanced transcription [52]. In con-
trast to the wild-type FOXO1 protein that can shuttle between
the nucleus and cytoplasm, the PAX3-- or PAX7--FOXO1
protein is localized exclusively in the nucleus. Finally, these fusion
proteins activate transcription of target genes 10- to 100-fold
more potently than wild-type PAX3 and PAX7 [32,53,54].
Numerous studies have demonstrated the oncogenic capac-
ity of the PAX3/PAX7--FOXO1 f sion protei . In chicken
embryo fibroblasts and murine NIH 3T3 fibroblasts, ectopic
expression of PAX3-FOXO1, but not wild-type PAX3,
resulted in transformation as evidenced by focus formation
and anchorage-independent growth in soft agar [55-57]. Based
on these early studies, PAX3-FOXO1 appears to function as
a dominant-acting oncogene [36]. This fusion likely contributes
to tumorigenesis through several mechanisms [58]. The finding
that an engineered PAX3-KRAB repressor suppressed the
oncogenicity of Rh30 ARMS cells in vitro and in vivo supports
the hypothesis that PAX3-FOXO1’s aberrant transcriptional
activity lies at the heart of its oncogenic potential [59].
Despite early reports demonstrating the transformative
capacity of the PAX3-FOXO1 fusion [55-57], additional studies
revealed that PAX3-FOXO1 is generally not sufficient for com-



































Figure 1. Schematic depiction of t(2;13)(q35;q14) and t(1;13)(p36;q14) chromosomal translocations and resultant PAX3/
7-FOXO1 chimeric fusion products. The vertical dashed line denotes the fusion point.
DBD: DNA-binding domain; FD: Forkhead d main; HD: Homeobox domain; PB: Paired box; TAD: Transcriptional activation domain.
A call to ARMS: targeting the Pax3-Foxo1 gene in ARMS
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amplifications	  of	  IGF1R	  have	  been	  observed.	  Furthermore,	  MDM2/FRS2	  amplifications	  and	  CDKN2A	  deletions	  or	  loss	  of	  heterozygosity	  (LOH)	  as	  well	  as	  gain	  of	  chromosome	  2,	  8	  and	  13	  were	  identified	  predominantly	  in	  fusion	  negative	  tumors.	  	  Overall,	  several	  studies	  showed	  that	  mutations	  were	  most	  commonly	  found	  in	  the	  RAS	  pathway	  (Chen	  et	  al.,	  2013;	  Paulson	  et	  al.,	  2011;	  Shern	  et	  al.,	  2014;	  Shukla	  et	  al.,	  2012),	  interestingly	  also	   significantly	   correlating	   with	   risk	   group	   classification	   (Chen	   et	   al.,	   2013).	  However,	   there	  was	  no	   significant	   increase	   in	   cytotoxicity	  of	  RAS	  pathway	   targeting	  drugs	   in	   primary	   orthotopic	   eRMS	   xenografts.	   This	   study	   further	   showed	   increased	  expression	  of	  p38MAPK	  pathway	  and	  decreased	  MCU/MICU1	  expression	  implicated	  in	  oxidative	  stress	  suggesting	  it	  as	  therapeutically	  relevant	  pathway	  in	  eRMS.	  	  In	  contrast,	  in	  fusion	  positive	  tumors	  neither	  cancer	  consensus	  genes,	  apart	  from	  the	  PAX3/7-­‐FOXO1	  translocation,	  nor	  any	  significantly	  enriched	  canonical	  pathway,	  could	  be	  identified.	  Very	  often	  the	  translocation	  was	  even	  the	  sole	  aberration	  detected	  (Fig.	  8).	  The	  only	  mutation	   found	   in	   two	   independent	   studies	  was	  PIKC3A	   in	  1	  out	  of	  17,	  respectively	  in	  only	  1	  out	  of	  53	  fusion	  positive	  aRMS	  patients	  next	  to	   just	  one	  tumor	  mutated	  in	  the	  transcriptional	  repressor	  BCOR	   in	  only	  one	  of	  the	  studies	  (Chen	  et	  al.,	  2013;	  Shern	  et	  al.,	  2014).	  However,	  amplifications	  of	  CDK4	  and	  MYCN	  were	  found	  with	  a	  slightly	  higher	  frequency	  (Shern	  et	  al.,	  2014).	  CDK4	  is	  a	  regulator	  of	  G1/S	  cell	  cycle	  transition,	  whereas	  MYCN	  is	  an	  oncogenic	  transcription	  factor,	  regulating	  expression	  of	  TERT,	  MDM2	  and	  IGF1R.	  Also,	  amplification	  of	  MIR-­‐17-­‐92,	  encoding	  a	  cluster	  of	  at	  least	  six	  miRNAs,	  was	  detected	   in	  a	   few	  cases	  and	  might	  be	   involved	   in	  cell	  survival,	  proliferation,	   differentiation,	   and	   angiogenesis.	   In	   addition,	   a	   further	   study	   showed	  that	   aberrations	   in	  ALK,	   a	   receptor	   tyrosine	   kinase	   activating	   the	   STAT3,	  AKT/PI3K	  and	   RAS/ERK	   pathways	   involved	   in	   proliferation,	   migration	   and	   survival	   are	   more	  commonly	   observed	   in	   aRMS	   than	   in	   eRMS	   (van	   Gaal	   et	   al.,	   2012b).	   	   Some	   aRMS	  tumors	  also	  depict	  loss	  of	  heterozygosity	  in	  11p15.5	  (Shern	  et	  al.,	  2014).	  In	  conclusion,	  the	  low	  numbers	  of	  genetic	  lesions	  per	  tumor	  without	  any	  recognizable	  consensus	   indicate	   that	  mainly	   the	   fusion	  protein	  and	  expression	  of	   its	   target	   genes	  mediate	  tumor	  formation	  and	  progression	  of	  aRMS.	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Fig.	   8.	   Genomic	   landscape	   of	   rhabdomyosarcoma.	   Genomic	   alterations	   of	   147	   rhabdomyosarcoma	  cases	  identified	  by	  whole	  exome	  or	  whole	  genome	  sequencing	  are	  depicted.	  Age,	  years	  at	  diagnosis;	  WES,	  whole	   exome	   sequencing;	  WGS,	  whole	   genome	   sequencing;	   NOS,	   not	   otherwise	   specified	   (Shern	   et	   al.,	  2014).	  
4.3.3 Functions	  of	  PAX3-­‐FOXO1	  
A	  number	  of	   studies	  have	   conducted	   gene	   expression	   and	  PAX3-­‐FOXO1	  binding	   site	  analysis.	  Comparing	  eRMS	  and	  aRMS	  tumors	  as	  well	  as	  introducing	  PAX3-­‐FOXO1	  into	  fusion	   negative	   RMS	   cells	   revealed	   a	   PAX3-­‐FOXO1	   dependent	   gene	   expression	  signature	   (Cao	  et	  al.,	  2010;	  Davicioni	  et	  al.,	  2006;	  De	  Pitta	  et	  al.,	  2006;	  Ebauer	  et	  al.,	  2007;	   Khan	   et	   al.,	   1998;	   Lae	   et	   al.,	   2007;	   Wachtel	   et	   al.,	   2004).	   Some	   of	   the	   most	  important	   and	   validated	   PAX3/7-­‐FOXO1	   targets	   include	   FGFR4,	   MET	   and	   CXCR4	  involved	   in	   proliferation,	  migration	   and	   invasion,	   the	   oncogenic	   transcription	   factor	  MYCN,	  the	  anti-­‐apoptotic	  BCL-­‐XL,	  ADAM	  protease	  and	  elastase	  promoting	  metastasis,	  AP2β	  mediating	  cell	  survival,	  IGF2,	  CNR1	  and	  CDH3	  inducing	  migration	  and	  invasion	  as	  well	  as	  maintaining	  expression	  of	  the	  CDK4	  cofactor	  cyclin	  D1	  (Fig.	  9)	  (Marshall	  and	  Grosveld,	   2012;	  Olanich	   and	  Barr,	   2013).	   Overall,	   it	   is	   very	   interesting	   that	   some	   of	  these	  target	  genes	  can	  additionally	  be	  impaired	  by	  genetic	  alterations.	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Fig. S7) that includes the paternally imprinted gene IGF2. 
Further evidence of insulin receptor signaling alterations in 
rhabdomyosarcoma were observed with focal amplification 
of IGF1R in 2.7% (1 PFP vs. 3 PFN) of cases (Supplementary 
Fig. S8A; ref. 21) and one somatic indel in the 3′-untrans-
lated region of IGF2 (RMS2037; Supplementary Table S5). 
Consistent with previous reports, 9.7% of the tumors dis-
played amplification of chromosomal region 12q13-q14, 
which has been shown to be associated with worse overall 
survival in rhabdomyosarcoma independent of gene fusion 
status (22). The 12q13-q14 amplicon was found predomi-
nantly in PFP tumors (12 PFP vs. 1 PFN). The minimum 
amplicon siz  (Supplementary Fig. S8B) includ d 25 genes, 
including the cyclin-dependent kinase gene CDK4. Recur-
rent focal amplification of 12q15 (9%; Supplementary Fig. 
S8C) that encompassed the genes FRS2 and MDM2 occurred 
predominantly in PFN tumors (  PFN vs. 1 PFP). Amplifica-
tion of 2p24 involving MYCN (5%) occurred predominantly 
in PFP tumors (8 PFP vs. 1 PFN; Supplementary Fig. S8D); 
amplification of the PAX7–FOXO1 fusion gene occurred in 
12/15 PAX7–FOXO1 tumors (Supplementary Fig. S8E), and 
amplification of 13q31-32 including the MIR17HG locus 
occurred exclusively in PFP tumors (4.5%; Supplementary 
Fig. S8F). Homozygous deletion of the tumor suppressor 
CDKN2A was found in 3% of samples, and LOH at this locus 
(9p21.3) occurred in 9% (1 PFP vs. 13 PFN) of the study pop-
ulation. This allelic loss rate was lower than the previously 
reported frequency of 25% (15). As previously described (23), 
recurrent gain of chromosome 8 was seen in 46% of the PFN 
population. Other chromosome level events included recur-
rent gains of chromosomes 2, 7, 11, and 13 and the recurrent 
loss of chromosomes 1p, 9, and 16 (Supplementary Fig. S9).
Pathway Analysis Integrating Mutations,  
Copy-Number Changes, and Structural Variations 
Implicates Alteration of FGFR Signaling
To identify dysregulat d pathways relevant to rhabdomyosa-
rcoma pathology, analysis incorporating structural variations, 
copy-number changes, and somatic mutations found in the 
WGS discovery set was performed. Using the 2,119 genes found 
to be somatically ltered in the discovery cohort (Supplemen-
tary Table S8), Reactome (24) overrepresentation analysis indi-
cated that fibroblast growth factor receptor (FGFR) signaling 
was the most significantly altered pathway (P = 4.6 × 10−5), with 
29 of 112 candidate genes represented. Remarkably, mutations 
in this pathway (Fig. 6A) were found in 88% of PFN samples 
(22 of 25 tumors) that were analyzed by WGS. When examined 
separately, the genes altered in PFP tumors (435 of 2,119) were 
not significantly enriched in any canonical pathways.
Figure 4. The genomic landscape of pediatric rhabdomyosarcoma (RMS) highlighting candidate alterations. Demographic characteristics, histologic 
subtypes, and selected genes with copy-number alterations or somatic mutations across 147 rhabdomyosarcoma cases. Unique s mple identifier and 
sequencing platform. Sex, males in blue, females in pink. Age, years at diagnosis divided into fewer than 5 years and greater than 5 years. Histologic diag-
no is, red, alveolar rhabdomyosarcoma (ARMS); blue, embryonal rhabdomyosarcoma (ERMS) including spindle and botryoid subtypes; gr y, rhabdomyosar-
coma not otherwise specified (NOS). Mixed alveolar and embryonal histology in green. Copy-number gains and losses for selected genes. Blue, losses; red, 
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Fig.	  9.	  PAX3-­‐FOXO1	  target	  genes.	  Target	  genes	  contribute	  to	  development	  and	  progression	  of	  alveolar	  rhabdomyosarcoma	  promoting	   invasion,	  migration,	  proliferation,	   transformation,	  and	  survival.	  Adapted	  from	  (Marshall	  and	  Grosveld,	  2012).	  
Although	  additional	  lesions	  like	  p53	  or	  Ink4/Arf	  (Cdkn2A/B)	  loss	  are	  necessary	  for	  the	  generation	  of	   aRMS	  mouse	  models	   and	   although	   the	   formation	  of	   aRMS-­‐like	   tumors	  from	  human	  skeletal	  myoblasts	  requires	  expression	  of	  TERT,	  MCYN	  and	  loss	  CDKN2A	  next	   to	   PAX3-­‐FOXO1	   expression	   (Keller	   et	   al.,	   2004;	   Naini	   et	   al.,	   2008),	   the	   fusion	  protein	   is	   suggested	   to	   be	   the	   major	   oncogenic	   driver	   in	   fusion	   positive	   tumors.	  Accordingly	  and	  as	  stated	  earlier,	  alterations	  in	  exactly	  these	  genes	  or	  pathways	  were	  observed	  in	  sequenced	  tumors,	   including	  amplification	  of	  CDK4,	  the	  protein	  of	  which	  is	  directly	  inhibited	  by	  CDKN2A,	  amplification	  of	  MYCN,	  upstream	  of	  TERT,	  deletion	  of	  
CDKN2A,	  and	  LOH	  at	  11p15.5	  encoding	  for	  the	  CDK	  inhibitor	  p57/KIP2	  (Shern	  et	  al.,	  2014).	   Thus,	   these	   studies	   demonstrate	   the	   oncogenicity	   of	   PAX3/7-­‐FOXO1	   and	  suggest	   cooperation	   mainly	   by	   CDK4	   and	   MYCN	   in	   tumorigenesis.	   In	   summary,	  considering	   the	   low	   frequency	   of	   genetic	   alterations	   apart	   from	   the	   translocation	   in	  aRMS	  reveals	   the	  biological	  relevance	  and	  the	  high	  potential	  of	   the	   fusion	  protein	  as	  therapeutic	  target.	  Most	   interestingly,	   comparing	   genetic	   alterations	   of	   translocation	   positive	   and	  negative	  tumors	  demonstrates	  that	  many	  genes	  upregulated	  by	  the	  fusion	  protein	  are	  alternatively	   activated	   by	   genetic	   alteration	   in	   fusion	   negative	   tumors,	   including	  
FGFR4,	   CCND2,	   IGF2,	   MET,	  MYOD1,	   and	   CNR1,	   which	   therefore	   likely	   contribute	   to	  tumor	  formation	  and	  progression	  (Fig.	  10)	  (Shern	  et	  al.,	  2014).	  	  	  
similar to those seen in PAX3 mutant Splotch mice. The
majority of defects appeared to be in neural develop-
ment, though defects were seen in hind limb skeletal
muscle; however, no tumors developed [121,122].
Lagutina et al. [120] developed a model where PAX3-
FOXO1 was knocked into the PAX3 locus. This knock-in
locus expressed low amounts of PAX3-FOXO1, which in
heterozygous pups was sufficient to result in developmental
defects in the heart and diaphragm, leading to congestive
heart failure and perinatal death, as well as malformations
of some hypaxial muscles. However, neither chimeric adults
nor their newborn heterozygous pups developed malignan-
cies. It was hypothesized that PAX3-FOXO1 expression
from the PAX3 control sequences was insufficient to cause
ARMS formation, and downstream regions of the FOXO1
locus may be required to induce sufficient PAX3-FOXO1
expression to induce tumor development.
A PAX7-FOXO1 model of ARMS was also attempted
in Drosophila [123]. Expression of UAS-hPAX7-FOXO1,
under control of myosin heavy-chain Gal4, also resulted
in developmental defects in the fly, evidenced by disor-
ganized myogenic patterning. Though nothing resem-
bling tumor formation was seen, this group did note
dissemination and infiltration of non-native tissue by
PAX7-FOXO1 expressing mononucleated cells, indicat-
ing an increase in invasive capacity of these cells.
Keller et al. [47] used a conditional PAX3-FOXO1
knock-in into the PAX3 locus, and Myf6-driven Cre ex-
pression. This allowed, upon Cre recombination, expres-
sion of PAX3-FOXO1 driven by the PAX3 promoter and
3’ FOXO1 genomic sequences that potentially contain cis-
regulatory elements, a region absent from previous PAX3
knock-in strategies. This was the first animal model that
successfully recapitulated the formation of ARMS, though
at the low frequency of approximately 0.4% (1/228) and
with latency of over 1 year (383 days). However, this fre-
quency was greatly enhanced, and latency greatly reduced,
in homozygote PAX3P3Fa/P3Fa mice also lacking Trp53 or
Figure 2 Review summary: Fusion gene regulated genes contributing to alveolar rhabdomyosarcoma. Rhabdomyosarcoma develops from an
unknown cell of origin from the mesodermal lineage that may be skeletal muscle specified. This cell likely expresses both PAX3/7 and FOXO1
and may also express Myf6. A gene fusion event resulting in a PAX3/7 DNA-binding domain fused to a more potent transcriptional activation
domain occurs. This fusion transcription factor is capable of inducing a group of PAX3-FOXO1-regulated genes that contribute to ARMS
development in conjunction with oth r genetic lesions.
Marshall and Grosveld Skeletal Muscle 2012, 2:25 Page 9 of 14
http://www.skeletalmusclejournal.com/content/2/1/25
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Fig.	   10.	  Pathways	   altered	   in	   rhabdomyosarcoma.	  Model	   is	   based	  on	  genomic	   landscapes	   generated	  based	  on	  whole	  exome	  and	  whole	  genome	  sequencing.	  Alteration	  type	  and	  frequency	  of	  individual	  genes	  are	  depicted.	  CNA,	  copy	  number	  deletions	  and	  amplifications	  (Shern	  et	  al.,	  2014).	  
Fusion	  positive	  and	  negative	  tumors	  further	  share	  the	  common	  phenotype	  of	  impaired	  terminal	   differentiation,	   which	   is	   predominantly	   but	   not	   only	   mediated	   through	  suppressed	   activity	   of	   the	  myogenic	   transcription	   factor	  MYOD	   resulting	   in	   reduced	  expression	   of	   the	   muscle	   differentiation	   factor	   myogenin	   and	   the	   muscle	   specific	  differentiation	   mediator	   miR-­‐206	   (Keller	   and	   Guttridge,	   2013).	   In	   eRMS,	   MYOD	  binding	  to	  E-­‐box	  proteins	  is	  competed	  by	  musculin	  (Keller	  and	  Guttridge,	  2013;	  Yang	  et	   al.,	   2009).	   In	   aRMS,	   myogenin	   transcription	   is	   epigenetically	   blocked	   by	   direct	  binding	  of	  the	  histone	  methyltransferase	  KMT1A	  to	  MYOD	  and	  by	  repression	  through	  the	   fusion	  target	  gene	   JARID2	   in	  complex	  with	  PRC2	  (Lee	  et	  al.,	  2011;	  Walters	  et	  al.,	  2014).	  Moreover,	  inhibition	  of	  MYOD	  target	  gene	  expression	  by	  PAX3-­‐FOXO1	  has	  been	  proposed	   as	   PAX3-­‐FOXO1	   expression	   diminished	   occupation	   of	   the	   myogenin	  promoter	  by	  RNA	  polymerase	  II	  and	  reduced	  histone	  H4	  acetylation	  (Calhabeu	  et	  al.,	  2013).	   In	   addition,	   fusion	   target	   genes	   including	   FGFR4,	   IGF1R	   and	   MET	   further	  support	  proliferation	  while	  inhibiting	  differentiation	  (Keller	  and	  Guttridge,	  2013).	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Our data demonstrate that most commonly the cooperating 
event is due to genetic amplification (such as MYCN, CDK4, 
and MIR-17-92) or deletion (CDKN2A, LOH of Chr11p15.5), 
and only in rare cases can an additional candidate somatic 
driver mutation be nominated. In contrast, fusion-negative 
tumors seem to have accumulated a higher degree of aneu-
ploidy and mutational burden at the time of clinical pres-
entation.
Despite the relatively low mutation rate, rhabdomyosa-
rcoma tumors do harbor a significant array of alterations, 
including chromosomal rearrangement, amplification, dele-
tion, and mutation of recurrent drivers and novel candidate 
therapeutic targe s. Many of the genetic alteratio s identified 
in this study, including FGFR4, IGF1R, PDGFRA, ERBB2/4, 
MET, MDM2, CDK4, and PIK3CA, are targeted by approved 
or late-stage therapeutics that could immediately inform 
clinical trials in rhabdomyosarcoma (Fig. 7). In this study, 
we found that the RAS pathway (including FGFR4, RAS, NF1, 
and PIK3CA) is mutationally activated in at least 45% of PFN 
tumors. Although directly targeting constitutively active RAS 
remains challenging, the recent success of the MAP–ERK 
kinase 1/2 (MEK1/2) inhibitor trametinib in melanomas 
with mutated NRAS demonstrates the utility of inhibiting the 
effector pathways altered by the mutation (38). Early preclini-
cal evidence has found efficacy of this method in rhabdomy-
osarcoma (39), and further efforts to precisely dissect the RAS 
effector pathways that are critical in rhabdomyosarcoma are 
currently under way.
A novel finding in this study is the discovery of recurrent 
mutations in BCOR affecting 7.4% of PFN tumors. BCOR is a 
transcriptional repressor that has been shown to interact with 
both class I and II histone deacetylases (40), and somatic muta-
tions in BCOR have been described in other pediatric tumors 
including acute myeloid leukemia (32), retinoblastoma (33), 
and medulloblastoma (34). Our discovery of its recurrent 
alteration in rhabdomyosarcoma reinforces this chromatin 
modifier (41) as a potential therapeutic target. Further func-
tional validation of the discovered mutations in BCOR, FBXW7, 
ARID1A, ZNF350, TRPC4AP, and others may provide targets 
for novel treatments in patients with rhabdomyosarcoma. 
Figure 7. Model pathway altered in rhabdomyosarcoma. Genes colored red are found in fusion-positive tumors, whereas genes colored blue are found 
in tumors without a PAX gene fusion. Alterations and their frequency in the population include mutations and small indels (M), copy number deletions and 









































































on January 27, 2014. © 2014 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst January 16, 2014; DOI: 10.1158/2159-8290.CD-13-0639 
	   26	  
Beyond	   its	   central	   role	   in	   oncogenic	   transformation	   and	   tumorigenesis,	   the	   fusion	  protein	  is	  also	  indispensable	  for	  maintenance	  of	  fusion	  positive	  tumor	  cells.	  	  Depletion	  of	  PAX3-­‐FOXO1	  leads	  to	  decreased	  proliferation,	  impaired	  motility,	  reduced	  invasion,	  and	   enhanced	   myogenic	   differentiation	   (Kikuchi	   et	   al.,	   2008).	   Furthermore,	   it	   is	  essential	  for	  tumor	  cell	  survival	  as	  its	  inhibition	  induces	  apoptosis	  (Bernasconi	  et	  al.,	  1996;	  Ebauer	  et	  al.,	  2007).	  Summarizing	  all	   these	  facts,	   fusion	  protein	  function	  is	  mimicking	  different	  malignant	  abnormalities	   also	   found	   in	   eRMS.	   Importantly,	   translocation	   negative	   RMS	   tumors	  that	  have	  traditionally	  been	  classified	  as	  aRMS	  by	  histological	  features	  clustered	  with	  eRMS	  tumors	  when	  comparing	  genetic	  landscapes.	  Thus,	  genetic	  data	  suggest	  that	  the	  fusion	   protein	   status	   is	  more	   accurate	   for	   classification	   of	   rhabdomyosarcoma	   than	  histology.	  
4.3.4 Regulation	  of	  PAX3-­‐FOXO1	  
Heterogeneity	   in	   Pax3-­‐Foxo1	   expression	   in	   primary	   and	   metastatic	   tumors	   of	   a	  genetically	  engineered	  conditional	  knock-­‐in	  aRMS	  mouse	  model	  suggested	  that	  Pax3-­‐Foxo1	   is	   temporally	   regulated	   in	   a	   cell	   cycle	   dependent	  manner.	   Indeed,	   a	   dynamic	  regulation	  with	  an	  enhanced	  expression	  of	  mRNA	  and	  protein	  in	  G2,	  but	  not	  M	  phase,	  could	   be	   shown	   for	  mouse	   as	  well	   as	   human	   aRMS	   cells	   indicating	   its	   regulation	   at	  transcriptional	   level	   (Kikuchi	   et	   al.,	   2014).	   Furthermore,	   genome-­‐wide	   expression	  analysis	   of	   2N	   and	   4N	   sorted	   cells,	   before	   and	   after	   Pax3-­‐Foxo1	   depletion,	   revealed	  several	   G2/M	   checkpoint	   adaptation	   genes	   including	   Plk1,	   Cdc25b,	   H2afx,	   and	  survivin	   to	   be	   downregulated	   upon	   knockdown	   of	   the	   fusion	   protein.	   In	   addition,	  radiation	   led	   to	   a	   higher	   percentage	   of	   DNA	   double-­‐strand	   breaks	   in	   Pax3-­‐Foxo1	  expressing	  mitotic	   cells	   and	   lower	   induction	   of	   apoptosis	   indicating	   that	   the	   fusion	  protein	   facilitates	   G2/M	   transition	   before	   DNA	   damage	   repair	   is	   completed.	  Consequent	   genomic	   instability	   and	   aneuploidy	   due	   to	   checkpoint	   adaptation	   are	  strategies	  of	  tumor	  cell	  survival	  (Kikuchi	  et	  al.,	  2014).	  	  As	  a	  principle	  of	  cell	  cycle	  progression	  proteins	  become	  posttranslationally	  modified	  and	   are	   controlled	   by	   the	   interplay	   of	   phosphorylation,	   dephosphorylation,	  ubiquitination,	   and	   subsequent	   proteolytic	   cleavage	   by	   the	   26S	   proteasome.	   For	   its	  dynamic	  cell	  cycle	  regulation,	  also	  PAX3-­‐FOXO1	  might	  be	  actively	  degraded.	   	  Roeb	  et	  al.	   demonstrated	   ubiquitination	   of	   PAX3-­‐FOXO1	   and	   therefore	   its	   subjection	   to	  proteasomal	   degradation	   (Roeb	   et	   al.,	   2007).	   Surprisingly,	   this	   even	   caused	   co-­‐
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degradation	   of	   its	   binding	   partner	   EGR1	   leading	   to	   impaired	   expression	   of	   the	   cell	  cycle	  regulators	  p57KIP2	  as	  well	  as	  p21	  and	  thus	  to	  maintenance	  of	  cell	  proliferation	  of	  myoblasts	  and	  interruption	  of	  myogenic	  differentiation	  (Hecker	  et	  al.,	  2010;	  Roeb	  et	  al.,	  2007;	  Roeb	  et	  al.,	  2008).	  These	  studies	  revealed	  a	  novel	   functional	  mechanism	  of	  PAX3-­‐FOXO1	   next	   to	   its	   role	   as	   transcription	   factor.	   Hence,	   it	   is	   likely	   that	   PAX3-­‐FOXO1	  also	  targets	  additional	   interaction	  partners	  by	  this	  mechanism.	  In	  conclusion,	  PAX3-­‐FOXO1	   is	   not	   just	   regulated	  during	   cell	   cycle	   but	   it	   actually	   actively	   overrides	  cell	  cycle	  checkpoints.	  Phosphorylation	  can	  modulate	  different	  biological	  processes	  like	  cellular	  localization,	  enzymatic	   activation	   or	   repression	   in	   cellular	   signal	   transduction,	   transactivation	   of	  transcription	   factors,	   DNA	   binding,	   protein-­‐protein	   interaction,	   stabilization	   or	  degradation	  to	  mediate	  cell	  cycle	  progression,	  growth,	  cell	  death,	  and	  differentiation.	  In	   PAX3-­‐FOXO1,	   phosphorylation	   was	   identified	   at	   least	   at	   four	   out	   of	   six	   serines	  (S187,	   S193,	   S197,	   S201,	   S205	   and	   S209)	   within	   the	   octapeptide	   region	   triggering	  DNA	   binding	   to	   mediate	   transcriptional	   activation.	   Moreover,	   PKC412,	   a	   broad-­‐spectrum	  kinase	   inhibitor,	  demonstrated	   reduction	  of	   transcriptional	  activity.	   It	  was	  suggested	   that	   these	   phospho-­‐sites	   work	   in	   concert,	   as	   only	   a	   combination	   of	  mutations	   at	   several	   of	   these	   sites	   was	   sufficient	   to	   partially	   rescue	   the	   inhibitory	  effect	  of	  PKC412	  (Amstutz	  et	  al.,	  2008).	  PKC,	  represented	  within	  the	  target	  profile	  of	  PKC412,	  was	  discussed	  as	  one	  of	  the	  potential	  upstream	  kinases	  since	  its	  influence	  on	  PAX3	  activity	  has	  also	  been	  shown	  in	  presomitic	  mesoderm	  (Fig.	  11)	  (Brunelli	  et	  al.,	  2007).	  
	  
Fig.	   11.	   Phosphorylation	   sites	   in	   PAX3.	   Localizations	   of	   phospho-­‐sites	   as	   identified	   by	   mass	  spectrometry	  of	  PAX3	  are	  schematically	  illustrated.	  FKHR	  =	  FOXO1.	  Adapted	  from	  (Amstutz	  et	  al.,	  2008).	  
results suggest that PKC412 affects the posttranslational modifica-
tion of PAX3.
To test whether phosphorylation directly affects PAX3/FKHR
activity, we mutated the six serine residues individually into
aspartate to mimic phosphorylation. However, these single
mutations did not affect sensitivity of PAX3/FKHR toward
PKC412 (data not shown). Instead, mutation of all six serine
residues together into aspartate (PAX3/FKHR 6!D) rescued, at
least partially, transcriptional activity of PAX3/FKHR (Fig. 5B, left).
As expressed protein levels of wild-type (wt) and mutated protein
were similar (Fig. 5B, right), this suggests involvement of more than
one of these sites in regulation of PAX3/FKHR activity. Additional
mutation of S180 into aspartate (PAX3/FKHR 7!D) did not lead to
a significant further increase in rescue (Fig. 5B), whereas mutation
of S222 led to complete loss of transactivation activity (data not
shown). In accordance with the behavior of the aspartate mutants,
also single loss-of-function mutations of the six serine residues into
alanine did not affect transactivation potencies (data not shown),
whereas multiple mutations decreased transactivation activity as
measured in transactivation assays using the 6!CD19 reporter
plasmid up to f50% (Fig. 5C).
To test whether these phosphorylation sites are involved in
regulation of PAX3 DNA binding, we treated nuclear extracts of
293T cells transfected with wt NterPAX3His or NterPAX3His 7!D
with CIP. EMSA experiments showed that, in contrast to wt
NterPAX3His, DNA binding of the mutant NterPAX3His 7!D to
Figure 4. The PAX3 part of PAX3/FKHR is phosphorylated in vivo. A, immunofluorescent detection of NterPAX3His with an a-Tetra-His antibody in transfected 293T
cells cultivated in the presence or absence of 10 Amol/L PKC412 for 24 h. B, top, phosphorimager detection of 32P (left) and a-Tetra-His immunodetection (right )
of Western blotted NterPAX3His protein purified from 32P-labeled 293T cells ectopically expressing NterPAX3His (right lanes ). Left lanes, mock-transfected cells were
processed as control. Bottom, silver-stained two-dimensional gel of NterPAX3His protein purified from 293T cells (upper ) and a-Tetra-His immunodetection of a
blotted two-dimensional gel of the same protein (lower ). C, EMSA of purified NterPAX3His protein (lanes 1–3) and nuclear extract of control-transfected (lane 4) or
NterPAX3His-transfected (lanes 5–10) 293T cells with oligos containing a homeodomain-binding (lanes 1–7 ) or a paired domain–binding (lanes 8–10) site.
Protein samples used for EMSA were preincubated with CIP buffer alone (lanes 1, 5 , and 8), CIP (lanes 2, 6 , and 9), or CIP in the presence of phosphatase inhibitors
(lanes 3, 7 , and 10), respectively. D, top left, MALDI-TOF mass spectrum of the peptide 186 to 216 of PAX3. NterPAX3His was purified from NterPAX3His-transfected
293T cells and digested by Lys C. Resulting peptides were isolated by chromatography and investigated for phosphorylation by MALDI-TOF-MS. 2P, 3P, and 4P
assign peaks of the 2-, 3-, and 4-fold phosphorylated peptide, respectively. Top right, schematic representation of the domain structure of PAX3 depicting the
localization of the identified phosphorylation sites in PAX3. Bottom, alignment of the PAX3 protein sequences from the indicated species in the region with identified
phosphorylation sites. Potential phosphorylation sites conserved among all four species (S187, S201, S205, and S209) are indicated.
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Phosphorylation	   of	   wild	   type	   Pax3	   was	   confirmed	   in	   a	   series	   of	   further	   studies	  showing	   phosphorylation	   of	   S205	   in	   proliferating	   mouse	   myoblasts,	   whereas	  phosphorylation	   of	   S201	   and	   S209	   was	   demonstrated	   during	   early	   myogenic	  differentiation.	  In	  these	  studies	  GSK3β	  and	  CK2	  were	  proposed	  as	  potential	  upstream	  kinases.	  Accordingly,	  also	  phosphorylation	  of	  PAX3-­‐FOXO1	  at	  S201	  and	  S205,	  but	  not	  S209,	  could	  be	  observed	  in	  proliferating	  as	  well	  as	  differentiating	  myoblasts	  (Fig.	  12)	  (Dietz	  et	  al.,	  2009;	  Dietz	  et	  al.,	  2011;	  Iyengar	  et	  al.,	  2012;	  Miller	  et	  al.,	  2008).	  
	  
Fig.	  12.	  Model	  for	  sequential	  phosphorylation	  events	  in	  Pax3	  (A)	  and	  Pax3-­‐FOXO1	  (B)	  during	  early	  
myogenic	  differentiation	  (Dietz	  et	  al.,	  2011).	  
944 K.N. Dietz et al. / The International Journal of Biochemistry & Cell Biology 43 (2011) 936–945
Fig. 7. Schematic of a model for the phosphorylation of (A) Pax3 and (B) Pax3-FOXO1 throughout early myogenic differentiation.
whether the altered phosphorylation status of Pax3-FOXO1 causes
the inability of the cells to termi ally differentiate. Several lines
of evidence indicate that the latter situation is the case. We previ-
ously demonstrated that when induced to differentiate, primary
myoblasts stably expressing Pax3-FOXO1 were unable to termi-
nally differentiate to form multi-nucleated myotubes. However,
these cells had entered the differentiation program, were capable
of expressing the latemyogenicmarkermyosin heavy chain (Miller
and Hollenbach, 2007), and were no longer proliferating (data not
shown). This fact demonstrates that under the conditions of the
experiment used in the present work the cells stably expressing
Pax3-FOXO1are in fact inanon-proliferative stateandhaveentered
the differentiation program. Therefore, since the fusion protein
is in a differentiating and not proliferative environment, these
results support the idea that the aberrant phosphorylation status
of Pax3-FOXO1 maintains the fusion protein in a phosphorylation
state prominent only in proliferating cells, thereby promoting the
aberrant expression of genes that subsequently inhibit terminal
differentiation to contribute to the development of ARMS.
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Also	  Zeng	  et	  al.	  (2010)	  reported	  that	  GSK3	  phosphorylates	  the	  fusion	  protein	  in	  vitro	  and	  that	   its	   inhibition	  by	  TWS119	  or	  knockdown	  of	  either	  GSK3α	  or	  GSK3β	  reduced	  transcriptional	   activity	   of	   PAX3-­‐FOXO1.	   However,	   specific	   sites	   have	   not	   been	  addressed	  in	  this	  study.	  	  Furthermore,	  a	  small	  molecule	  library	  screen	  identified	  the	  compound	  fascaplysin,	  an	  inhibitor	   of	   CDK4/cyclin	   D1,	   to	   suppress	   PAX3-­‐FOXO1	   activity	   by	   increasing	   its	  cytoplasmic	   levels	   while	   total	   protein	   levels	   were	   not	   affected.	   Accordingly,	   CDK4	  directly	  phosphorylated	  the	  fusion	  protein	  at	  S430	  in	  vitro	  and	  enhanced	  PAX3-­‐FOXO1	  activity.	  	  However,	  additional	  CDK4	  sites	  have	  been	  proposed,	  as	  mutation	  of	  this	  one	  site	  did	  not	  fully	  abolish	  phosphorylation	  by	  CDK4	  (Liu	  et	  al.,	  2013).	  This	  is	  of	  special	  interest	  as	  gain	  of	  CDK4	  was	  one	  of	   the	   few	  mutations	  observed	   in	  sequenced	  aRMS	  tumors	  and	  loss	  of	  Ink4a/Arf	  locus,	  leading	  to	  activation	  of	  the	  Cdk4	  pathway,	  together	  with	   PAX3-­‐FOXO1	   expression	   induced	   in	   vivo	   tumor	   formation	   (Keller	   et	   al.,	   2004;	  Shern	  et	  al.,	  2014).	  The	   role	   of	   phosphorylation	   by	   AKT	   is	   complex	   and	   remains	   controversial.	   AKT	  activation	   in	   aRMS	  was	   reported	   to	   correlate	  with	  poor	  prognosis	   (Cen	   et	   al.,	   2007;	  Guenther	  et	  al.,	  2013;	  Petricoin	  et	  al.,	  2007).	  On	  the	  one	  hand,	   its	  attenuated	  activity	  sustained	   PAX3-­‐FOXO1	   transactivation,	   whereas	   on	   the	   other	   hand,	   differentiation	  dependent	  hyperactivation	  of	  AKT	   inhibited	  PAX3-­‐FOXO1	  by	  phosphorylation	  under	  differentiation-­‐permissible	   conditions	   and	   therefore	   blocked	   terminal	   myogenic	  differentiation	   by	   suppressing	  MyoD	   expression	   (Jothi	   et	   al.,	   2012).	   Thus,	   AKT	  was	  suggested	   to	   balance	   fusion	   protein	   activity	   (Jothi	   and	   Mal,	   2012).	   Interestingly,	  thapsigargin,	   a	   sarco-­‐/endoplasmic	   reticulum	  Ca2+	  ATPase	   inhibitor,	   induced	  AKT	   to	  phosphorylate	   the	   fusion	   protein	   by	   affecting	   intracellular	   Ca2+	   levels.	   This	  phosphorylation	   in	   turn	   inhibited	   DNA	   binding	   of	   PAX3-­‐FOXO1	   and	   subsequently	  induced	   its	   proteasomal	   degradation	   supporting	   an	   inhibitory	   function	   of	   AKT	  phosphorylation	  (Jothi	  et	  al.,	  2013).	  However,	   the	  exact	  mechanism	  of	  this	   inhibition	  remains	   unclear.	   One	   possibility	   is	   that	   the	   inhibition	   is	   directly	   mediated	   by	  phosphorylation	  of	   the	   two	  AKT	  consensus	  sites	  S437	  and	  S500	  but	  also	  an	   indirect	  effect	   was	   suggested,	   for	   example	   through	   blockade	   of	   downstream	   GSK3	   reducing	  PAX3-­‐FOXO1	  transactivation	  (Jothi	  et	  al.,	  2013).	  In	   summary,	   regulation	   of	   PAX3-­‐FOXO1	   by	   phosphorylation	   is	   highly	   complex	   and	  probably	  dynamic,	  also	  depending	  on	  cell	  cycle	  and	  myogenic	  differentiation	  state.	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4.4 Polo-­‐like	  kinase	  1	  	  
4.4.1 PLK	  family	  and	  structure	  
The	  PLK	  family	  is	  comprised	  of	  five	  serine/threonine	  kinases	  (PLK1	  -­‐	  PLK5)	  with	  key	  roles	   in	  cell	  cycle	  control.	  PLK1	  and	  PLK4	  are	  widely	  considered	  as	  oncogenes	  while	  PLK2,	   PLK3	   and	   PLK5	   are	   primarily	   linked	   to	   tumor	   suppressive	   functions	   mainly	  involved	   in	   replication	   checkpoint	   signaling,	   DNA	   damage	   response	   signaling	   and	  apoptosis	   induction.	   Interestingly,	   compensatory	   balances	   of	   different	   family	  members	   have	   been	   described,	   which	   might	   be	   based	   on	   their	   highly	   homologous	  features	  (Craig	  et	  al.,	  2014;	  Mason	  et	  al.,	  2014).	  PLK1	  -­‐	  PLK4	  are	  characterized	  by	  an	  N-­‐terminal	  kinase	  domain,	  which	  is	  truncated	  in	  PLK5.	  In	  addition,	  PLK1,	  PLK2,	  PLK3	  and	  PLK5	  possess	  two	  polo-­‐box	  binding	  domains	  (PBD)	   functioning	   as	   phospho-­‐recognition	   modules	   necessary	   for	   protein-­‐protein	  interactions	   and	   subcellular	   localization,	   whereas	   the	   cryptic	   PBD	   domain	   of	   PLK4	  forms	  homodimers	  (Fig.	  13)	  (Lee	  et	  al.,	  2014).	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4.4.2 Regulation	  and	  functions	  of	  PLK1	  
PLK1	   is	   regulated	   in	   a	   temporal	  but	   also	   in	   a	   spatial	  manner.	   It	   is	  mainly	   expressed	  starting	   at	   late	   S	   phase	   and	   peaking	   in	   G2/M	   phase.	   p53,	   p21,	   RB,	   E2F,	   and	   the	  CDE/CHR	   element	   (cell	   cycle	   dependent	   element/cell	   cycle	   gene	   homology	   region	  element)	   repress	   PLK1	   expression,	   whereas	   FOXM1	   induces	   its	   transcription.	  Interestingly,	  a	  positive	  feedback	  loop	  exists,	  as	  PLK1	  itself	  is	  able	  to	  activate	  FOXM1.	  Furthermore,	  PLK1	  is	  activated	  by	  T-­‐loop	  phosphorylation	  at	  T210	  by	  Aurora	  A/BORA	  or	  by	  Aurora	  B	  to	  relieve	  the	  suppressive	  interaction	  of	  polo-­‐box	  binding	  domain	  and	  kinase	  domain	  (Archambault	  and	  Glover,	  2009).	  PI3K/Akt	  dependent	  phosphorylation	  at	  S99	  for	  14-­‐3-­‐3γ	  binding	   is	  required	  for	  metaphase/anaphase	  transition	  (Kasahara	  et	   al.,	   2013).	   The	   polo-­‐box	   binding	   domain	   is	   responsible	   for	   binding	   of	   interaction	  partners	  primed	  at	  consensus	  recognition	  motifs	  by	  proline-­‐directed	  kinases	  such	  as	  CDKs	  or	  by	  self-­‐priming.	  Substrate	  binding	  might	  further	  enhance	  kinase	  activity.	  On	  the	   contrary,	   deactivation	   is	   probably	   mediated	   by	   protein	   phosphatase	   1	   (PP1).	  Further	   inactivation	  is	  achieved	  by	  cell	  cycle	  dependent	  proteolysis	   in	   late	  M	  and	  G1	  phase	   after	   ubiquitination	   by	   the	   E3	   ligase	   APCCdh1	   (Cdh1	   activated	   anaphase	  promoting	   complex)	   for	   degradation	   via	   the	   26S	   proteasome	   (Archambault	   and	  Glover,	  2009).	  	  Mouse	   models	   have	   been	   generated	   to	   investigate	   Plk1	   function.	   Homozygous	  knockout	  (Plk1-­‐/-­‐)	  embryos	  were	  not	  viable	  and	  did	  not	  develop	  beyond	  the	  eight-­‐cell	  stage	   indicating	   vital	   Plk1	   functions	   during	   very	   early	   development.	   Plk1+/-­‐	   mice	  developed	   lymphomas	   and	   pulmonary	   carcinomas	   suggesting	   that	   Plk1	  haploinsufficiency	   might	   promote	   tumorigenesis.	   However,	   the	   sample	   size	   of	   this	  study	  was	  very	  small	  and	  Plk1	  status	  has	  not	  been	  determined	  (Craig	  et	  al.,	  2014;	  Lu	  et	  al.,	  2008).	  A	  more	  recent	  study	  by	  Raab	  et	  al.	  (2011)	  used	  an	  inducible	  RNAi	  system	  to	  knockdown	   Plk1	   in	   vivo	   resulting	   in	   no	   significant	   phenotypic	   consequences.	  Nevertheless,	   teratomas	   formed	   by	   embryonic	   stem	   cells	   in	   which	   Plk1	   has	   been	  depleted	  were	  significantly	  smaller	  than	  those	  formed	  by	  control	  embryonic	  stem	  cells	  indicating	  that	  Plk1	  depletion	  inhibits	  tumor	  growth	  in	  vivo	  (Raab	  et	  al.,	  2011).	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4.4.3 PLK1	  as	  cell	  cycle	  regulator	  






Fig.	  14.	  Key	  functions	  of	  PLK1	  in	  cell	  cycle	  regulation	  (Schoffski,	  2009).	  
PLK1	  is	  involved	  in	  centrosome	  maturation	  by	  taking	  over	  the	  function	  of	  ninein-­‐like	  protein	   (NLP)	   in	   prophase	   to	   recruit	   the	   γ-­‐tubulin	   ring	   complex	   (γ-­‐TuRC)	   to	  centrosomes	   for	   microtubule	   nucleation.	   Furthermore,	   it	   phosphorylates	   kizuna	  suggested	   to	   function	   in	  mitotic	   centrosome	   architecture	   and	   localizes	   Aurora	   A	   to	  centrosomes	  (Fig.	  15A).	  Before	  mitosis,	  CDK1	  is	  phosphorylated	  by	  WEE1	  and	  MYT1	  to	  keep	  it	  inactive.	  	  PLK1	  then	  induces	  mitotic	  entry	  by	  phosphorylating	  and	  activating	  the	   counteracting	   phosphatase	   CDC25	   as	   well	   as	   by	   inhibiting	  WEE1	   and	  MYT1.	   In	  addition,	   it	   also	   phosphorylates	   cyclin	   B1	   promoting	   full	   activity	   of	   CDK1/cyclin	   B1	  (Fig.	  15B)	  (Strebhardt,	  2010).	  Also	  RNAi	  and	  PLK1	  inhibitor	  studies	  indicate	  that	  PLK1	  activity	  is	  important	  but	  not	  essential	  for	  mitotic	  entry	  while	  it	  is	  absolutely	  essential	  for	  mitotic	  progression	  (Lenart	  et	  al.,	  2007;	  van	  Vugt	  et	  al.,	  2004).	  PLK1	  depletion	  was	  thyroid cancer, ovarian cancer, head and neck cancer, non-Hodgkin’s lymphomas [NHLs]) [4 – 6, 17–19]. Overex-
pression is associated with a poor prognosis in several
tumor types and a lower overall survival rate [6, 20, 21]. In
vitro and in vivo data suggest that PLK1 overexpression
could also be involved in carcinogenesis [4–6, 17–21].
PLK2 is a centrosomal kinase involved in centriole du-
plication, and PLK2 inhibition is associated with a decrease
in cellular proliferation [22].
Increased PLK3 activity, during G2–M transition, oc-
curs in response to DNA damage, and overexpression of
PLK3 induces a decrease in chromatin condensation and
apoptosis [22]. However, in some cancer tissues, PLK3 ex-
pression levels are decrease [22].
PLK4 is necessary for proper centriole duplication, with
PLK4 mRNA levels that are low in G1 and begin to rise
through S and G2, peaking during mitosis [22]. Silencing of
PLK4 results in disorganized mitotic spindles and apoptosis
[22]. Overexpression of PLK4 leads to multiple centrosome
formation [22].
PLK Inhibition and Polo Arrest
In vitro, Plk1 depletion in cancer cells dramatically in-
hibits cell proliferation and decreases viability [23]. De-
Figure 2. Schematic diagrams of Polo-like kinase (PLK)1 regulation of the cell cycle (A) and PLK1 inhibition (B), showing the
characteristic Polo arrest phenotype [5, 6, 16].
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shown	   to	   arrest	   cells	   in	   prometaphase.	   The	   metaphase/anaphase	   transition	   is	  controlled	  by	  the	  ubiquitin	  ligase	  anaphase	  promoting	  complex	  APC/C,	  which	  is	  kept	  in	   an	   inactive	   state	   until	   all	   chromosomes	   are	   properly	   aligned	   and	  kinetochors	   are	  bipolarly	   attached	   in	   metaphase.	   On	   the	   one	   hand,	   PLK1	   phosphorylates	   the	   SA2	  subunit	   of	   cohesin,	   a	  multi-­‐protein	   ring	   complex	   surrounding	   the	   sister	   chromatids	  while	   shugoshin	   1	   and	   protein	   phosphatase	   2A	   (PP2A)	   still	   protect	   them	   from	  separation.	   On	   the	   other	   hand,	   mitotic	   progression	   is	   guaranteed	   by	   activation	   of	  APC/C	  through	  PLK1	  dependent	  phosphorylation	  of	  EMI1.	   	  Like	  this,	  PLK1	  promotes	  the	   cleavage	   of	   cohesion	   protein	   1	   subunit	   (SCC1)	   by	   separase	   resulting	   in	   sister	  chromatid	   segregation	   (Fig.	   15C).	   	   Finally,	   PLK1	   is	   also	   involved	   in	  mitotic	   exit	   and	  cytokinesis.	   PLK1	   phosphorylates	   and	   docks	   to	   MKLP2	   and	   PRC1	   localized	   at	   the	  spindle	  midzone	   in	   between	   the	   sister	   chromatids.	   This	   enables	   it	   to	   phosphorylate	  the	  Rho	  GTPase-­‐activating	  protein	  HsCYK4	   for	   recruitment	  of	   the	   rho	  GTP	  exchange	  factor	   ECT2	   leading	   to	   assembly	   of	   the	   contractile	   ring	   and	   the	   generation	   of	   the	  cleavage	  furrow	  (Fig.	  15D)	  (Chopra	  et	  al.,	  2010;	  Strebhardt,	  2010).	  	  Interestingly,	   in	   cancer	   cells	   PLK1	   is	   also	   significantly	   expressed	   during	   interphase	  suggesting	  additional	  cell	  cycle	  functions.	  Indeed,	   it	  becomes	  more	  and	  more	  evident	  that	  PLK1	  is	  also	  implicated	  in	  G1/S	  transition	  and	  DNA	  replication	  as	  well	  as	  in	  stress	  response	   to	   DNA	   damage	   in	   cancer	   cells	   (Cholewa	   et	   al.,	   2013).	   E2F	   regulates	   the	  transcription	   of	   cell	   cycle	   control	   and	  DNA	   synthesis	   genes	   such	   as	   PLK1.	   Frequent	  deregulation	   of	   E2F	   is	   associated	   with	   carcinogenesis	   and	   might	   cause	   PLK1	  overexpression.	  PLK1	  in	  turn	  promotes	  DNA	  replication	  under	  stress	  conditions	  in	  the	  presence	   of	   DNA	   damage	   by	   phosphorylation	   of	   ORC2	   and	   therefore	   mediates	  checkpoint	  adaptation	  in	  S-­‐phase	  potentially	  causing	  genomic	  instability	  (Cholewa	  et	  al.,	  2013).	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Fig.	  15.	  Mitotic	  functions	  and	  targets	  of	  PLK1	  (Strebhardt,	  2010).	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The observation of monopolar spindles in Drosophila melanogaster cells 
carrying a polo mutation1 and in cultured human cells with disrupted 
PLK113 suggested that PLK1 is essential for centrosome functions and  
the assembly of bipolar spindles (see the figure, part a). One of these 
functions is the recruitment of the γ-tubulin ring complex (γ-TuRC), 
which can nucleate new microtubules, to centrosomes during 
prophase13. Ninein-like protein (NLP), a component of the centrosome, 
recruits γ-TuRC and stimulates microtubule nucleation during 
interphase231. PLK1 phosphorylates NLP, leading to its dissociation  
from other centrosomal proteins.
Overexpression of an NLP mutant lacking PLK1 phosphorylation sites 
induces defects in mitotic spindle formation231. At the onset of mitosis, 
PLK1-mediated phosphorylation of NLP inhibits the dynein–dynactin-
dependent targeting of NLP to the centrosome. This could represent a 
crucial step in the maturation process, which allows the centrosome to 
switch from the interphasic state to the mitotic state231,232. Centrioles 
organize pericentriolar material (PCM) to form centrosomes. The 
depletion of the centrosomal PLK1 substrate kizuna or the inhibition of 
kizuna phosphorylation by PLK1 causes fragmentation and dissociation 
of the PCM from centrioles at prometaphase, resulting in multipolar 
spindles and suggesting that kizuna is essential for the mitotic 
centrosome architecture233. PLK1 also controls the localization of the 
kinase Aurora A, which has a vital role in the function and the maturation 
of centrosomes172,234.
G2/M transition
The complex of cyclin-dependent kinase 1 (CDK1) and cyclin B1, the key 
driver for the entry into M phase, is controlled by an intricate regulatory 
network. On accumulation of cyclin B1 during G2, CDK1–cyclin B1 
complexes form that are kept inactive through the inhibitory 
phosphorylation of CDK1 at Thr14 and Tyr15 by the WEE1 and  
membrane-associated CDK1-inhibitory (MYT1) kinases (see the figure, 
part b). Once the dual-specific phosphatase CDC25 dephosphorylates 
and thereby activates CDK1–cyclin B1, cells enter mitosis. PLK1 seems to 
be part of a regulatory circuit that promotes the activation of CDK1 by 
phosphorylating the positive regulator CDC25 and inhibiting the 
negative regulators WEE1 and MYT1 (REFS 235–238). In addition, cyclin 
B1 is initially phosphorylated at Ser133 on centrosomes in prophase by 
PLK1 (REFS 239,240). Recent data suggest that the activity of PLK1 at 
centrosomes is controlled by protein phosphatase 1C241. However, in 
unperturbed cell divisions PLK1 might control the rate of mitotic entry, 
but it is not essential for this process242.
Kinetochore functions and sister chromatide cohesion
In human cells various proteins (including the polo-box interacting 
protein (PBIB1), the inner centromere protein (INCENP), the spindle 
checkpoint component BUBR1 and the mitotic checkpoint kinase 
BUB1) target PLK1 to the kinetochore/centromere region of 
chromosomes37,243–245. The spindle assembly checkpoint (SAC) delays 
the transition to anaphase until all sister kinetochores experience 
bipolar attachment and are under equal tension (see the figure, part c). 
PLK1 activity is particularly high on non-attached kinetochores 
suggesting a role of PLK1 in kinetochore attachment or in SAC 
regulation246. Sister chromatids of replicated chromosomes are held 
together by a ring-shaped multi-protein complex, cohesin. In 
vertebrates cohesin dissociates from chromosomes in two waves.  
The vast majority is removed by the action of the so-called prophase 
pathway, in which PLK1 phosphorylates the SA2 subunit of cohesin247. 
However, a small centromeric fraction of cohesin is unresponsive to this 
pathway and ensures chromosome pairing until the end of metaphase. 
A centromeric protein complex consisting of protein phosphatase 2A 
(PP2A) and shugoshin 1 protects this subpopulation of cohesin from the 
prophase pathway and there are indications that this might occur by 
antagonizing the activity of PLK1 (REFS 248–250). The E3 ubiquitin 
ligase anaphase-promoting complex/cyclosome (APC/C) and its 
inhibitor EMI1 are also located at the centrosome. In prophase, 
phosphorylation of EMI1 by PLK1 argets EMI1 for destruction251–253.  
The phosphorylation of APC/C subunits by PLK1 may further contribute 
to the activation of the APC/C allowing progression beyond 
prometaphase254,255. One of the many APC/C substrates is securin, 
which binds to and inhibits the protease, separase256. Once activated, 
separase cleaves the mitotic sister chromatid cohesion protein 1 (SCC1) 
subunit of the remaining centromeric cohesin protein complex, and 
sister chromatid separation can finally take place257,258.
Mitotic exit and cytokinesis
The spindle apparatus controls the formation of the cleavage furrow in 
the late stages of mitosis as a prerequisite for the generation of two 
physically distinct daughter cells. The spindle midzone, which is 
situated between the two sets of separated sister chromosomes and 
which represents a bundle of antiparallel microtubule arrays, includes a 
protein complex dubbed centralspindlin. Centralspindlin encompasses 
the Rho GTPase-activating protein HsCYK4 and the kinesin motor 
protein MKLP1 (REFS 259,260) (see the figure, part d). PLK1 
self-organizes onto the central spindle by phosphorylating and docking 
at midzone proteins PRC1 and MKLP2 (REFS 36,38). PLK1 then 
phosphorylates HsCYK4, thereby creating a docking site for the Rho 
GTP exchange factor ECT2 (REF. 261). This mechanism seems to be 
crucial for the assembly of an actomyosin ring at the cell cortex, which 
then constricts through localized activation of the small GTPase RhoA, 
leading to cleavage furrow formation163,262– 264. 
Box 3 | Cellular functions of polo-like kinase 1 (PLK1)
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4.4.4 PLK1	  in	  tumorigenesis	  
Overexpression	   of	   PLK1	   causes	   malignant	   transformation	   of	   human	   fibroblasts	  leading	  to	  tumor	  growth	  when	  engrafted	  in	  nude	  mice,	  thus	  indicating	  a	  pivotal	  role	  in	  carcinogenesis	   (Smith	  et	   al.,	   1997).	  The	   tumorigenic	  potential	  of	  PLK1	  can	  partly	  be	  explained	  by	  deregulation	  of	  the	  cell	  cycle.	  However,	  beyond	  its	  function	  in	  cell	  cycle	  regulation,	  PLK1	  is	  directly	  associated	  with	  all	  three	  cancer	  core	  processes	  and	  eight	  out	  of	  twelve	  cancer	  cell	  signaling	  pathways,	  which	  have	  been	  described	  by	  Vogelstein	  et	   al.	   (2013)	   (Figs.	   2	   and	   16)	   (Cholewa	   et	   al.,	   2013).	   Furthermore,	   several	   studies	  examined	   multiple	   interaction	   mechanisms	   of	   the	   oncogene	   PLK1	   and	   the	   master	  tumor	  suppressor	  p53	  demonstrating	   that	   the	   two	  proteins	  negatively	  regulate	  each	  other.	   p53	   is	   defined	   as	   a	   stress	   response	   gene	   that	   induces	   cell	   cycle	   arrest	   or	  apoptosis.	  Along	   these	   lines,	   p53	   can	   also	   inhibit	   the	   transcription	  of	  PLK1	  and	   it	   is	  speculated	  that	  p53	   loss	  of	   function,	  next	   to	  E2F	  deregulation,	  could	  be	  the	  basis	   for	  PLK1	  overexpression	   in	   cancer.	   In	   addition	  p21,	   a	   transcriptional	   target	   of	   p53,	   can	  mediate	   repression	   via	   the	   CDE	   element	   or	   by	   direct	   binding	   to	   the	  PLK1	   promoter	  during	  oncogene-­‐induced	  senescence.	  Generating	  feedback	  loops,	  also	  PLK1	  is	  able	  to	  repress	   p21	   expression	   and	   to	   control	   the	   activity	   of	   p53.	   First,	   PLK1	   can	   reduce	  transcriptional	   activity	   and	   the	   pro-­‐apoptotic	   function	   of	   p53	   by	   direct	   binding.	  Second,	   PLK1	   activity	   can	   induce	   degradation	   of	   p53	   by	   promoting	   the	   p53-­‐MDM2	  association	  and	  by	  phosphorylation	  of	   the	   topoisomerase	   I	  binding	  protein	   topors,	  a	  combined	   ubiquitin	   and	   SUMO	   E3	   ligase,	   inhibiting	   sumoylation	   while	   enhancing	  ubiquitination	  of	  p53.	  Third,	  PLK1	  phosphorylates	  GTSE1	  leading	  to	  nuclear	  export	  of	  p53	   and	   therefore	   promoting	   its	   proteasomal	   degradation	   during	   DNA	   damage	  recovery	  (Fig.	  16)	  (Cholewa	  et	  al.,	  2013).	  Overall,	  p53	  inactivation	  by	  PLK1	  is	  a	  central	  step	   of	   checkpoint	   termination	   leading	   to	   enhanced	   aneuploidy	   and	   genomic	  instability.	  Further	   studies	   revealed	   an	   active	   function	   of	   PLK1	   in	   invasion	   through	   the	  extracellular	  matrix	  by	  phosphorylation	  of	  vimentin	  regulating	  β1-­‐integrin	  cell	  surface	  levels	   (Rizki	   et	   al.,	   2007).	   In	  addition,	  downregulation	  of	  PLK1	   in	   thyroid	   carcinoma	  cells	  also	  resulted	  in	  downregulation	  of	  metalloproteases	  MMP-­‐2	  and	  MMP-­‐9	  and	  the	  adhesion	  protein	  CD44v6,	  which	  mediate	  cancer	  cell	  invasion	  (Zhang	  et	  al.,	  2012).	  PLK1	   is	   also	   suggested	   to	   protect	   against	   apoptosis	   as	   its	   expression	  was	   shown	   to	  maintain	  levels	  of	  anti-­‐apoptotic	  survivin,	  BCL-­‐2	  and	  MCL1	  (Feng	  et	  al.,	  2009).	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Fig.	  16.	  PLK1	  interactions	  with	  cancer	  associated	  pathways.	  (A)	  PLK1	  is	  involved	  in	  G1/S	  and	  G2/M	  transition,	   and	  DNA	  damage	   control.	   It	   is	   regulated	  by	  multiple	   feedback	   loops.	   (B)	   Summary	  of	   direct	  PLK1	  interactions	  with	  proteins	  associated	  with	  cancer	  promoting	  signaling	  pathways	  and	  core	  cellular	  processes.	  Green,	   transcribed	  by	  oncogenic	  driver	   genes;	   red,	   transcribed	  by	   tumor-­‐suppressive	  driver	  genes	  (Cholewa	  et	  al.,	  2013).	  
4.4.5 PLK1	  as	  cancer	  target	  
PLK1	  was	  found	  to	  be	  overexpressed	   in	  a	  variety	  of	  different	  adult	  solid	  tumors	  and	  leukemias	  as	  well	  as	   in	  pediatric	   tumors	   including	  neuroblastoma,	  medulloblastoma,	  glioblastoma,	  osteosarcoma,	  and	  also	  alveolar	  rhabdomyosarcoma,	  which	  importantly	  has	  been	  shown	  to	  be	  unfavorable	   for	  outcome	  (Ackermann	  et	  al.,	  2011;	  Duan	  et	  al.,	  2010;	  Hu	  et	  al.,	  2009;	  Strebhardt	  and	  Ullrich,	  2006;	  Triscott	  et	  al.,	  2013).	  	  Depletion	  of	  PLK1	  in	  cancer	  cells	  demonstrated	  strong	  effects	  on	  proliferation	  and	  cell	  viability,	  which	  could	  be	  explained	  by	  formation	  of	  mono-­‐polar	  spindles,	  activation	  of	  the	   spindle	   assembly	   checkpoint,	   cell	   cycle	   arrest	   in	   G2/M	   called	   polo	   arrest,	   and	  induction	   of	   apoptosis	   (Liu	   and	   Erikson,	   2003;	   Spankuch-­‐Schmitt	   et	   al.,	   2002a;	  Spankuch-­‐Schmitt	   et	   al.,	   2002b).	   These	   early	   studies	   provided	   the	   basis	   for	  pharmaceutical	   development	   and	   evaluation	   of	   PLK1	   inhibitors.	   Available	   inhibitors	  are	   either	   targeting	   the	   ATP	   binding	   site	   or	   the	   polo-­‐box	   binding	   domain	   and	  demonstrated	   high	   efficacies	   with	   relatively	   good	   specificity	   in	   preclinical	   studies	  (Craig	  et	  al.,	  2014).	  One	  of	  the	  first	  compounds,	  BI	  2536	  has	  been	  tested	  in	  preclinical	  xenograft	  studies	  of	  childhood	  cancer.	  In	  neuroblastoma	  xenografts	  BI	  2536	  abrogated	  tumor	  growth	  and	  
mammalian homolog family of Plks consists of ﬁve described
members, Plk1–5, which are characterized by the presence of
an N-terminal kinase and C-terminal polo-box domain (17, 18).
The Plk family is a group of highly conserved serine/threonine
kinases that is typically associated with cell-cycle progression
and mitosis; however, recent studies have suggested involve-
ment of this kinase family in cancer (reviewed in ref. 19). Plk1
has emerged as a key mitotic regulator and is most commonly
known for being a critical component of centrosome matura-
tion, kinetochore–microtubule attachment, bipolar spindle
formation, and cytokinesis (20–23). However, studies have
rev aled diverse range of biologic functions beyond typical
mitotic events, including Plk10s involvement with p27 and
RhoA, regulatory l ops with the transcription factors FoxM1
and Stat3, extensive interplay with Cdk1, phosphorylation
of p53 family members p63 and p73, as well as a recent
implication in DNA replication (24–32). Furthermore, the
overexpression of Plk1 has been linked to poor disease prog-
nosis and a decreased survival rate, whereas the inhibition of
Plk1 activity has emerged as a promising therapeutic target for
cancer management in the clinical setting (33, 34). The exact
role of Plk1 in carcinogenesis has yet to be determined;
however, preclinical evidence suggests that Plk1 expression
may be necessary for cancer cell survival and is overexpressed
in a variety of cancers, including melanoma, breast, ovarian,
thyroid, colon, prostate, pancreatic, head and neck, non–small
cell lung cancer, and non-Hodgkin lymphomas (35–43).
The cell cycle: ﬁlling in the gaps
The cell cycle is a highly orchestrated progression of
events that culminates in cellular division and the produc-
tion of two daughter cells. Progression through each of the
four main phases, G1 (Gap 1), S (Synthesis), G2 (Gap 2), and
M (mitosis), is tightly regulated through phosphorylation
and ubiquitination events primarily driven by the "master
cell-cycle regulators," cyclins, and cyclin-dependent kinases
(c k). Plk1 xp ession is directly associated with the pro-
gression of these phases, where it begins to accumulate
during the S-phase, peaks at the G2–M transition, plateaus
throughout mitosis, and has a sharp reduction upon mitotic
exit (1). Of note, the expression of Plk1 in cancer cells differs
from that of nontransformed cells in that it localizes to the
nucleus before G2–M and can be easily detected even in the
G1–S phase, suggesting that Plk1 must have cancer cell–
speciﬁc functions in the interphase. This notion is supported
by the observation that Plk1 is indeed involved in the G1–S
transition and DNA replication in cancer cells (44–46). The
nuclear localization of Plk1 during the interphase of cancer
cells has been neglected for a long time in the ﬁeld as one
tends to focus on its classical mitotic functions, but this






























































































Figure 1. Plk1-interacting pathways. Plk1 overexpression and the resulting contribution to aberrant DNA damage control and genomic instability are
accentuated by multiple feedback loops highlighting the interaction of Plk1 with several pathways involved in cell-cycle progression and the DNA damage
response (A); and eight of 12 signaling pathways (middle ring) and all three core cellular processes (outer ring) identiﬁed by Vogelstein and colleagues
(12) to confer a selective growth advantage in cancer (B). Plk1 has a direct interaction with a wide range of proteins (inner ring) that are transcribed
by oncogenic (green) or tumor-suppressive (red) driver genes. Furthermore, Plk1 directly interacts with several proteins that are integral to the described
pathways (orang ; refs. 4–12, 32, 70, 72, 99–104).
Cholewa et al.
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resulted	   in	   steady	   tumor	   volume	   (Ackermann	   et	   al.,	   2011;	   Grinshtein	   et	   al.,	   2011).	  Treatment	  of	  osteosarcoma	  xenografts	   induced	  a	  reduction	  of	   tumor	  volume	  and	  for	  medulloblastoma	   xenografts	   an	   extended	   survival	   was	   observed	   (Liu	   et	   al.,	   2011;	  Triscott	   et	   al.,	   2013).	   The	   studies	   showed	   prevention	   of	   cell	   cycle	   progression	   and	  apoptosis.	  However,	  none	  of	  the	  studies	  demonstrated	  tumor-­‐specific	  mechanisms	  at	  molecular	  level.	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5 Aim	  of	  the	  thesis	  
Oncogenic	  transcription	  factors	  are	  frequently	  mutated	  and	  associated	  with	  aberrant	  gene	   expression	   in	   various	   different	   cancers.	   Thus,	   they	   are	   considered	   promising	  therapeutic	   targets,	   especially	   in	   aRMS,	   which	   represents	   a	   nearly	   perfect	  model	   of	  oncogene	   addiction	   as	   it	   is	   mainly	   driven	   and	   maintained	   by	   the	   chimeric	  transcription	   factor	   PAX3-­‐FOXO1.	   Most	   aRMS	   studies	   concentrated	   rather	   on	  downstream	   functions	   of	   the	   fusion	   protein	   to	   investigate	   its	   functions	   than	   on	  upstream	   regulation.	   Subsequently,	  many	   target	   genes	   have	   been	   characterized	   and	  later	  suggested	  as	   therapeutic	   targets	   in	  aRMS.	  But	  certainly,	   for	   the	  development	  of	  improved	   therapies,	   distinguishing	   downstream	   driver	   pathways	   from	   passenger	  pathways	  remains	  a	   challenge.	  Therefore,	  we	   think	   that	  directly	   targeting	   the	   fusion	  protein	   on	   top	   of	   the	   oncogenic	  machinery	   is	  more	   efficient	   than	   interference	  with	  single	   downstream	   effectors.	   However,	   due	   to	   the	   lack	   of	   enzymatic	   activity,	   deep	  binding	  pockets,	  and	  their	  nuclear	  localization,	  transcription	  factors	  are	  less	  accessible	  to	   small-­‐molecule	   inhibitors	   than	   for	   example	   active	   sites	   of	   kinases.	   Also,	   the	  structure	   of	   PAX3-­‐FOXO1	   has	   not	   been	   resolved	   and	   is	   likely	   to	   be	   intrinsically	  disordered	  impeding	  a	  biochemistry-­‐based	  design	  of	  novel	  compounds.	  Unfortunately,	  cost-­‐intense	   development	   of	   PAX3-­‐FOXO1	   specific	   compounds	   indicated	   for	   a	   rare	  malignancy	   and	   a	   small	   market	   is	   rather	   unlikely,	   especially	   from	   the	   economic	  perspective	   of	   the	   pharmaceutical	   industry.	   To	   circumvent	   the	   pharmacological	  challenge	   of	   direct	   compound	   binding,	   we	   first	   of	   all	   aimed	   at	   identifying	   kinases	  involved	  in	  PAX3-­‐FOXO1	  regulation.	  	  Working	  out	  biological	  processes	  and	  validating	  single	  kinases	  and	  their	  mechanisms	  create	  the	  basis	  for	  a	  model	  of	  the	  fusion	  protein	  regulatory	   environment.	   This	   enables	   the	   rational	   selection	   of	   drug	   targets	   such	   as	  kinases	  associated	  with	  the	  fusion	  protein	  and	  the	  choice	  of	  anti-­‐cancer	  drugs	  that	  are	  developed	  for	  a	  broader	  range	  of	  cancer	  entities	  and	  applicable	  for	  preclinical	  in	  vivo	  treatment	  of	  xenograft	  tumors	  and	  prospective	  clinical	  trials	  in	  children.	  Furthermore,	  we	   aimed	   at	   investigating	   the	   clinical	   relevance	   of	   potential	   drug	   targets	   and	   their	  prognostic	   value	   in	   patient	   biopsies.	   Overall,	   our	   final	   goal	   is	   to	   improve	   treatment	  strategies	   and	   therapy	   outcome	   for	   alveolar	   rhabdomyosarcoma	   and	   to	   reduce	  treatment-­‐related	  side	  effects.	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6 Manuscript	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   PLK1	   phosphorylates	   PAX3-­‐FOXO1,	  
the	   inhibition	   of	   which	   triggers	   regression	   of	  
alveolar	  rhabdomyosarcoma	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6.1 Abstract	  
Pediatric	   tumors	  harbor	  very	   low	  numbers	  of	  somatic	  mutations	  and	   therefore	  offer	  few	   targets	   to	   improve	   therapeutic	   management	   with	   targeted	   drugs.	   In	   particular,	  outcomes	   remain	   dismal	   for	   patients	   with	   metastatic	   alveolar	   rhabdomyosarcoma	  (aRMS),	  where	  the	  chimeric	  transcription	  factor	  PAX3/7-­‐FOXO1	  has	  been	   implicated	  but	  problematic	  to	  target.	  In	  this	  report,	  we	  addressed	  this	  challenge	  by	  developing	  a	  two-­‐armed	   screen	   for	  druggable	  upstream	   regulatory	   kinases	   in	   the	  PAX3/7-­‐FOXO1	  pathway.	  Screening	  libraries	  of	  kinome	  siRNA	  and	  small	  molecules,	  we	  defined	  PLK1	  as	   an	   upstream-­‐acting	   regulator.	   Mechanistically,	   PLK1	   interacted	   with	   and	  phosphorylated	   PAX3-­‐FOXO1	   at	   the	   novel	   site	   S503	   leading	   to	   protein	   stabilization.	  Notably,	   PLK1	   inhibition	   led	   to	   elevated	   ubiquitination	   and	   rapid	   proteasomal	  degradation	  of	  the	  PAX3-­‐FOXO1	  chimeric	  oncoprotein.	  On	  this	  basis,	  we	  embarked	  on	  a	  preclinical	  validation	  of	  PLK1	  as	  target	  in	  a	  xenograft	  mouse	  model	  of	  aRMS,	  where	  the	   PLK1	   inhibitor	   BI	   2536	   reduced	   PAX3-­‐FOXO1-­‐mediated	   gene	   expression	   and	  elicited	   tumor	   regression.	   Clinically,	   analysis	   of	   human	   aRMS	   tumor	   biopsies	  documented	  high	  PLK1	  expression	  to	  offer	  prognostic	  significance	  for	  both	  event-­‐free	  and	   overall	   survival.	   Taken	   together,	   these	   preclinical	   studies	   validate	   the	   PLK1	   -­‐	  PAX3-­‐FOXO1	  axis	  as	  a	  rational	  target	  to	  treat	  alveolar	  rhabdomyosarcoma.	  	  
6.2 Introduction	  	  
Rhabdomyosarcoma	   is	   the	   most	   common	   pediatric	   soft	   tissue	   sarcoma	   and	   can	   be	  divided	   into	   two	  main	   subgroups	  with	   different	   outcomes	   reflecting	   distinct	   genetic	  backgrounds.	   Alveolar	   rhabdomyosarcoma	   (aRMS)	   is	   more	   aggressive	   than	  embryonal	  rhabdomyosarcoma	  (eRMS)	  and	  often	  displays	  resistance	  to	  conventional	  chemo-­‐	  and	  radiotherapy	  resulting	  in	  a	  5-­‐year	  survival	  rate	  of	  only	  30%	  (Breneman	  et	  al.,	   2003).	   Until	   now,	   there	   are	   no	   alternative	   therapeutic	   strategies	   to	   these	  conventional	  treatments.	  Searching	  for	  appropriate	  molecular	  targets,	  large	  proteomic	  screening	   and	   sequencing	   approaches	  have	  been	  undertaken	   showing	   that	   pediatric	  tumors	   harbor	   far	   fewer	   somatic	   mutations	   than	   adult	   tumors	   (Vogelstein	   et	   al.,	  2013).	   In	   contrast	   to	   eRMS,	   analyzing	   genetic	   landscapes	   of	   alveolar	  rhabdomyosarcoma	   even	   further	   minimized	   the	   number	   of	   potential	   targets	   and	  excluded	  enrichment	  of	  any	  mutated	  oncogenic	  canonical	  pathway	  in	  the	  majority	  of	  patients	   (Chen	   et	   al.,	   2013;	   Shern	   et	   al.,	   2014).	   These	   findings	   indicate	   that	   aRMS	   is	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driven	  by	  very	  few	  individual	  oncogenes	  and	  consequently	  reinforce	  the	  focus	  on	  the	  role	  of	  the	  tumor	  specific	  chimeric	  transcription	  factor	  PAX3/7-­‐FOXO1.	  	  The	  fusion	  protein	  is	  expressed	  in	  about	  80%	  of	  aRMS	  tumors	  suggesting	  a	  dominant	  role	   as	   oncogenic	  driver	   (Shern	   et	   al.,	   2014;	   Sorensen	   et	   al.,	   2002).	   Its	   transforming	  capacity	  (Linardic,	  2008;	  Olanich	  and	  Barr,	  2013)	  is	  underlined	  by	  the	  ability	  to	  affect	  multiple	   oncogenic	   downstream	   pathways	   (Cao	   et	   al.,	   2010;	   Davicioni	   et	   al.,	   2006;	  Ebauer	   et	   al.,	   2007;	   Khan	   et	   al.,	   1998;	   Lae	   et	   al.,	   2007;	   Wachtel	   et	   al.,	   2004).	  Furthermore,	   aRMS	   is	   addicted	   to	  expression	  of	   the	   fusion	  protein	  as	   its	   continuous	  activity	   is	   essential	   for	   maintaining	   tumor	   cell	   survival	   (Ayyanathan	   et	   al.,	   2000;	  Bernasconi	   et	   al.,	   1996).	   Finally,	   its	   presence	   has	   also	   important	   prognostic	  significance	   (Missiaglia	   et	   al.,	   2012;	   Stegmaier	   et	   al.,	   2011).	   PAX3-­‐FOXO1	   is,	   in	  conclusion,	   a	   highly	   relevant	   potential	   target	   and	   offers	   the	   opportunity	   for	  development	  of	  novel	  directed	  therapies.	  However,	  directly	  antagonizing	  transcription	  factors	   remains	   a	   pharmaceutical	   challenge	   and	   alternative	   indirect	   strategies	  interfering	  with	  the	  regulatory	  network	  of	  the	  fusion	  protein	  need	  to	  be	  developed.	  PAX3-­‐FOXO1	   is	   characterized	   by	   high	   expression,	   exclusive	   nuclear	   subcellular	  localization,	   enhanced	   protein	   stability,	   and	   increased	   transcriptional	   activity	  compared	  to	  wild	  type	  PAX3	  or	  FOXO1	  (Bennicelli	  et	  al.,	  1999;	  Bennicelli	  et	  al.,	  1996;	  Davis	  and	  Barr,	  1997;	  del	  Peso	  et	  al.,	  1999;	  Miller	  and	  Hollenbach,	  2007).	  Currently,	  we	  aim	  at	  mechanistically	  understanding	  these	  different	  levels	  of	  regulation	  required	  for	   the	  oncogenic	   function.	  We,	  as	  well	  as	  others,	  were	  able	   to	  demonstrate	   that	   the	  transcriptional	   activity	   of	   PAX3-­‐FOXO1	   depends	   on	   its	   phosphorylation	   state	  providing	  novel	  therapeutic	  opportunities	  (Amstutz	  et	  al.,	  2008;	  Jothi	  et	  al.,	  2013;	  Liu	  et	  al.,	  2013a).	  Polo-­‐like	   kinase	  1	   (PLK1)	   is	   known	  as	   key	   regulator	   of	  mitosis	  with	   critical	   roles	   in	  mitotic	   entry,	   centrosome	   maturation,	   cohesin	   release,	   bipolar	   spindle	   formation,	  mitotic	  exit,	  and	  cytokinesis.	  Overexpression	  of	  PLK1	  is	  linked	  to	  poor	  prognosis	  in	  a	  variety	   of	   different	   cancers	   (Holtrich	   et	   al.,	   1994;	   Strebhardt	   and	   Ullrich,	   2006).	   In	  contrast	  to	  healthy	  cells,	  it	  localizes	  to	  the	  nucleus	  already	  before	  G2/M	  in	  cancer	  cells	  and	   can	   be	   detected	   during	   the	   entire	   interphase	   (Cholewa	   et	   al.,	   2013).	   Therefore,	  cancer-­‐cell	   specific	   functions	   in	   G1/S	   transition	   and	   DNA	   replication	   are	   suggested	  beyond	   its	   role	   in	   regulation	   of	  mitosis.	   Interestingly,	   PLK1	   is	   associated	  with	   PI3K	  and	   MAPK	   pathways,	   both	   of	   which	   are	   thought	   to	   play	   important	   roles	   in	   aRMS	  (Guenther	  et	  al.,	  2013;	  Renshaw	  et	  al.,	  2013).	  Hence,	  PLK1	  overexpression	  might	  not	  just	   be	   a	   consequence	   of	   enhanced	   proliferation,	   but	   it	   is	   likely	   that	   PLK1	   actively	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contributes	  to	  early	  carcinogenesis.	  However,	  a	  specific	  role	  for	  PLK1	  in	  aRMS	  has	  not	  yet	  been	  described.	  Here,	   we	   utilized	   a	   two-­‐armed	   screening	   strategy	   to	   identify	   PLK1	   as	   upstream	  regulator	  of	  PAX3-­‐FOXO1,	  whereby	  PLK1	  phosphorylated	  and	  subsequently	  stabilized	  the	  fusion	  protein.	  Since	  we	  observed	  objective	  regression	  of	  xenograft	  tumors	  upon	  PLK1	   inhibition	   and	   found	   that	   PLK1	   expression	   in	   patient	   biopsies	   has	   significant	  prognostic	   value,	   we	   propose	   the	   PLK1	   -­‐	   PAX3-­‐FOXO1	   axis	   to	   be	   a	   very	   promising	  novel	  target	  for	  aRMS	  therapy.	  
6.3 Material	  and	  methods	  
Cell	  lines	  The	  aRMS	  cell	  lines	  Rh4,	  Rh41	  (Peter	  Houghton,	  St.	  Jude	  Children's	  Hospital,	  Memphis,	  TN,	  USA),	  RMS13	  (Roland	  Kappler,	  Ludwig–Maximilian	  University	  Munich,	  Germany),	  Rh3,	   Rh5,	   Rh10	   (Susan	   Ragsdale,	   St.	   Jude	   Children's	   Hospital,	   Memphis,	   TN,	   USA),	  CW9019	  (Soledad	  Gallego,	  Hospital	  Universitari	  Vall	  d'Hebron,	  Barcelona,	  Spain)	  and	  Rh30	   as	   well	   as	   HEK293T	   cells	   (American	   Type	   Culture	   Collection	   ATCC,	   LGC	  Promochem,	  Molsheim	  Cedex,	   France)	  were	   cultured	   in	  Dulbecco's	  modified	   Eagle's	  medium	   (Sigma-­‐Aldrich,	   Buchs,	   Switzerland),	   supplemented	   with	   100	   U/ml	  penicillin/streptomycin,	   2	   mM	   L-­‐glutamine	   and	   10%	   FBS	   (Life	   Technologies,	   Zug,	  Switzerland)	   in	   5%	   CO2	   at	   37°C.	   RD	   and	   Rh36	   eRMS	   cells	  were	   kindly	   provided	   by	  Peter	  Houghton	  (St.	   Jude	  Children's	  Hospital,	  Memphis,	  TN,	  USA).	   	  Ruch2	  and	  Ruch3	  cell	  lines	  were	  established	  in	  our	  laboratory	  (Scholl	  et	  al.,	  2000).	  	  aRMS	  and	  eRMS	  cell	   lines	  were	   tested	  and	  authenticated	  by	   cell	   line	   typing	  analysis	  (STR	  profiling)	  in	  2011/2014	  and	  positively	  matched	  (Hinson	  et	  al.,	  2013).	  	  
Plasmids	  and	  transfection	  methods	  Rh4	   cells	   were	   stably	   transfected	   with	   reporter	   plasmids	   containing	   the	   luciferase	  gene	  downstream	  of	  the	  AP2β	  promoter	  (pGl4.19,	  Promega,	  Dübendorf,	  Switzerland)	  and	   selected	   with	   1	   mg/ml	   G-­‐418	   sulfate	   (Promega,	   Dübendorf,	   Switzerland)	   to	  generate	   Rh4-­‐AP2β-­‐LF	   cells.	   	   Rh4luc	   and	   RMS13luc	   were	   generated	   by	   retroviral	  infection	  with	   the	  plasmid	  pLIB-­‐LN	  (Takara	  Bio	  Europe/Clontech,	  Saint-­‐Germain-­‐en-­‐Laye,	  France)	  and	  selection	  using	  1	  mg/ml	  G-­‐418	  sulfate.	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FLAG-­‐tagged	  PAX3-­‐FOXO1	  and	  FLAG-­‐tagged	  GFP	  were	  generated	  by	  insertion	  of	  cDNA	  into	   pCMV-­‐SC-­‐NF	   (N-­‐terminal	   FLAG,	   Stratagene,	   Agilent	   Technologies,	   Basel,	  Switzerland).	   PAX3-­‐FOXO1	   was	   cloned	   into	   pMSCV-­‐IRES-­‐GFP	   (Addgene,	   no.	   33336,	  Cambridge,	   MA,	   USA)	   to	   perform	   site	   directed	   mutagenesis	   using	   QuikChange	  recommendations	   (Stratagene,	   Agilent	   Technologies,	   Basel,	   Switzerland).	   Parental	  DNA	  template	  was	  digested	  with	  DpnI	  (Thermo	  Scientific,	  Reinach,	  Switzerland).	  Rh4	  and	  RD	  cells	  were	  transfected	  using	  JetPrimeTM	  (Polyplus-­‐Transfections,	  Illkirch,	  France),	  HEK293T	  cells	  by	  CaPO4.	  	  
siRNA	  kinome	  library	  screens	  and	  data	  analysis	  A	  kinome	  siRNA	  library	  targeting	  719	  kinases	  was	  used	  (Ambion	  Silencer®	  V3	  Kinase	  siRNA	   Library,	   Life	   Technologies,	   Zug,	   Switzerland)	   together	   with	   a	   sub-­‐library	  targeting	   47	   kinases	   (Ambion	   Silencer®	   Select	   Costum	   siRNA	   Library,	   Life	  Technologies)	  with	  3	  unique	  siRNA	  sequences	  per	  gene.	  Ambion	  non-­‐targeting	  siRNA	  served	  as	  negative	  control,	  whereas	  PAX3-­‐FOXO1	  break-­‐point	  specific	  siRNA	  (Kikuchi	  et	   al.,	   2008),	   luciferase	   specific	   siRNA	   (pGL4,	   Custom	   Select)	   and	   KIF11	   siRNA	  (AM4639;	   all	   Ambion,	   Life	   Technologies)	   were	   used	   as	   positive	   controls.	   Reverse	  transfection	  was	  carried	  out	  with	  1x104	  cells	  per	  96-­‐well	  at	  a	  final	  concentration	  of	  50	  nM	  using	  N-­‐TER	  nanoparticle	  transfection	  reagent	  (Sigma-­‐Aldrich).	  Luciferase	  activity	  was	   determined	   by	   the	   Luciferase	   Assay	   System	   E1501	   (Promega,	   Dübendorf,	  Switzerland)	   48h	   post	   transfection	   and	   values	   normalized	   to	   viable	   cell	   numbers	  determined	   by	   WST-­‐1	   assay	   (Roche	   Diagnostics,	   Rotkreuz,	   Switzerland).	  Measurements	   were	   normalized	   using	   the	   per-­‐plate	   median	   normalization	   method	  (excluding	   controls).	   Triplicate	   median-­‐normalized	   luciferase	   values	   were	   averaged	  for	   each	   kinase	   before	   calculating	   the	   ratio	   to	   the	   averaged	   WST-­‐1	   absorbance	  (normalized	   luciferase	  activity).	  Cell	  viability	  of	  Rh4	  and	  RMS13	  cells	  was	  measured	  72h	   post	   transfection	   using	  WST-­‐1.	   Both	   screens	  were	   performed	   in	   triplicates	   and	  non-­‐targeting,	  PAX3-­‐FOXO1,	  pGL4	  and	  KIF11	  siRNAs	  were	   included	   in	  duplicates	  on	  each	  plate.	  	  
Small-­‐molecule	  compounds	  screen	  and	  dose	  response	  studies	  A	  small-­‐molecule	   compound	   library	   (Supplementary	  Tab.	   S2)	   covering	  161	  different	  inhibitors	  was	  used	  to	  treat	  5x103	  Rh4-­‐AP2-­‐LF	  cells	  per	  96-­‐well	  24h	  after	  plating	  at	  a	  final	   concentration	   of	   500	   nM	   for	   24h.	   Luciferase	   activity/cell	   viability	   ratio	   was	  
	   45	  
determined	   as	   described	   above.	   For	   dose	   response	   curves,	   this	   ratio	   was	   plotted	  against	  the	  logarithm	  of	  drug	  concentrations	  and	  IC50	  values	  were	  calculated	  by	  non-­‐linear	   regression	   curve	   fitting	   using	   GraphPad	   Prism	   software	   (GraphPad	   Software	  Inc.,	  San	  Diego,	  CA,	  USA).	  	  
PLK1	  silencing	  and	  small-­‐molecule	  inhibition	  Knockdowns	  of	  PLK1	  and	  PLK4	  were	  achieved	  by	  reverse	  transfection	  of	  1.9-­‐3.8x105	  cells	   in	  6-­‐well	  plates	  using	  scrambled	  (4390846)	  or	  PLK1	  and	  PLK4	  directed	  siRNAs	  (25	   nM	   1341,	   8	   nM	   S449,	   25	   nM	   S21083;	   all	   Ambion,	   Life	   Technologies)	   with	  INTERFERinTM	   according	   to	   the	   manufacturer’s	   protocol	   (Polyplus-­‐Transfections,	  Illkirch,	  France).	  Cells	  were	  lysed	  48h	  post	  transfection.	  	  2x105	   cells	   per	   6-­‐well	   were	   treated	   24h	   after	   seeding	   using	   15	   nM	   BI	   2536	   (Axon	  Medchem,	   Groningen,	   NL)	   or	   20	   nM	  BI	   6727	   (Selleck	   Chemicals,	   Houston	   TX,	   USA).	  Cells	  were	  lysed	  for	  RNA	  or	  protein	  extraction	  after	  48h.	  For	  proteasomal	  degradation	  studies,	   10	   nM	   -­‐	   50	   nM	   Bortezomib	   (Cilag,	   Schaffhausen,	   Switzerland)	   was	  simultaneously	  added	  and	  cells	  were	  lysed	  after	  20h.	  	  
Caspase	  3/7	  activity	  assay	  For	  caspase	  3/7	  activity	  assays	  cells	  were	  seeded	  and	  treated	  in	  white	  96-­‐well	  plates	  with	   clear	   bottom	   (Greiner	   Bio	   one,	   Frickenhausen,	   Germany).	   Caspase	   activity	  was	  determined	  by	  Caspase-­‐Glo®	  3/7	  Assay	  (Promega,	  Dübendorf,	  Switzerland)	  according	  to	   the	   manufacturer’s	   instructions.	   Luminescence	   was	   measured	   using	   the	   multi-­‐detection	  micro-­‐plate	  reader	  Synergy	  HT	  (Bio-­‐Tek	  Instrument,	  Winooski,	  USA).	  	  
Cell	  cycle	  analysis	  Cells	  were	  treated	  in	  6-­‐well	  plates,	  detached	  by	  trypsin	  (0.05%	  Trypsin,	  w/	  EDTA,	  Life	  Technologies),	  washed	   in	  PBS,	   fixed	   in	  70%	   ice-­‐cold	   ethanol	   and	   incubated	  at	   -­‐20°C	  for	   at	   least	   2h.	   Before	   flow	   cytometry	   analysis	   (Beckman	   Coulter	   Cytomics	   FC500;	  Hialeah,	  FL,	  USA),	  cells	  were	  washed	  by	  PBS	  and	  resuspended	  in	  500	  μl	  PI	  solution	  (20	  μg/ml	  PI	  and	  200	  μg/ml	  RNase	  in	  PBS	  with	  0.1%	  Triton	  X-­‐100).	  Data	  were	  processed	  by	  FlowJo	  software	  (Treestar,	  Ashland,	  OR,	  USA).	  	  
	   46	  
qRT-­‐	  PCR	  Total	  RNA	  was	  extracted	  using	  the	  Qiagen	  RNeasy	  Kit	  (Qiagen,	  Basel,	  Switzerland)	  and	  reverse-­‐transcribed	   using	   oligo	   (dT)	   primers	   and	   Omniscript	   reverse	   transcriptase	  (Qiagen).	   qRT-­‐PCR	   was	   performed	   for	   PLK1	   (Hs00153444_m1),	   PLK4	  (Hs00179514_m1),	   PAX3-­‐FOXO1	   (Hs03024825_ft),	   AP2β	   (Hs00231468_m1),	   FGFR4	  (Hs01106908_m1),	   CDH3	   (Hs00999918_m1),	   PIPOX	   (Hs04188864_m1)	   and	   MYL1	  (Hs00984899_m1)	  using	  TaqMan	  gene	  expression	  master	  mix	  (all	  Life	  Technologies).	  Cycle	   threshold	   (CT)	   values	   were	   normalized	   to	   GAPDH	   (Hs02758991_g1).	   Relative	  expression	   levels	   were	   calculated	   using	   the	   ΔΔCT	   method	   based	   on	   experiments	  performed	   in	   triplicates.	   Geometric	   mean	   values	   and	   the	   95%	   confidence	   interval	  were	  calculated	  based	  on	  four	  to	  six	  biological	  replicates.	  	  
Immunoblotting	  Total	   cell	   extracts	   were	   separated	   using	   4-­‐12%	   Bis-­‐Tris	   SDS-­‐PAGE	   gels	   (Life	  Technologies)	   and	   transferred	   to	   nitrocellulose	   membranes	   (PROTAN,	   Schleicher	   &	  Schuell,	  Kassel,	  Germany).	  After	  blocking	  with	  5%	  milk	  powder	   in	  TBS/0.1%	  Tween,	  membranes	  were	  incubated	  with	  primary	  antibodies	  overnight	  at	  4°C.	  After	  washing	  in	  TBS/0.1%	  Tween,	  membranes	  were	  incubated	  with	  IgG	  HRP-­‐linked	  antibody	  for	  1h	  at	   room	   temperature.	   Proteins	   were	   detected	   using	   ECL	   detection	   reagent	   (Fisher	  Scientific,	  Wohlen,	  Switzerland)	  after	  washing	  in	  TBS/0.1%	  Tween.	  	  	  
Antibodies	  Western	   blot	   membranes	   were	   incubated	   with	   anti-­‐FOXO1	   (H-­‐128;	   1:1000;	   Santa	  Cruz	  Biotechnology,	  Heidelberg,	  Germany),	  anti-­‐PLK1	  (clone	  35-­‐206,	  05-­‐844;	  1:1000;	  Millipore,	   Zug,	   Switzerland),	   anti-­‐FOXO1A	   phospho	   S322	   +	   S325	   (phospho	   S503	   +	  S506	   in	   PAX3-­‐FOXO1;	   ab60945;	   1:500	   Abcam,	   Cambridge,	   UK),	   anti-­‐HA	   (05-­‐904;	  1:1000;	   Millipore,	   Zug,	   Switzerland),	   anti-­‐PLK4	   (clone	   6H5,	   MABC544	   1:250;	  Millipore,	   Zug,	   Switzerland),	   NMYC	   (9405;	   1:1000;	   Cell	   Signaling,	   Bioconcept,	  Allschwil,	  Switzerland)	  or	  anti-­‐PARP	  (9542;	  1:1000;	  Cell	  Signaling)	  antibodies.	  Anti-­‐β-­‐Tubulin	   I	   mouse	   mAb	   (1:40,000;	   Sigma-­‐Aldrich),	   anti-­‐β-­‐Actin	   (13E5)	   rabbit	   mAb	  (4970;	   1:1000;	   Cell	   Signaling)	   and	   anti-­‐GAPDH	   (D16H11)	   XPTM	   rabbit	   mAb	   (5174;	  1:1000;	   Cell	   Signaling)	   were	   used	   as	   loading	   controls.	   Membranes	   were	   incubated	  with	   the	   secondary	   antibodies	   anti-­‐mouse	   IgG	   HRP-­‐linked	   antibody	   (7076;	   1:2000;	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Cell	  Signaling)	  or	  anti-­‐rabbit	   IgG	  HRP-­‐linked	  antibody	   (7074;	  1:2000;	  Cell	   Signaling)	  for	  1h	  at	  room	  temperature.	  	  IP	  experiments	  were	  performed	  using	  anti-­‐FOXO1	  (H-­‐128;	  Santa	  Cruz	  Biotechnology),	  anti-­‐PAX3/7	   (N-­‐19,	   Santa	   Cruz	   Biotechnology)	   or	   monoclonal	   ANTI-­‐FLAG®	   M2	  antibody	  (F1804,	  Sigma-­‐Aldrich).	  For	  immunohistochemistry,	  mouse	  anti-­‐Myf4	  monoclonal	  antibody	  (1:20;	  Novocastra	  Laboratories	   Ltd.),	   AP2β	   (1:40;	   Santa	   Cruz	   Biotechnology)	   and	   rabbit	   p-­‐cadherin	  antibody	  	  (1:100;	  Santa	  Cruz	  Biotechnology)	  were	  used.	  	  
Co-­‐immunoprecipitation	  Cells	  from	  one	  confluent	  10	  cm	  dish	  were	  lysed	  in	  1	  ml	  lysis	  buffer	  and	  incubated	  for	  10	  min	   at	   4°C	  with	   Dynabeads®	   Protein	   G	   (Novex	   by	   Life	   Technologies)	   coupled	   to	  indicated	  antibodies.	  Beads	  were	  washed	  three	  times	  with	  lysis	  buffer,	  proteins	  eluted	  in	  1x	  NuPage	  LDS	  sample	  buffer	  (Life	  Technologies)	  at	  70°C	  and	  analyzed	  by	  Western	  blotting.	  	  
Stability	  assay	  2x105	  RD	  cells	  were	  seeded	  per	  6-­‐well	  the	  day	  before	  transfection	  with	  1	  μg	  pMSCV-­‐PAX3-­‐FOXO1-­‐IRES-­‐GFP	   or	   pMSCV-­‐PAX3-­‐FOXO1-­‐S503A-­‐IRES-­‐GFP.	   Cells	   were	   treated	  with	  35	  μM	   cycloheximide	   (Sigma-­‐Aldrich)	   or	  DMSO	   for	  6h	  before	   lysis	   and	  protein	  extraction.	  Protein	  levels	  were	  analyzed	  by	  Western	  blotting.	  	  
Purification	  of	  FLAG-­‐PAX3-­‐FOXO1	  	  Rh4,	  RMS13	  or	  HEK293T	  cells	  were	  transfected	  with	  pCMV-­‐FLAG-­‐PAX3-­‐FOXO1	  in	  15	  cm	   plates,	   lysed	   40h	   post	   transfection	   and	   FLAG-­‐PAX3-­‐FOXO1	   was	  immunoprecipitated	   using	   75	   μl	   Dynabeads®	   per	   plate	   coupled	   to	   8	   μg	  monoclonal	  ANTI-­‐FLAG®	  M2	  antibody.	  After	  washing,	  bead-­‐bound	  FLAG-­‐PAX3-­‐FOXO1	  was	  either	  used	  for	  in	  vitro	  kinase	  assays	  or	  the	  protein	  was	  eluted	  by	  1x	  NuPage	  LDS	  buffer	  and	  directly	  subjected	  to	  mass	  spectrometry.	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In	  vitro	  kinase	  assay	  	  Bead-­‐bound	   protein	   was	   dephosphorylated	   using	   300	   units	   CIAP	   enzyme	   (alkaline	  phosphatase,	  calf	  intestinal	  HC,	  Promega,	  Dübendorf,	  Switzerland)	  for	  90	  min	  at	  37°C	  (50	   mM	   Tris	   HCl	   pH	   7.5,	   1	   mM	   MgCl2,	   0.1	   mM	   ZnCl2).	   FLAG-­‐PAX3-­‐FOXO1	   was	  phosphorylated	   after	   washing	   using	   500	   ng	   or	   2.5	   μg	   of	   recombinant	   PLK1	   (Life	  Technologies)	  for	  30	  min	  at	  30°C	  (250	  mM	  HEPES	  pH	  7.5,	  50	  mM	  MgCl2,	  12.5	  mM	  DTT,	  0.05%	  Triton	  X-­‐100,	  200	  μM	  ATP).	  4x	  NuPage	  LDS	  buffer	  was	  added	   for	  elution	  and	  proteins	   were	   separated	   by	   gel	   electrophoresis.	   After	   staining	   with	   colloidal	  coomassie	   (Instant	   blue,	   Expedeon,	   Harston,	   UK),	   the	   band	   corresponding	   to	   FLAG-­‐PAX3-­‐FOXO1	  was	  excised	  and	  prepared	  for	  mass	  spectrometry.	  	  
Mass	  spectrometry	  4x	  NuPage	  LDS	  buffer	  (Life	  Technologies)	  was	  added	  to	  in	  vitro	  kinase	  assay	  reactions	  for	   elution	   and	   proteins	   were	   separated	   by	   gel	   electrophoresis.	   	   After	   staining	   gels	  with	   colloidal	   coomassie	   (Instant	   blue,	   Expedeon,	   Harston,	   UK),	   the	   band	  corresponding	  to	  PAX3-­‐FOXO1	  was	  excised,	  washed	  3x	  with	  50%	  ACN	  and	  dried	  in	  a	  speed	  vacuum	  centrifuge.	  Reduction	  of	  disulphide	  bridges	  was	  achieved	  by	  adding	  10	  mM	  DTT	   in	  50	  mM	  AmBic	   (pH8)	   for	  45	  min	  at	  56°C.	  DTT	  was	   removed	  and	  50	  mM	  IAM	  was	  added	  for	  alkylation	  of	  cysteines.	  After	  1h	  of	  incubation	  at	  room	  temperature,	  the	  gel	  pieces	  were	  again	  washed	  3x	  and	  dried.	  Digestion	  was	  performed	  with	  50	  ng	  of	  trypsin	  or	  chymotrypsin	  (V511C,	  V1061,	  Promega,	  Dübendorf,	  Switzerland)	  overnight	  at	  37°C.	  Peptides	  were	  extracted	  using	  50%	  ACN/5%	  TFA,	  dried,	  resuspended	  in	  3%	  ACN/0.1%	   TFA,	   and	   purified	   using	   ZipTip	   C18	   column	   tips.	   Finally,	   peptides	   were	  dried	  in	  a	  speed	  vacuum	  centrifuge,	  resuspended	  in	  3%	  ACN,	  0.2%	  formic	  acid	  and	  10	  mM	   citric	   acid	   solution	   and	   injected	   into	   the	   mass	   spectrometer	   (LTQ	   OrbitrapXL;	  Thermo	   Fischer	   Scientific,	   Bremen,	   Germany)	   coupled	   to	   an	   Eksigent-­‐Nano-­‐HPLC	  system	   (Eksigent	   Technologies,	   Dublin,	   CA,	   USA).	   	   Solvent	   composition	   was	   0.1%	  formic	  acid	  for	  channel	  A,	  and	  0.1%	  formic	  acid	  and	  99.9%	  acetonitrile	  for	  channel	  B.	  Peptides	  were	  loaded	  on	  a	  self-­‐made	  tip-­‐column	  (75	  µm	  ×	  80	  mm)	  packed	  with	  Magic	  RP	  C18	  AQ,	  200A,	  3	  μm	  beads	   (Bischoff	  GmbH,	  Leonberg,	  Germany),	   and	  eluted	  at	   a	  flow	  rate	  of	  200	  nL/min	  by	  a	  gradient	  of	  5-­‐30%	  ACN	  in	  55	  min,	  30-­‐50%	  in	  5	  min,	  50-­‐95%	  in	  5	  min.	  	  Full-­‐scan	  MS	  spectra	  (300−2.000	  m/z)	  were	  acquired	  at	  a	  resolution	  of	  60.000	  at	  400	  m/z	  after	  reaching	  an	  accumulation	  value	  of	  500.000.	  Collision-­‐induced	  dissociation	  (CID)	  fragmentation	  was	  performed	  on	  the	  five	  most	   intense	  signals	  per	  cycle.	   CID	   spectra	   were	   acquired	   using	   a	   normalized	   collision	   energy	   of	   35	   and	   a	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maximum	   injection	   time	   of	   50	   ms.	   Charge	   state	   screening	   was	   enabled,	   and	  unassigned	   and	   singly	   charged	   states	   were	   rejected.	   Precursor	   masses	   previously	  selected	  for	  MS/MS	  were	  excluded	  from	  further	  selection	  for	  45	  s,	  and	  the	  exclusion	  window	  was	  set	  to	  20	  ppm.	  The	  size	  of	  the	  exclusion	  list	  was	  set	  to	  a	  maximum	  of	  500	  entries.	   The	   samples	   were	   acquired	   using	   internal	   lock	   mass	   calibration	   on	   m/z	  429.088735	  and	  445.120025.	  	  
Database	  search	  and	  protein	  identification	  The	  MS	  raw	  files	  were	  converted	  into	  Mascot	  generic	  files	  (mgf)	  with	  Mascot	  Distiller	  software	   2.4.3.3	   (Matrix	   Science	   Ltd.,	   London,	   UK)	   and	   peak	   lists	   searched	   using	  Mascot	  Server	  2.3.02	  against	  the	  forward	  UniProtKB/Swiss-­‐Prot	  database	  for	  human,	  concatenated	  to	  a	  reversed	  decoyed	  FASTA	  database	  consisting	  of	  a	   total	  of	  135,183	  proteins	   and	   260	   common	   protein	   contaminants	   (NCBI	   taxonomy	   ID	   9606,	   release	  date	  2012-­‐04-­‐12).	  The	  protein	  sequence	  of	  PAX3-­‐FOXO1	  (gi|431254|gb|AAC50053.1|)	  was	  included	  in	  the	  database	  as	  in	  (Shapiro	  et	  al.,	  1993).	  The	  parameters	  for	  precursor	  tolerance	  and	   fragment	   ion	   tolerance	  were	  set	   to	  ±	  5	  ppm	  and	  ±	  0.8	  Da,	   respectively.	  Carbamidomethylation	   of	   cysteine	   was	   set	   as	   fixed	   modification,	   while	  phosphorylation	  (S,	  T,	  Y)	  and	  oxidation	  (M)	  were	  set	  as	  variable.	  Peptides	  having	  an	  expectation	  value	  higher	  as	  0.05	  and/or	  a	  Mascot	  score	  lower	  as	  20	  were	  excluded.	  All	  the	  spectra	  of	  phosphorylated	  peptides	  were	  manually	  validated.	  	  
Ubiquitination	  studies	  Rh4	  cells	  were	   transfected	  with	  pCMV-­‐FLAG-­‐PAX3-­‐FOXO1	  plasmid	  and	  pCDNA3-­‐HA-­‐ubiquitin	  at	  a	  ratio	  of	  1:2	  for	  48h.	  Cells	  were	  treated	  with	  200	  nM	  PLK1	  inhibitors	  for	  21h	  prior	  to	  addition	  of	  10	  μM	  MG-­‐132	  (Calbiochem,	  Millipore,	  Zug,	  Switzerland)	  for	  5h.	  After	   lysis	  (2%	  SDS,	  150	  mM	  NaCl,	  10	  mM	  Tris/HCl,	  2	  mM	  Na3VO4,	  50	  mM	  NaF),	  samples	  were	  boiled	   for	  10	  min,	  sonicated,	  diluted	  with	  9	  volumes	  of	  dilution	  buffer	  (150	  mM	  NaCl,	  10	  mM	  Tris/HCl,	  2	  mM	  EDTA,	  1%	  TritonX)	  and	  incubated	  for	  30	  min	  at	  4°C.	  IP	  was	  performed	  using	  Dynabeads®	  coupled	  to	  ANTI-­‐FLAG®	  M2	  antibody	  for	  1h	  at	  4°C.	  Beads	  were	  washed	  three	  times	  with	  lysis	  buffer,	  proteins	  eluted	  with	  3x	  FLAG	  peptide	  (Sigma-­‐Aldrich)	  and	  analyzed	  by	  Western	  blotting.	  	  
	   	  
	   50	  
Xenograft	  studies	  5x106	  Rh4,	  Rh4luc	  or	  RMS13luc	  cells	  were	  engrafted	  subcutaneously	   in	  6	  weeks	  old	  NOD/Scid	   il2rg-­‐/-­‐	  mice	   (male	   and	   female,	   20-­‐25	   g,	   Charles	  River,	   Sulzfeld,	   Germany).	  Mice	   bearing	   established	   tumors	   with	   volumes	   of	   65	   -­‐	   470	   mm3	   were	   treated	  intravenously	   with	   either	   sterile	   0.9%	   NaCl	   or	   BI	   2536	   at	   40	   mg/kg	   on	   two	  consecutive	  days	  weekly	  for	  three	  cycles.	  BI	  2536	  was	  formulated	  in	  hydrochloric	  acid	  (0.1	  N)	  diluted	  with	  0.9%	  NaCl	   (Steegmaier	  et	  al.,	  2007).	  Total	   tumor	  volumes	  were	  determined	  either	  by	  measuring	  two	  diameters	  (d1,	  d2)	  in	  right	  angles	  using	  a	  digital	  caliper	   (V=	   (4/3)	  π	   r³;	   r=	   (d1+d2)/4)	  or	  by	   in	  vivo	   imaging.	  D-­‐luciferin	   (Caliper	  Life	  Sciences,	   Oftringen,	   Switzerland)	   was	   injected	   intraperitoneally	   (10	   µl/g	   body	  weight),	  and	  tumors	  were	  monitored	  by	  the	  IVIS	  Lumina	  XR	  imaging	  system	  (Caliper	  Life	  Sciences).	  Control	  mice	  were	  euthanized	  when	  reaching	  a	  tumor	  volume	  of	  1000	  mm3.	  	  	  
Immunohistochemistry	  Three-­‐micron	   thick	   sections	   of	   formalin-­‐fixed,	   paraffin-­‐embedded	   tissue	   were	  mounted	   on	   glass	   slides	   (SuperFrost	   Plus;	   Menzel,	   Braunschweig,	   Germany),	  deparaffinized,	   rehydrated	   and	   stained	   with	   hematoxylin	   and	   eosin	   (H&E).	  Immunohistochemical	   stainings	   were	   performed	   using	   the	   Ventana	   Benchmark	  system	  (Ventana	  Medical	  Systems,	  Tucson,	  AZ)	  and	  Ventana	  UltraView	  DAB	  reagents.	  	  
Tissue	  arrays	  Tissue	  arrays	  have	  been	  previously	  described	  (Grass	  et	  al.,	  2009;	  Wachtel	  et	  al.,	  2006).	  Immunohistochemistry	   was	   performed	   on	   Leica	   BondMax	   instruments	   using	  Refine	  HRP-­‐Kits	   (Leica	   DS9800,	   Leica	   Microsystems	   Newcastle,	   Ltd.).	   Paraffin-­‐slides	   were	  dewaxed,	   followed	   by	   pretreatment	   (Epitop	   Retrieval	   Buffer	   2,	   45	  min,	   100°C)	   and	  incubated	   with	   anti-­‐PLK1	   antibody	   (1:600).	   Tumors	   showing	   at	   least	   1-­‐5%	   of	   cells	  with	   a	   very	   high	   staining	   intensity	   were	   assigned	   to	   the	   high	   expression	   group.	   In	  contrast,	  tumors	  with	  low	  expression	  showed	  homogenous	  overall	  staining	  of	  reduced	  intensity.	   	   Anti-­‐Ki-­‐67	   rabbit	   monoclonal	   antibody	   (MIB1;	   30-­‐9;	   Ventana	   Medical	  Systems)	  was	  used	  as	  proliferation	  marker	  (<	  50%	  =	  low;	  >	  50%	  =	  high).	  TMAs	  were	  analyzed	  double-­‐blinded.	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6.4 Results	  
Kinome-­‐wide	  siRNA	  screen	  identifies	  PAX3-­‐FOXO1	  regulators	  	  To	  identify	  kinases	  regulating	  the	  activity	  of	  the	  oncogenic	  transcription	  factor	  PAX3-­‐FOXO1,	  we	   established	   a	   stable	   reporter	   cell	   line	   to	  monitor	   fusion	   protein	   activity	  (Fig.	   1A).	   Rh4	   aRMS	   cells	   with	   a	   transcriptome	   very	   similar	   to	   tumor	   biopsies	  (Wachtel	   et	   al.,	   2004)	   were	   stably	   transfected	   with	   a	   PAX3-­‐FOXO1-­‐responsive	  luciferase	   reporter	   employing	   a	   well-­‐characterized	   endogenous	   AP2β	   promoter	  fragment	   (Ebauer	   et	   al.,	   2007)	   to	   generate	   Rh4-­‐AP2β-­‐LF	   cells.	   Depletion	   of	   PAX3-­‐FOXO1	   by	   siRNA	   (Kikuchi	   et	   al.,	   2008)	   or	   silencing	   of	   luciferase	   itself	   resulted	   in	   a	  more	   than	   70%	  decrease	   in	   luciferase	   activity	   (Supplementary	   Fig.	   S1A).	   Therefore,	  this	   reporter	   assay	   constitutes	   a	   valid	   tool	   for	   functional	   screening	   of	   PAX3-­‐FOXO1	  upstream	  regulators.	  	  First,	  we	  performed	  a	   kinome-­‐wide	   siRNA	   screen	   (Fig.	   1A).	  Rh4-­‐AP2β-­‐LF	   cells	  were	  transfected	  with	  three	  unique	  siRNA	  sequences	  targeting	  each	  of	  the	  719	  kinases	  (Fig.	  1B	   and	   Supplementary	   Fig.	   S1B).	   PAX3-­‐FOXO1,	   KIF11	   (mitotic	   motor	   protein)	   and	  luciferase	   control	   siRNAs	   were	   included	   on	   each	   plate	   and	   the	   ratio	   of	   luciferase	  activity	   to	   cell	   viability	   from	   averaged	   triplicate	   values	   was	   determined	   for	   each	  siRNA.	  Only	   siRNAs	   that	   reduced	   this	   ratio	  by	  at	   least	  1.5	  SDs	   from	   the	  mean	  of	   the	  luciferase	  control	  were	  considered	  as	  potential	  candidates.	  Applying	  this	  criterion	  for	  at	   least	   two	   independent	   siRNAs,	   we	   identified	   47	   candidates	   that	   potentially	  contribute	  to	  the	  activity	  of	  PAX3-­‐FOXO1	  (Supplementary	  Tab.	  S1).	  Importantly,	  these	  kinases	  are	  all	  expressed	  in	  Rh4	  cells	  and	  primary	  aRMS	  tumors,	  at	  least	  at	  the	  mRNA	  level	  (Davicioni	  et	  al.,	  2006;	  Wachtel	  et	  al.,	  2004).	  To	  narrow	  down	  the	  list	  of	  candidates,	  we	  applied	  a	  secondary	  viability	  screen	  using	  an	  siRNA	  library	  containing	  three	  additional	  targeting	  sequences	  per	  kinase	  (sequence	  panels	   A,	   B	   and	   C).	   We	   determined	   mean	   relative	   cell	   viability	   after	   individual	  silencing	  for	  72	  hours	  in	  Rh4	  and	  RMS13	  cells.	   	  Next	  to	  two	  positive	  controls	  (PAX3-­‐FOXO1	   and	   KIF11)	   included	   on	   each	   screening	   plate,	   we	   found	   that	   knockdown	   of	  PLK1	   clearly	  had	   the	   strongest	   impact	  on	   cell	   viability	   in	  both	   cell	   lines	   (up	   to	  61%	  reduction),	   whereas	   the	   per-­‐plate	   means	   reached	   only	   7%	   to	   22%	   (Fig.	   1C).	   These	  results	  suggest	  that	  PLK1	  expression	  might	  be	  important	  for	  aRMS	  cell	  survival.	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Small-­‐molecule	   inhibitor	   screen	   reveals	   PLK1	   as	   potential	   PAX3-­‐FOXO1	  
regulator	  In	   parallel	   to	   the	   siRNA	   screen,	   we	   conducted	   a	   small-­‐molecule,	   mainly	   kinase-­‐directed	  drug	  screen,	   to	   further	  examine	  the	  regulation	  of	  PAX3-­‐FOXO1	  activity	  (Fig.	  1A).	   	   This	   approach	   is	   able	   to	   directly	   identify	   available	   pharmaceutical	   inhibitory	  compounds.	  We	   treated	  Rh4-­‐AP2β-­‐LF	  cells	  with	  161	   inhibitors	   (Supplementary	  Tab.	  S2)	  at	  a	  final	  concentration	  of	  500	  nM	  and	  measured	  cell	  viability	  as	  well	  as	  luciferase	  activity	   after	   24	   hours.	   	   Ranking	   compound	   activity	   according	   to	   ratio	   of	   luciferase	  activity	   over	   cell	   viability,	   10	   out	   of	   161	   inhibitors	   reduced	   normalized	   luciferase	  activity	  by	  at	   least	  44%	  compared	   to	  untreated	  Rh4-­‐AP2β-­‐LF	  cells	   (Fig.	  1D).	   	  With	  a	  normalized	   luciferase	   reduction	  by	  76%	   (relative	   ratio	   0.24),	   the	   top	   candidate	  was	  the	  PLK1	  inhibitor	  BI	  2536	  (Steegmaier	  et	  al.,	  2007).	  	  To	   further	   validate	   BI	   2536,	   Rh4-­‐AP2β-­‐LF	   cells	   were	   treated	   with	   increasing	  concentrations	   for	   24	   hours.	   This	   resulted	   in	   a	   dose	   dependent	   reduction	   of	  normalized	   luciferase	   activity	   with	   an	   IC50	   of	   17.40	   nM	   (Fig	   1E;	   IC50/48h	  =15.75	   nM;	  IC50/72h	   =10.20	   nM,	   Supplementary	   Fig.	   S1C).	   Interestingly,	   the	   median	   IC50	  value	   of	  aRMS	   cell	   lines	  was	   15.03	   nM	   versus	   a	  median	   IC50	   of	   31.86	   nM	   in	   eRMS	   cell	   lines	  (Supplementary	  Fig.	  S2A).	  PLK1	  inhibition	  by	  BI	  2536	  induced	  apoptosis	  in	  Rh4	  cells	  as	  shown	  by	  PARP	  cleavage	  (Supplementary	  Fig.	  S2B)	  as	  well	  as	  by	  relative	  increase	  in	  caspase	  3/7	  activity	  (Supplementary	  Fig.	  S2C).	  To	  demonstrate	  the	  potential	  relevance	  of	  PLK1	  in	  aRMS,	  we	  analyzed	  the	  expression	  of	  PLK1	  protein	  across	  a	  panel	  of	  eight	  different	  aRMS	  cell	  lines	  by	  immunoblotting.	  All	  of	  the	  cell	  lines	  expressed	  the	  kinase	  with	  Rh4,	  Rh41	  and	  RMS13	  cells	  displaying	  the	  highest	  protein	  levels	  (Fig.	  1F).	  	  In	   conclusion,	   we	   identified	   PLK1	   as	   the	   most	   promising	   candidate	   kinase	   by	   both	  siRNA	  and	   small-­‐molecule	   compound	  screen,	  which	   therefore	   represents	   a	  potential	  target	  for	  treatment	  of	  aRMS.	  	  	  	  
PLK1	  inhibition	  reduces	  PAX3-­‐FOXO1	  activity	  	  To	   confirm	   PLK1	   as	   regulator	   of	   the	   fusion	   protein,	   we	   analyzed	   a	   panel	   of	   PAX3-­‐FOXO1	   target	  genes.	  We	  measured	   relative	  mRNA	  expression	  of	   the	  activated	   target	  genes	  AP2β,	  FGFR4,	  CDH3	  and	  PIPOX	  (Cao	  et	  al.,	  2010;	  Davicioni	  et	  al.,	  2006;	  Lae	  et	  al.,	  2007;	  Marshall	  et	  al.,	  2012;	  Thuault	  et	  al.,	  2013;	  Wachtel	  et	  al.,	  2004;	  Wachtel	  et	  al.,	  2006)	  and	  the	  repressed	  differentiation	  marker	  MYL1	  (De	  Pitta	  et	  al.,	  2006)	  by	  qRT-­‐PCR	   after	   48	   hours	   of	   either	   PLK1	   silencing	   (si1341	   and	   siS449)	   or	   small-­‐molecule	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inhibition	  (BI	  2536	  and	  BI	  6727).	  In	  RMS13	  cells,	  knockdown	  of	  PLK1	  achieved	  80%	  (si1341)	   and	   82%	   (siS449)	   of	   silencing	   without	   affecting	   PAX3-­‐FOXO1	   mRNA	  expression.	  However,	  expression	  of	  all	  target	  genes	  was	  significantly	  modulated	  (Fig.	  2A).	   In	   Rh4	   cells,	   knockdown	   efficiencies	   by	   si1341	   reached	   86%	   with	   similar	  modulation	   of	   target	   gene	   expression,	   whereas	   silencing	   by	   siS449	   reached	   81%	  without	  significant	  effects	  on	  target	  genes	  (Fig.	  2B).	  Nevertheless,	  treatment	  with	  both	  inhibitors,	  BI	  2536	  and	  BI	  6727,	  significantly	  affected	  target	  gene	  expression	  in	  both	  cell	  lines.	  	  In	   summary,	   PLK1	   inhibition,	   either	   by	   genetic	   or	   pharmacological	   means,	  significantly	   altered	   transcription	   of	   PAX3-­‐FOXO1	   downstream	   targets	   suggesting	   a	  specific	  link	  between	  the	  kinase	  and	  the	  fusion	  protein.	  	  
PLK1	  binds	  to	  and	  phosphorylates	  PAX3-­‐FOXO1	  	  We	  assessed	  direct	  interaction	  of	  PLK1	  and	  PAX3-­‐FOXO1	  by	  co-­‐immunoprecipitation	  of	   the	  endogenous	  proteins	   in	  Rh4	  cells.	  PAX3-­‐FOXO1	  was	  pulled	  down	  using	  either	  anti-­‐PAX3	   or	   anti-­‐FOXO1	   antibody.	   In	   both	   cases,	   PLK1	  was	   co-­‐immunoprecipitated	  with	   the	   fusion	  protein	  but	  not	  with	   the	  negative	   control	   as	   shown	  by	  Western	  blot	  analysis	  (Fig.	  3A).	  In	  a	  reciprocal	  approach,	  the	  kinase	  was	  pulled	  down	  by	  anti-­‐PLK1	  antibody	   and	   PAX3-­‐FOXO1	   was	   found	   to	   co-­‐immunoprecipitate	   as	   well	   (Fig.	   3B).	  These	  findings	  indicate	  that	  PLK1	  and	  PAX3-­‐FOXO1	  can	  directly	  interact	  in	  aRMS	  cells.	  Furthermore,	  we	   interrogated	   this	   interaction	  under	  drug	   treatment	  conditions.	  Rh4	  cells	  were	  transfected	  with	  FLAG-­‐tagged	  PAX3-­‐FOXO1	  or	  FLAG-­‐tagged	  GFP,	  which	  was	  then	  immunoprecipitated	  after	  DMSO	  or	  BI	  2536	  treatment	  for	  16	  hours	  using	  an	  anti-­‐FLAG	  antibody.	  Again,	  we	  found	  PLK1	  to	  interact	  with	  the	  fusion	  protein,	  but	  not	  with	  GFP	   (Fig.	  3C).	   Surprisingly,	   interaction	  even	   increased	  after	   treatment	  with	  BI	  2536,	  which	   arrested	   cells	   in	   G2/M	   (Supplementary	   Fig.	   S2D	   and	   (Lenart	   et	   al.,	   2007;	  Steegmaier	  et	  al.,	  2007)).	  This	  indicates	  that	  PLK1	  might	  control	  PAX3-­‐FOXO1	  mainly	  at	  the	  transition	  to	  mitosis.	  PLK1	   substrates	   contain	   the	   consensus	   motifs	   [D/E/N]Xp[S/T]	   or	   p[S/T]F	  (Kettenbach	   et	   al.,	   2012)	   and	   several	   of	   these	   can	   also	   be	   found	   in	   PAX3-­‐FOXO1	  suggesting	  that	  it	  might	  be	  a	  direct	  target	  of	  PLK1.	  In	  silico	  analysis	  using	  GPS-­‐Polo	  1.0	  (Liu	  et	  al.,	  2013b)	  predicted	  S503	  and	  S457	  as	  potential	  phosphorylation	  sites	  with	  a	  high	  cut-­‐off	   threshold	   (Fig.	  3D).	  To	  directly	  analyze	  whether	  one	  of	   these	   consensus	  sites	  is	  phosphorylated	  in	  the	  fusion	  protein,	  FLAG-­‐tagged	  PAX3-­‐FOXO1	  was	  purified	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from	   aRMS	   cells.	   Using	  mass	   spectrometry,	  we	   identified	   the	   peptide	   TSSNASTISGR	  containing	   S503	   as	   one	   out	   of	   eleven	   phospho-­‐peptides	   (Supplementary	   Tab.	   S3).	  Furthermore,	   applying	   a	   phospho-­‐specific	   antibody	   to	   exactly	   localize	   the	  phosphorylated	   residue,	  we	  detected	  phosphorylation	  at	   S503+S506	   (corresponding	  to	   phospho-­‐S322+S325	   in	   FOXO1	   against	   which	   the	   antibody	   is	   directed)	   directly	  demonstrating	  that	  the	  predicted	  site	  is	  phosphorylated	  in	  aRMS	  cells	  (Fig.	  3E).	  	  To	   assess	   whether	   PLK1	   can	   phosphorylate	   S503,	   we	   purified	   FLAG-­‐PAX3-­‐FOXO1	  from	   HEK293T	   cells,	   dephosphorylated	   the	   protein	   by	   calf	   intestine	   alkaline	  phosphatase	   (CIAP)	   and	   subsequently	   performed	   in	   vitro	   kinase	   assays	   using	  recombinant	   PLK1.	   Mass	   spectrometry	   confirmed	   that	   PLK1	   phosphorylated	   the	  peptide	  TSSNASTISGR.	  In	  total,	  this	  peptide	  contains	  six	  serine	  or	  threonine	  sites,	  but	  the	   data	   indicated	   that	   only	   S503	   or	   T504	   could	   be	   considered	   as	   potential	  phosphorylation	  sites	  (Supplementary	  Fig.	  S3).	  To	  distinguish	  these	  two	  possibilities,	  we	   used	   the	   phospho-­‐specific	   antibody	   recognizing	   phospho-­‐S503+S506.	   Western	  blot	   analysis	   indeed	   revealed	   specific	   phosphorylation	   at	   these	   positions	   indicating	  that	  S503	  is	  the	  site	  being	  phosphorylated	  by	  PLK1	  (Fig.	  3F).	  	  These	   data	   suggest	   that	   PLK1	   and	   PAX3-­‐FOXO1	   are	   direct	   interaction	   partners	   and	  that	  PLK1	  can	  phosphorylate	  the	  fusion	  protein	  at	  S503.	  	  	  
PLK1	  stabilizes	  PAX3-­‐FOXO1	  protein	  	  To	  further	  explore	  the	  biological	  functions	  of	  this	  phosphorylation	  site,	  we	  transfected	  RD	   eRMS	   cells	   lacking	   endogenous	   PAX3-­‐FOXO1	   with	   plasmids	   expressing	   either	  PAX3-­‐FOXO1	  wild	  type	  or	  mutated	  PAX3-­‐FOXO1-­‐S503A.	  Cells	  were	  then	  treated	  with	  cycloheximide	   for	   6	   hours	   to	   assess	   protein	   turnover	   by	   immunoblotting	   and	  densitometric	   quantification.	   Interestingly,	   the	  mutant	   protein	  was	   significantly	   less	  stable	  than	  the	  wild	  type	  protein	  (protein	  amount	  reduced	  by	  47%)	  (Figs.	  4A	  and	  4B).	  	  Next,	  the	  stability	  of	  endogenous	  PAX3-­‐FOXO1	  upon	  PLK1	  depletion	  was	  examined	  in	  two	  aRMS	  cell	   lines.	  Treatment	  with	  siRNA	  1341	  for	  48	  hours	  reduced	  PLK1	  protein	  by	   43%	   in	   RMS13	   cells,	   respectively	   by	   53%	   in	   Rh4	   cells	   and	   induced	   a	   slight	  degradation	   of	   PAX3-­‐FOXO1	   (23%	   and	   11%,	   calculated	   from	   representative	   blots	  shown	   in	  Fig.	   4C).	  After	   silencing	  with	   the	  more	   efficient	   siRNA	  S449	   	   (reduction	  of	  PLK1	   by	   94%	   (RMS13)	   and	   83%	   (Rh4)),	   we	   observed	   degradation	   of	   the	   fusion	  protein	  by	  48%	  and	  41%	  compared	  to	  scrambled	  control	   treatment	  (Fig.	  4D).	  These	  results	  suggest	  that	  stability	  of	  PAX3-­‐FOXO1	  is	  modulated	  by	  phosphorylation	  at	  S503.	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Indeed,	   inhibition	   of	   PLK1	   activity	   by	  BI	   2536	   (15	  nM)	   and	  BI	   6727	   (20	  nM)	   led	   to	  similar	   reduction	  of	  PAX3-­‐FOXO1	  protein	   levels	   (53%	  and	  64%	   in	  RMS13,	  44%	  and	  49%	  in	  Rh4	  cells)	  (Fig.	  4E).	  In	  addition,	  increased	  ubiquitination	  of	  PAX3-­‐FOXO1	  upon	  PLK1	   inhibition	   confirmed	   its	   proteasomal	   degradation	   (Fig.	   4F),	   which	   moreover,	  could	   be	   rescued	   by	   adding	   low	   concentrations	   of	   the	   proteasomal	   inhibitor	  bortezomib	  (Adams	  et	  al.,	  1999)	  in	  a	  dose	  dependent	  manner	  (Fig.	  4G).	  	  In	  conclusion,	  these	  experiments	  imply	  that	  PLK1-­‐mediated	  phosphorylation	  at	  S503	  protects	   PAX3-­‐FOXO1	   from	  ubiquitination	   and	   consequent	   proteasomal	   degradation	  and	  thus	  maintains	  the	  transcriptional	  activity	  of	  the	  fusion	  protein.	  	  
PLK1	  inhibition	  causes	  tumor	  regression	  in	  xenografts	  Based	   on	   our	   in	   vitro	   results,	   we	   further	   validated	   PLK1	   as	   an	   in	   vivo	   target	   using	  xenograft	   mouse	   models.	   Immunocompromised	   NOD/Scid	   il2rg-­‐/-­‐	   (NSG)	   mice	   were	  engrafted	  subcutaneously	  with	  Rh4,	  Rh4luc	  and	  RMS13luc	  cells	  expressing	  luciferase	  for	  in	  vivo	  imaging.	  Mice	  with	  established	  tumors	  of	  varying	  sizes	  (65	  mm3	  -­‐	  470	  mm3)	  were	   treated	   intravenously	  with	  vehicle	  or	  BI	  2536	  at	   a	  dose	  of	  40	  mg/kg	   for	   three	  weeks	  on	   two	  consecutive	  days	  per	  week	   (Steegmaier	  et	  al.,	  2007).	  Every	   treatment	  group	  of	  three	  to	  five	  mice	  included	  two	  mice	  with	  large	  tumors	  of	  at	  least	  300	  mm3.	  Absolute	  tumor	  volumes	  measured	  by	  caliper	  in	  mice	  bearing	  Rh4	  tumors	  revealed	  a	  complete	  tumor	  regression	  upon	  BI	  2536	  treatment	  in	  all	  mice,	  even	  when	  the	  starting	  volume	  was	  as	  high	  as	  370	  mm3	  (Fig.	  5A).	  Similarly,	  luciferase	  activity	  was	  reduced	  in	  both	   cell	   lines	   by	   close	   to	   100%	   (Figs.	   5A	   and	  5B).	   Tumors	   of	   additional	  mice	  were	  treated	   for	   two	   cycles	   only,	   isolated	   after	   a	   two-­‐week	   recovery	   phase,	   paraffin-­‐embedded,	   and	   immunohistochemically	   stained.	   Vehicle	   treated	   tumors	   showed	  highly	  cellular	  histology	  with	  strong	  expression	  of	  myogenin	  and	  AP2β	  consistent	  with	  aRMS.	   In	   contrast,	   treated	   xenografts	   displayed	   a	   high	   degree	   of	   necrotic	   areas	   and	  fibrosis.	   Importantly,	   expression	   of	   PAX3-­‐FOXO1	   target	   genes	   AP2β	   and	   p-­‐cadherin	  (CDH3)	  was	  significantly	  lower	  compared	  to	  untreated	  xenografts.	  These	  data	  impressively	  illustrate	  that	  PLK1	  activity	  plays	  a	  major	  role	  in	  aRMS	  tumor	  cell	  survival	  corroborating	  our	   in	  vitro	   results.	  Therefore,	  PLK1	   inhibitors	  such	  as	  BI	  2536	  might	  represent	  very	  potent	  novel	  treatment	  options	  for	  aRMS.	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PLK1	   is	   overexpressed	   in	   human	   tumor	   biopsies	   and	   correlates	   with	   PAX3-­‐
FOXO1	  activity	  and	  survival	  To	  ensure	  that	  our	  findings	  are	  not	  restricted	  to	  aRMS	  cell	  lines,	  PLK1	  expression	  was	  analyzed	  in	  patient	  tumor	  biopsies.	  We	  utilized	  PLK	  mRNA	  expression	  data	  of	  PAX3-­‐FOXO1	  positive	  aRMS	  tumors	  from	  two	  independent	  data	  sets	  (Davicioni	  et	  al.,	  2006;	  Wachtel	  et	  al.,	  2004)	  and	  compared	  them	  to	  PLK	  expression	  in	  normal	  muscle	  tissue	  (Bakay	  et	  al.,	  2006).	  We	  found	  that	  mRNA	  levels	  of	  PLK1	  and	  PLK4,	  but	  not	  PLK2	  and	  PLK3,	  were	  significantly	  higher	  in	  tumor	  samples	  than	  in	  normal	  muscle	  biopsies	  (Fig.	  6A	  and	  Supplementary	  Fig.	  S4).	  	  To	   validate	   PLK1	   as	   a	   clinically	   relevant	   therapeutic	   target,	   we	   immuno-­‐histochemically	   stained	   a	   tissue	   microarray	   including	   tumor	   biopsies	   of	   49	   aRMS	  patients.	  Tumors	  were	  divided	  into	  high	  and	  low	  expressing	  subgroups	  as	  described	  in	  the	  material	   and	  methods	   section	   	   (Fig.	   6B).	   To	   correlate	  PAX3-­‐FOXO1	  activity	  with	  PLK1	  expression	  in	  vivo,	  we	  assessed	  in	  parallel	  expression	  of	  the	  PAX3-­‐FOXO1	  target	  gene	  AP2β.	  In	  a	  majority	  of	  tumors	  (34	  out	  of	  45),	  AP2β	  staining	  from	  the	  same	  tumor	  significantly	  correlated	  with	  expression	  of	  PLK1	  (Pearson	  correlation	  p-­‐value:	  0.0004,	  Fig.	   6C).	   This	   was	   not	   the	   case	   for	   co-­‐staining	   with	   the	   proliferation	   marker	   MIB1	  (Supplementary	   Fig.	   S5).	   These	   results	   support	   our	   previous	   findings	   and	   a	  mechanism	  whereby	  activity	  of	  PAX3-­‐FOXO1	  is	  modulated	  by	  PLK1.	  Importantly,	  outcome	  as	  measured	   for	  event-­‐free	   (EFS)	  and	  overall	   survival	   (OS)	  by	  Kaplan-­‐Meier	  analysis	  was	  significantly	  worse	  for	  patients	  with	  high	  PLK1	  expression	  (Fig.	   6D).	   Five-­‐year	   survival	   rates	   for	   patients	   in	   the	   PLK1	   high	   expression	   cohort	  were	  only	  15.4%	  (EFS)	  and	  20.2%	  (OS).	  Therefore,	  the	  hazard	  ratio	  for	  events	  was	  2.3	  times	  higher	  (Wald	  test:	  p	  =	  0.019)	  and	  for	  death	  even	  3.16	  times	  higher	  (Wald	  test:	  p	  =	   0.004)	   for	   patients	   with	   high	   PLK1	   expression.	   Moreover,	   multivariate	   analysis	  including	  the	  factors	  age,	  sex	  and	  tumor	  localization	  identified	  PLK1	  status	  as	  the	  only	  significant	  risk	  associated	  variable	  (Tab.	  1).	  The	  very	  dismal	  survival	  rates	  for	  the	  high	  expression	   cohort	   emphasize	   the	   importance	   of	   PLK1	   expression	   and	   suggest	   that	  PLK1	  is	  a	  prognostic	  risk	  factor	  for	  fusion	  positive	  RMS.	  In	  summary,	  our	  results	  imply	  that	  PLK1	  is	  a	  highly	  attractive	  target	  for	  the	  treatment	  of	  aggressive	  aRMS,	  which	  warrants	  further	  investigations	  in	  clinical	  studies.	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6.5 Discussion	  
This	   study	  describes	  a	  novel	  PLK1	   -­‐	  PAX3-­‐FOXO1	  oncogenic	   axis	   in	  aRMS.	  We	  show	  modulation	   of	   PAX3-­‐FOXO1	   activity	   by	   PLK1	   based	   on	   direct	   protein-­‐protein	  interaction	  and	  phosphorylation	  at	  S503	  leading	  to	  stabilization	  of	  the	  fusion	  protein.	  In	  addition,	  in	  vivo	  treatment	  with	  PLK1	  inhibitor	  demonstrated	  tumor	  regression	  and	  immunohistochemical	   analysis	   of	   PLK1	   protein	   expression	   in	   human	   biopsies	  revealed	  its	  novel	  prognostic	  impact.	  	  To	   improve	   previous	   screenings	   for	   targets	   in	   aRMS,	  which	   concentrated	  mainly	   on	  cell	  viability	   (Hu	  et	  al.,	  2009),	  we	   focused	  on	   transcriptional	  activity	  of	  PAX3-­‐FOXO1	  by	   employing	   aRMS	   (Rh4)	   cells	   stably	   expressing	   an	   AP2β-­‐promoter	   reporter	  construct.	   Using	   the	   ratio	   of	   reporter	   activity	   versus	   cell	   viability,	   we	   were	   able	   to	  exclude	  generally	  cytotoxic	  drugs.	  Strikingly,	  a	  kinome-­‐wide	  siRNA	  as	  well	  as	  a	  small-­‐molecule	   library	   screen	   identified	   PLK1	   as	   top	   hit.	   KEGG	   pathway	   analysis	   (string-­‐db.org)	   showed	   that	   several	   additional	   candidates	   are	   associated	   with	   MAPK	   or	  phosphatidylinositol	   signaling,	   both	  of	  which	  have	  been	  previously	   reported	   in	  RMS	  (Guenther	  et	  al.,	  2013;	  Renshaw	  et	  al.,	  2013)	  To	   confirm	   PLK1	   as	   an	   upstream	   modulator	   of	   PAX3-­‐FOXO1	   activity,	   we	   assessed	  expression	   of	   known	   endogenous	   PAX3-­‐FOXO1	   target	   genes	   (AP2β,	   FGFR4,	   CDH3,	  PIPOX	  and	  MYL1)	  upon	  inhibition	  by	  two	  drugs	  as	  well	  as	  by	  two	  different	  siRNAs	  in	  two	   aRMS	   cell	   lines.	   We	   observed	   significant	   target	   gene	   modulation,	   with	   the	  exception	  of	  one	  siRNA	  in	  Rh4	  cells.	  It	  is	  likely	  that	  the	  lack	  of	  effect	  might	  be	  due	  to	  compensatory	  effects	  by	  other	  members	  of	  the	  PLK	  family	  since	  BI	  2536	  and	  BI	  6727	  are	  known	  to	  affect	  the	  activities	  of	  PLK2,	  PLK3,	  and	  potentially	  PLK4	  (Rudolph	  et	  al.,	  2009;	   Steegmaier	   et	   al.,	   2007).	   Indeed,	   next	   to	   PLK1	   also	   PLK4	   is	   overexpressed	   in	  aRMS	  biopsies	  compared	  to	  normal	  muscle	  and,	  although	  not	  identified	  in	  the	  primary	  screen,	   its	   depletion	   reduced	   target	   gene	   expression	   in	   Rh4	   cells	   suggesting	  overlapping	   functions	  of	  PLK1	  and	  PLK4	   (Supplementary	  Fig.	   S6).	  Nevertheless,	   our	  findings	  support	  the	  conclusion	  that	  PLK1	  regulates	  PAX3-­‐FOXO1	  activity.	  To	  further	  sustain	  this	  notion,	  we	  demonstrated	  direct	  protein-­‐protein	  interaction	  of	  the	   endogenous	   proteins	   by	   co-­‐immunoprecipitations	   in	   aRMS	   cells.	   Also,	  recombinant	  PLK1	  phosphorylated	  the	  fusion	  protein	  at	  S503	  in	  in	  vitro	  kinase	  assays.	  This	  residue	  is	  located	  within	  a	  very	  conserved	  domain	  in	  the	  FOXO1	  part	  of	  the	  fusion	  protein	  and	  the	  corresponding	  serine	  in	  wild	  type	  FOXO1	  (S322)	  is	  a	  site	  known	  to	  be	  phosphorylated	  by	  recombinant	  CK1	  (Rena	  et	  al.,	  2002).	  A	  recent	  study	  demonstrated	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that	  wild	  type	  FOXO1	  interacts	  with	  and	  is	  phosphorylated	  also	  by	  PLK1	  during	  G2/M	  (Yuan	   et	   al.,	   2014).	   Similarly,	   we	   observed	   enhanced	   interaction	   in	   this	   cell	   cycle	  phase.	  However,	  phosphorylation	  of	  wild	  type	  FOXO1	  triggers	  nuclear	  export	  (Rena	  et	  al.,	  2002;	  Yuan	  et	  al.,	  2014),	  whereas	  PAX3-­‐FOXO1	  is	  located	  exclusively	  in	  the	  nucleus	  (del	   Peso	   et	   al.,	   1999;	   and	   own	   observations).	   Hence,	   phosphorylation	   of	   S503	   by	  PLK1	  must	   have	   different	   consequences.	   In	   fact,	   we	   observed	   faster	   degradation	   of	  PAX3-­‐FOXO1-­‐S503A	   compared	   to	   wild	   type	   after	   cycloheximide	   block	   due	   to	  enhanced	  ubiquitination	  upon	  PLK1	  inhibition.	  It	  has	  previously	  also	  been	  shown	  that	  PAX3-­‐FOXO1	  has	  increased	  posttranslational	  stability	  compared	  to	  wild	  type	  proteins	  (Miller	   and	   Hollenbach,	   2007).	   Our	   results	   are	   furthermore	   in	   line	   with	   studies	  demonstrating	   PLK1	   to	   mediate	   stabilization	   of	   transcription	   factors	   such	   as	   the	  oncogene	  MYC	  (Tan	  et	  al.,	  2013).	  Interestingly,	  we	  found	  the	  fusion	  target	  gene	  NMYC	  to	   be	   degraded	   upon	   PLK1	   inhibition,	   either	   by	   a	   direct	   or	   indirect	   mechanism	  (Supplementary	  Fig.	  S7),	  which	  might	   further	  sensitize	  aRMS	  as	  well	  as	  other	  NMYC	  expressing	   tumors	   to	   PLK1	   inhibitors.	   In	   accordance	  with	   the	   proposed	   function	   of	  PAX3-­‐FOXO1	   in	   checkpoint	   adaptation	   (Kikuchi	   et	   al.,	   2014),	   PLK1	   might	   prevent	  premature	  degradation	  of	  PAX3-­‐FOXO1	  during	  the	  transition	  phase.	  In	  summary,	  this	  suggests	   a	  model	  whereby	  PLK1	  phosphorylation	   can	   stabilize	  PAX3-­‐FOXO1,	  mainly	  during	  G2/M	  transition,	  whereas	  at	  the	  same	  time	  it	  would	  inhibit	  the	  wild	  type	  tumor	  suppressor	  FOXO1	  to	  ensure	  cell	  cycle	  progression	  and	  survival.	  	  We	   observed	   an	   almost	   complete	   tumor	   regression	   in	   vivo	   upon	   treatment	   with	   BI	  2536	  in	  two	  different	  aRMS	  cell	  lines.	  This	  is	  in	  agreement	  with	  an	  objective	  response	  demonstrated	   for	   the	   Rh30r	   aRMS	   xenograft	   by	   the	   Pediatric	   Preclinical	   Testing	  Program	   (Gorlick	   et	   al.,	   2014).	  This	  particular	   xenograft	  was	  derived	   from	  a	  patient	  that	  had	  failed	  prior	  therapies	  suggesting	  that	  PLK1	  expression	  might	  be	  of	  prognostic	  relevance.	   Indeed,	   expression	   of	   PLK1	   in	   49	   aRMS	   tumor	   biopsies	   significantly	  predicted	  poor	  prognosis	  for	  event-­‐free	  and	  overall	  survival.	  To	  our	  knowledge,	  PLK1	  expression	  is	  therefore	  one	  of	  the	  first	  predictive	  markers	  next	  to	  EPHB4	  that	  is	  able	  to	  stratify	  patients	  within	  the	  group	  of	  fusion-­‐positive	  tumors	  (Aslam	  et	  al.,	  2014).	  	  Summarizing,	  our	  data	  suggest	   that	  PLK1	   is	  a	  highly	  relevant	  clinical	   target	   in	  aRMS	  with	  several	  PLK1	  inhibitors	  already	  in	  clinical	  development.	  Since	  it	  has	  been	  shown	  that	   mice	   can	   tolerate	   higher	   systemic	   exposure	   to	   PLK1	   inhibitors	   than	   humans	  (Gorlick	  et	  al.,	  2014),	   it	   is	   likely	   that	  combination	   therapies	  need	   to	  be	  developed	   to	  overcome	   this	   obstacle.	   Nevertheless,	   this	   study	   reveals	   an	   important	   new	   role	   for	  PLK1	   in	  aRMS	  biology	  apart	   from	   its	  known	  function	   in	  cell	   cycle	   that	  might	  explain	  
	   59	  
increased	   sensitivity.	   Hence,	   our	   results	   should	   be	   directly	   translatable	   to	   clinical	  studies.	  
6.6 Figure	  legends	  
Fig.	  1.	  siRNA	  and	  drug	  screening	  identify	  PLK1	  as	  regulator	  of	  PAX3-­‐FOXO1	  (A)	   Schematic	   representation	   of	   screening	   strategy.	   PAX3-­‐FOXO1	   is	   phosphorylated,	  transcriptionally	  active	  and	  induces	  expression	  of	  the	  luciferase	  gene,	  which	  is	  under	  the	   control	   of	   the	   PAX3-­‐FOXO1-­‐responsive	   AP2β	   promoter.	   Kinase	   silencing	   and	  small-­‐	  molecule	  inhibition	  reduce	  PAX3-­‐FOXO1	  transcriptional	  activity	  and	  result	  in	  a	  decreased	  expression	  of	  the	  luciferase	  gene.	  (B)	  Results	  of	  kinome-­‐wide	  siRNA	  screen.	  RNA	  silencing	  was	  carried	  out	  for	  48h	  using	  50	   nM	   siRNA.	   The	   luciferase	   readout	   was	   normalized	   to	   cell	   viability	   measured	   by	  WST-­‐1	  assay.	  siRNAs	  targeting	  luciferase	  (pGL4)	  and	  PAX3-­‐FOXO1	  served	  as	  positive	  controls	   for	   reduced	   activity/cell	   viability	   ratio	   (LF/V)	   and	   siKIF11	   for	   reduced	   cell	  viability.	   Reduced	   LF/V	   ratio	   upon	   PLK1	   silencing	   is	   marked	   in	   black.	   Data	   points,	  mean	  of	  three	  independent	  experiments	  performed	  in	  triplicates;	  threshold,	  1.5	  SDs	  of	  mean	  of	  luciferase	  knockdown.	  (C)	  Sub-­‐screen	  of	  candidate	  kinases.	  RNA	  silencing	  was	  carried	  out	  in	  Rh4	  and	  RMS13	  cells	  for	  72h	  using	  50	  nM	  siRNA.	  Cell	  viability	  was	  measured	  by	  WST-­‐1	  assay	  and	  set	  relative	   to	   scrambled	   knockdown.	   Data	   points,	   mean	   of	   three	   independent	  experiments	   performed	   in	   triplicates;	   Student’s	   t-­‐test	   for	   PLK1	   knockdown	   ***	   p	   <	  0.001,	  **	  p	  <	  0.01.	  (D)	  Illustration	  of	  the	  ten	  most	  effective	  drugs.	  Rh4-­‐AP2β-­‐LF	  cells	  were	  treated	  with	  a	  small-­‐molecule	   compound	   library	   at	   a	   final	   concentration	   of	   500	   nM	   for	   24h	   and	  luciferase	  activity	  (LF)	  and	  cell	  viability	  (V)	  were	  measured.	  Relative	  values	  compared	  to	   untreated	   cells	   as	  well	   as	   the	   resulting	   LF/V	   ratios	   are	   shown.	  Columns,	  mean	   of	  technical	  triplicates;	  bars,	  SD.	  (E)	   Drug	   response	   curve	   of	   BI	   2536	   based	   on	   LF/V	   ratio.	   Rh4-­‐AP2β-­‐LF	   cells	   were	  treated	   with	   increasing	   concentrations	   of	   BI	   2536	   for	   24h.	   LF/V	   values	   were	  measured	   relative	   to	  untreated	   cells.	  Data	  points,	  mean	  of	   technical	   triplicates;	   non-­‐linear	  regression	  curve	  fitting	  using	  Prism	  GraphPad.	  (F)	  PLK1	  expression	  in	  aRMS	  cell	  lines	  shown	  by	  Western	  blot	  analysis.	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Fig.	  2.	  PLK1	  silencing	  and	  inhibition	  reduce	  PAX3-­‐FOXO1	  activity	  Relative	   mRNA	   expression	   of	   PAX3-­‐FOXO1	   and	   its	   target	   genes	   upon	   PLK1	  knockdown	   and	   inhibition.	   CT	   values	   relative	   to	   scrambled	   knockdown	   or	   DMSO	  treatment	  were	  measured	  by	  qRT-­‐PCR	  and	  normalized	  to	  GAPDH	  expression.	  	  (A	  and	  B)	  PLK1	  was	  silenced	  for	  48h	  using	  two	  different	  sequences	  (25	  nM	  si1341	  and	  8	  nM	  siS449)	  in	  RMS13	  and	  Rh4	  cells.	  (C	  and	  D)	  RMS13	  and	  Rh4	  cells	  were	  treated	  with	  15	  nM	  BI	  2536	  or	  20	  nM	  BI	  6727	  for	  48h.	  
Columns,	   geometric	   mean	   of	   at	   least	   4	   independent	   experiments	   performed	   in	  triplicates;	  bars,	  95%	  confidence	  interval;	  	  *	  significant	  according	  to	  95%	  CI.	  	  
Fig.	  3.	  PLK1	  phosphorylates	  PAX3-­‐FOXO1	  (A)	   Western	   blot	   analysis	   showing	   endogenous	   Co-­‐IP	   of	   PLK1	   after	   PAX3-­‐FOXO1	  immunoprecipitation	  in	  Rh4	  cells.	  Beads-­‐only	  were	  used	  as	  negative	  control.	  (B)	   Western	   blot	   analysis	   showing	   endogenous	   Co-­‐IP	   of	   PAX3-­‐FOXO1	   after	   PLK1	  immunoprecipitation	  in	  Rh4	  cells.	  Beads-­‐only	  were	  used	  as	  negative	  control.	  (C)	   Western	   blot	   analysis	   of	   PLK1	   after	   FLAG	   immunoprecipitation	   from	   Rh4	   cells	  expressing	  FLAG-­‐PAX3-­‐FOXO1.	  Cells	  were	   treated	  with	  DMSO	  or	  15	  nM	  BI	  2536	   for	  16h.	  FLAG-­‐GFP	  was	  used	  as	  negative	  control.	  (D)	   In	   silico	   analysis	   using	   the	   phospho-­‐site	   prediction	   software	   GPS-­‐Polo	   1.0	   for	  phosphorylation	  of	  PAX3-­‐FOXO1	  by	  PLK.	  	  	  (E)	   Western	   blot	   analysis	   of	   FLAG-­‐PAX3-­‐FOXO1	   purified	   from	   Rh4	   cells	   using	   anti	  phospho-­‐S503+S506	  antibody.	  (F)	  PLK1	  in	  vitro	  kinase	  assay.	  HEK293T	  cells	  were	  transfected	  by	  FLAG-­‐PAX3-­‐FOXO1	  expressing	   plasmid,	   purified,	   dephosphorylated	   by	   CIAP,	   and	   re-­‐phosphorylated	   by	  recombinant	   PLK1.	   Phospho-­‐peptide	   identified	   by	   mass	   spectrometric	   analysis	   and	  Western	  blot	  analysis	  using	  anti	  phospho-­‐S503+S506	  antibody	  are	  shown.	  	  
Fig.	  4.	  PLK1	  stabilizes	  PAX3-­‐FOXO1	  (A)	  Western	   blot	   analysis	   of	   exogenous,	  wild	   type	   or	   phospho-­‐mutant	   PAX3-­‐FOXO1	  degradation.	  RD	  cells	  were	  transfected	  with	  PAX3-­‐FOXO1	  wild	  type	  or	  PAX3-­‐FOXO1-­‐
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S503A	  expressing	  constructs	  and	  treated	   for	  6h	  with	  DMSO	  or	  35	  μM	  cycloheximide	  (CHX).	  	  (B)	   Quantification	   of	   exogenous	   PAX3-­‐FOXO1	   degradation	   by	   densitometry.	   Levels	  were	  normalized	   to	  GAPDH.	  Columns,	  mean	  of	   three	   independent	  experiments;	  bars,	  SD;	  Student’s	  t-­‐test	  **	  p=	  0.0052.	  (C	  and	  D)	  Western	  blot	  analysis	  of	  endogenous	  PAX3-­‐FOXO1	  degradation	  upon	  PLK1	  silencing.	  RMS13	  and	  Rh4	  cells	  were	   transfected	  with	  25	  nM	  si1341	  or	  8	  nM	  siS449	  for	  48h.	  	  (E)	   Western	   blot	   analysis	   of	   endogenous	   PAX3-­‐FOXO1	   degradation	   upon	   PLK1	  inhibition.	  RMS13	  and	  Rh4	  cells	  were	  treated	  with	  DMSO,	  15	  nM	  BI	  2536	  or	  20	  nM	  BI	  6727	  for	  48h.	  	  (F)	   Ubiquitination	   studies.	   Western	   blot	   analysis	   after	   FLAG	   immunoprecipitation	  from	   Rh4	   cells	   expressing	   FLAG-­‐PAX3-­‐FOXO1	   and	   HA-­‐ubiquitin.	   Cells	   were	   treated	  with	  DMSO,	  200	  nM	  BI2536	  or	  200	  nM	  BI6727	  for	  21h	  prior	  to	  addition	  of	  10	  μM	  MG-­‐132	  for	  5h.	  	  (G)	  Western	  blot	  analysis	  showing	  rescue	  of	  endogenous	  PAX3-­‐FOXO1	  degradation	  by	  the	  proteasomal	  inhibitor	  bortezomib.	  Rh4	  cells	  were	  treated	  with	  15	  nM	  BI	  2536	  for	  20h.	  Bortezomib	  was	  simultaneously	  titrated	  to	  the	  cells.	  Densitometric	  quantification	  normalized	  to	  β-­‐tubulin	  is	  indicated.	  	  	  
Fig.	  5.	  PLK1	  inhibition	  causes	  tumor	  regression	  in	  vivo	  
In	  vivo	   drug	   treatment	   of	  NOD/Scid	   il2rg-­‐/-­‐	  mice	   engrafted	  with	  Rh4	   (n=10),	   Rh4luc	  (n=6)	   and	   RMS13luc	   (n=6)	   (luc	   =	   luciferase	   expressing).	   Mice	   bearing	   established	  tumors	  were	   treated	   intravenously	   for	   three	   cycles	  with	  either	  vehicle	   control	  or	  BI	  2536	   at	   a	   dose	   of	   40	   mg/kg	   twice	   weekly	   on	   two	   consecutive	   days	   (indicated	   by	  triangles).	  	  (A)	  Absolute	  and	  relative	  tumor	  volumes	  upon	  treatment.	  Absolute	  tumor	  volume	  was	  measured	  by	  caliper	  (upper	  two	  panels).	  In	  vivo	  imaging	  was	  performed	  for	  luciferase	  expressing	   tumors.	   Relative	   bioluminescence	   (photons/second)	   is	   depicted	   (lower	  four	  panels).	  	  (B)	   Illustration	  of	   tumor	  regression	  by	  picture	  series	  during	   treatment	  phase	  of	   two	  representative	  mice.	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(C)	   Immunohistochemistry	  of	  a	  control	  and	  a	  BI	  2536	  treated	  tumor.	  Rh4luc	   tumors	  were	   treated	   for	   two	   cycles	   with	   either	   vehicle	   control	   or	   BI	   2536	   at	   a	   dose	   of	   40	  mg/kg.	   Tumors	   were	   excised	   two	   weeks	   after	   the	   end	   of	   treatment	   and	  immunohistochemically	  stained.	  	  	  
Fig.	  6.	  PLK1	  is	  an	  overexpressed,	  prognostic	  marker	  that	  correlates	  with	  PAX3-­‐
FOXO1	  activity	  in	  tumor	  biopsies	  (A)	   PLK1	   gene	   expression	   in	   normal	   human	   muscle	   (n=121)	   and	   in	   PAX3-­‐FOXO1	  positive	   aRMS	  patient-­‐derived	   biopsies	   (n=46)	  measured	   by	  microarray	   (Affymetrix	  HG-­‐U133A).	  Box	  plot,	  minimum	  to	  maximum;	  Student’s	  t-­‐test	  p	  <	  0.0001.	  (B)	   Patient-­‐derived	   tissue	   microarray	   immunohistochemically	   stained	   for	   PLK1	  (n=49)	  and	  AP2β	  (n=45)	  expression.	  Patients	  were	  grouped	  according	  to	  high	  (n=26)	  and	   low	   (n=23)	  PLK1	  expression	  and	  high	   (n=28)	  and	   low	  AP2β	   (n=17)	  expression.	  Representative	   tumor	   of	   PLK1	   high	   expression	   cohort	   and	   a	   tumor	   with	   very	   low	  expression	  are	  shown	  next	  to	  AP2β	  staining	  of	  the	  same	  tumor.	  	  (C)	   Pearson	   correlation	   of	   PLK1	   and	   AP2β	   expression	   based	   on	   tissue	   microarray	  (n=45);	  p=	  0.0004.	  (D)	  Kaplan-­‐Maier	  survival	  curves	  of	  PLK1	  low	  and	  high	  expression	  cohorts	  based	  on	  tissue	  microarray.	  	  Log-­‐rank	  test.	  
6.7 Supplementary	  figure	  legends	  
Fig.	  S1.	  Establishment	  of	  screening	  approach	  Establishment	   and	   validation	   of	   the	   screening	   approach	   using	   a	   stable	   endogenous	  reporter	   cell	   system.	   aRMS	   cells	  were	   transfected	  with	   the	  AP2β	   luciferase	   reporter	  construct.	  (A)	  siRNA	  mediated	  knockdown	  was	  carried	  out	  for	  48h	  at	  a	  concentration	  of	  50	  nM	  targeting	   luciferase	   and	   PAX3-­‐FOXO1.	   Luciferase	   activity	   was	   normalized	   to	   cell	  viability	  measured	  by	  WST-­‐1.	  PAX3-­‐FOXO1	  knockdown	  efficiency	  was	  assessed	  using	  Western	  blotting	  (inlay).	  Columns,	  mean	  of	  four	  independent	  experiments	  performed	  in	  triplicates;	  bars,	  SD;	  Student’s	  t-­‐test	  ***	  p	  <	  0.0001.	  (B)	  Methodology	  of	  the	  functional	  kinome-­‐wide	  siRNA	  screen.	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(C)	   Drug	   response	   curve	   of	   BI	   2536	   based	   on	   LF/V	   ratio.	   Rh4-­‐AP2β-­‐LF	   cells	   were	  treated	   with	   increasing	   concentrations	   of	   BI	   2536	   for	   48h	   (upper	   panel)	   and	   72h	  (lower	   panel).	   LF/V	   values	   were	   measured	   relative	   to	   untreated	   cells.	   Data	   points,	  mean	   of	   technical	   triplicates;	   non-­‐linear	   regression	   curve	   fitting	   using	   Prism	  GraphPad.	  	  
Fig.	  S2.	  BI	  2536	  causes	  apoptosis	  and	  cell	  cycle	  arrest	  (A)	  IC50	  values	  for	  BI	  2536	  were	  calculated	  for	  different	  aRMS	  and	  eRMS	  cell	  lines	  after	  72h.	  (B)	  Rh4	  cells	  were	  treated	  with	  15	  nM	  BI	  2536	  for	  24h.	  PARP	  cleavage	  is	  presented	  by	  Western	  blot	  analysis.	  (C)	  Rh4	  cells	  were	  treated	  with	  increasing	  concentrations	  of	  BI	  2536	  for	  24h	  and	  48h.	  Relative	  caspase	  3/7	  activity	  is	  displayed.	  	  (D)	   Rh4	   cells	  were	   treated	  with	   15	   nM	  BI	   2536	   for	   24h.	   Cell	   cycle	   distribution	  was	  measured	  by	  FACS	  analysis	  after	  PI-­‐staining.	  
	  
Fig.	  S3.	  PLK1	  phosphorylates	  PAX3-­‐FOXO1	  in	  vitro	  Representative	  MS	  spectra	  for	  identification	  of	  the	  phospho-­‐peptide	  TSSNASTISGR.	  (A)	   Dephosphorylated	   peptide	   showing	   the	   ion	   at	   620	   m/z	   representative	   of	  unmodified	  S503.	  (B)	   Peptide	   after	   PLK1	   in	   vitro	   kinase	   assay	   showing	   a	   shift	   of	   the	   ion	   to	   700	  m/z	  indicating	  phosphorylation	  of	  S503	  or	  T504.	  	  
Fig.	  S4.	  PLK4	  is	  overexpressed	  in	  tumor	  biopsies	  PLK2,	  PLK3	  and	  PLK4	  gene	  expression	  in	  normal	  human	  muscle	  (n=121)	  and	  in	  PAX3-­‐FOXO1	   positive	   aRMS	   patient-­‐derived	   biopsies	   (n=46)	   measured	   by	   microarray	  (Affymetrix	   HG-­‐U133A).	   Box	   plot,	  minimum	   to	   maximum;	   Student’s	   t-­‐test	   ***	   p	   <	  0.0001.	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Fig.	  S5.	  PLK1	  staining	  does	  not	  correlate	  with	  MIB1	  staining	  in	  tumor	  biopsies	  Pearson	   correlation	   of	   PLK1	   and	  MIB1	   staining	   based	   on	   tissue	  microarray	   (n=42);	  	  	  p=	  0.1137.	  
	  
Fig.	  S6.	  PLK4	  silencing	  reduces	  PAX3-­‐FOXO1	  activity	  Relative	  mRNA	  expression	  of	  PAX3-­‐FOXO1	  and	  its	  target	  genes	  upon	  PLK1,	  PLK4	  and	  PLK1+PLK4	  knockdowns.	  CT	  values	  relative	  to	  scrambled	  knockdown	  were	  measured	  by	  qRT-­‐PCR	  and	  normalized	   to	  GAPDH	  expression.	  Silencing	  was	  performed	   for	  48h	  using	   8	   nM	   siPLK1	   (s449)	   and	   25	   nM	   siPLK4	   in	   Rh4	   cells.	  Western	   blot	   analysis	   is	  showing	   PLK4	   knockdown	   efficiency.	   Columns,	   geometric	   mean	   of	   4	   independent	  experiments	   performed	   in	   triplicates;	   bars,	   95%	   confidence	   interval;	   	   *	   significant	  according	  to	  95%	  CI.	  	  
Fig.	  S7.	  PLK1	  inhibition	  causes	  NMYC	  degradation	  Western	  blot	  analysis	  of	  endogenous	  NMYC	  degradation	  upon	  PLK1	  inhibition.	  RMS13	  and	  Rh4	  cells	  were	  treated	  with	  DMSO,	  15	  nM	  BI	  2536	  or	  20	  nM	  BI	  6727	  for	  48h.	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Pearson correlation: p= 0.0004 
PLK1 5yr EFS  95% CI 5yr OS 95% CI 
low 
n=23 42.4% 26.1-68.8% 59.7% 42.4-84.0% 
high 
n=26 15.4%  6.2-37.9 % 20.2% 8.6-47.2% 
PLK1 AP2β 
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 relative risk p-value 
 
Event Free Survival 
Age 0.996 0.892 
Sex (male vs. female) 0.709 0.367 
Localization (unfavorable vs. favorable) 0.704 0.577 
PLK1 (high vs. low) 2.340 0.028 
 
Overall Survival 
Age 1.016 0.571 
Sex (male vs. female) 0.701 0.392 
Localization (unfavorable vs. favorable) 1.230 0.797 
PLK1 (high vs. low) 2.560 0.020 
 
Tab. 1. Multivariate analysis 	  
Tab. 1 
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6.9 Supplementary	  figures	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Cell$line BI$2536$IC50 Type 
Rh4 14.58(nM alveolar 
Rh30 15.48(nM alveolar 
RMS13 14.18(nM alveolar 
Rh41 16.70(nM alveolar 
RD 33.04(nM embryonal 
Rh36 30.67(nM embryonal 
Ruch2 44.74(nM embryonal 
Ruch3( 14.70(nM embryonal 
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972.3880 744.4160 437.7279 602.3914 232.2378 885.4490 673.3589 771.4161 390.1910 189.2935 911.3013 258.1308 1024.4263 1114.3390 
# b Seq. y #
1 102.055 T 11
2 189.087 S 979.4803 10
3 276.119 S 892.448 9
4 390.1619 N 805.416 8
5 461.1991 A 691.373 7
6 548.2311 S 620.336 6
7 649.2788 T 533.304 5
8 762.3628 I 432.257 4
9 849.3949 S 319.172 3
10 906.4163 G 232.14 2
11 R 175.119 1
# b Seq. y #
1 102.055 T 11
2 189.087 S 1059.447 10
3 276.119 S 972.415 9
4 390.1619 N 885.383 8
5 461.1991 A 771.34 7
6 548.2311 S 700.303 6
7 729.2451 T 613.2705 5
8 842.3292 I 432.2565 4
9 929.3612 S 319.172 3
10 986.3826 G 232.14 2
11 R 175.119 1
y8 
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Fig. S4 
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6 PLK1 high / MIB1 high 
PLK1 low / MIB1 low 
PLK1 high / MIB1 low 
PLK1 low / MIB1 high 
	  	   	  Fig. S5 
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130 kDa 
	   	  Fig. S6 
	   78	  

































	   	  Fig. S7 
	   79	  
Gene 
Symbol 







AGK acyl glycerol kinase 
ALPK3 alpha-kinase 3 
AKT3  v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) + 
BUB1B budding uninhibited by benzimidazoles 1 homolog beta (yeast) + 
CAMK2N1  calcium/calmodulin-dependent protein kinase II inhibitor 1 
CDC2L5  cell division cycle 2-like 5 (cholinesterase-related cell division controller) + 
CSNK1A1  casein kinase 1, alpha 1 
DDR1  discoidin domain receptor tyrosine kinase 1 
EPHA2  EPH receptor A2 
GLYCTK  glycerate kinase 
GUK1  guanylate kinase 1 
ITGB1BP3  integrin beta 1 binding protein 3 
KCNE1 potassium voltage-gated channel, Isk-related family, member 1 
MAP3K7CL MAP3K7 C-terminal-like protein/TAK1-like protein 
MAPKSP1  MAPK scaffold protein 1 + 
MAST2 microtubule associated serine/threonine kinase 2 
MKNK1 MAP kinase-interacting serine/threonine kinase 1 + 
MUSK muscle, skeletal, receptor tyrosine kinase 
MYLK4 myosin light chain kinase family, member 4 
NEK2 NIMA (never in mitosis gene a)-related kinase 2 + 
NMRK1 nicotinamide riboside kinase 1 
PFKL phosphofructokinase, liver 
PI4KA phosphatidylinositol 4-kinase, catalytic, alpha  + 
PI4K2B phosphatidylinositol 4-kinase type 2 beta + 
PIK3C2A phosphoinositide-3-kinase, class 2, alpha + 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit, 3 (gamma) + 
PIM1 pim-1 oncogene + 
PIM3 pim-3 oncogene + + 
PIP4K2A phosphatidylinositol-4-phosphate 5-kinase, type II, alpha + 
PIP4K2B phosphatidylinositol-4-phosphate 5-kinase, type II, beta 
PLK1 polo-like kinase 1 + 
PRKCA protein kinase C, alpha + + + 
PRKD1 protein kinase D1 
RFK riboflavin kinase 
RPS6KA5 ribosomal protein S6 kinase, 90kD, polypeptide 5 + 
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 + 
SH3BP4 SH3-domain binding protein 4 
SIK3 SIK family kinase 3 
SKP2 S-phase kinase-associated protein 2 (p45) + 
SLK STE20-like kinase 
TEX14 testis expressed 14 + 
TRIB2 tribbles homolog 2 (Drosophila) 
TRIB3 tribbles homolog 3 (Drosophila) 
TTK TTK protein kinase + 
UCK1 uridine-cytidine kinase 1 
YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1  
ZMYND8 zinc finger, MYND-type containing 8 
	   	  Tab. S1 




Compound name Company Target 
   
ABT-737 Abbott, Baar/Zug, Switzerland BCL-2, BCL-xl inhibitor 
OSI-027 Active Biochem, Maplewood, NJ, USA mTORC1/2 inhibitor 
PP242 Active Biochem, Maplewood, NJ, USA mTORC1/2 inhibitor 
IGC-001 AdooQ Bioscience, Irvine, CA, USA Beta-catenin inhibitor 
A 769662  Axon Medchem, Groningen, NL AMPK activator  
ABT-102  Axon Medchem, Groningen, NL TRVP1 antagonist  
AEG 3482  Axon Medchem, Groningen, NL JNK inhibitor  
AG 013736 - Axitinib  Axon Medchem, Groningen, NL VEGFR inhibitor  
AMN 107 (Nilotinib)  Axon Medchem, Groningen, NL BCR-ABL inhibitor  
Apratastat  Axon Medchem, Groningen, NL TACE/MMP inhibitor  
AS 252424  Axon Medchem, Groningen, NL PI3K p110 gamma inhibitor  
Atazanivir  Axon Medchem, Groningen, NL Protease inhibitor  
AZD 2281 - Olaparib  Axon Medchem, Groningen, NL PARP inhibitor  
AZD 7762  Axon Medchem, Groningen, NL CHK inhibitor  
BACE 1 inhibitor  Axon Medchem, Groningen, NL Beta secretase inhibitor 
BI 2536  Axon Medchem, Groningen, NL PLK-1 inhibitor  
BMS 189961  Axon Medchem, Groningen, NL RAR gamma agonist  
BMS 270394  Axon Medchem, Groningen, NL RAR gamma agonist  
Bosutinib (SKI 606)  Axon Medchem, Groningen, NL BCR-ABL/SRC inhibitor  
Butabindide  Axon Medchem, Groningen, NL TPPII inhibitor  
BX 795  Axon Medchem, Groningen, NL PDK1/TBK1 inhibitor  
BX 912  Axon Medchem, Groningen, NL PDK1 inhibitor 
BZ - Gamma Secretase inhibitor  Axon Medchem, Groningen, NL Gamma secretase inhibitor  
Cediranib  Axon Medchem, Groningen, NL VEGFR inhibitor  
CH 55 Axon Medchem, Groningen, NL RARα/β agonist  
Chir98014  Axon Medchem, Groningen, NL GSK-3 inhibitor  
CI-1033 - Canertinib  Axon Medchem, Groningen, NL EGFR inhibitor  
Combretastatin-A4 (CA-4)  Axon Medchem, Groningen, NL Inhibitor of tubulin polymerization  
CP 690550  Axon Medchem, Groningen, NL JAK-3 inhibitor  
CT 99021 - CHIR 99021  Axon Medchem, Groningen, NL GSK-3 inhibitor  
DAPT  Axon Medchem, Groningen, NL Gamma secretase inhibitor  
Dasatinib  Axon Medchem, Groningen, NL BCR-ABL/SRC inhibitor  
DBZ  Axon Medchem, Groningen, NL Gamma secretase inhibitor  
Deguelin  Axon Medchem, Groningen, NL Anti-cancer agent  
DM 3189 Axon Medchem, Groningen, NL BMP inhibitor  
Doramapimod  Axon Medchem, Groningen, NL p38 MAPK inhibitor  
DR 2313  Axon Medchem, Groningen, NL PARP inhibitor  
FK 866  Axon Medchem, Groningen, NL NAPRT1 inhibitor, anti-cancer agent  
GDC 0879  Axon Medchem, Groningen, NL B-Raf inhibitor  
GDC 0941  Axon Medchem, Groningen, NL PI3K inhibitor 
GSK 269962A  Axon Medchem, Groningen, NL ROCK1 inhibitor  
GW 441756  Axon Medchem, Groningen, NL TrkA inhibitor  
GW 786034  Axon Medchem, Groningen, NL VEGFR/KIT/PDGFR inhibitor  
GW 843682X  Axon Medchem, Groningen, NL PLK inhibitor  
HU-308  Axon Medchem, Groningen, NL CB2 agonist  
Imatinib  Axon Medchem, Groningen, NL Bcr-Abl inhibitor  
Iressa (Gefitinib)  Axon Medchem, Groningen, NL EGFR inhibitor  
JWH 018  Axon Medchem, Groningen, NL CB2 agonist  
JWH 073  Axon Medchem, Groningen, NL CB1/2 agonist  
JWH 133  Axon Medchem, Groningen, NL CB2 agonist  
Ko 143  Axon Medchem, Groningen, NL BCRP inhibitor  
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Lamotrigine  Axon Medchem, Groningen, NL Glutamate antagonist  
Lapatinib  Axon Medchem, Groningen, NL EGFR/ErbB-2 inhibitor  
LE-135  Axon Medchem, Groningen, NL RAR antagonist  
LY 2157299  Axon Medchem, Groningen, NL TGF beta inhibitor  
LY 294002  Axon Medchem, Groningen, NL PI3K inhibitor  
Masitinib mesylate  Axon Medchem, Groningen, NL KIT/PDGFR inhibitor 
MK 1775  Axon Medchem, Groningen, NL Wee1 inhibitor  
Myoseverin  Axon Medchem, Groningen, NL Microtubule inhibitor  
NSC 348884  Axon Medchem, Groningen, NL Nucleophosmin inhibitor 
NSC 625987  Axon Medchem, Groningen, NL CDK4 inhibitor  
NU 1025  Axon Medchem, Groningen, NL PARP inhibitor  
NU 7441  Axon Medchem, Groningen, NL DNA-PK inhibitor  
NVP-BAG956  Axon Medchem, Groningen, NL PI3K/PDK1 inhibitor  
NVP-BEZ235  Axon Medchem, Groningen, NL PI3K/mTOR inhibitor  
NVP-TAE684  Axon Medchem, Groningen, NL ALK inhibitor  
OSI 774 - Erlotininb  Axon Medchem, Groningen, NL EGFR inhibitor  
Palmitoylethanolamide  Axon Medchem, Groningen, NL Endocannabinoid  
PD 0325901  Axon Medchem, Groningen, NL MEK inhibitor  
PD 166793  Axon Medchem, Groningen, NL MMP inhibitor  
PD 169316  Axon Medchem, Groningen, NL p38 MAPK inhibitor  
PD 180970  Axon Medchem, Groningen, NL Src kinase inhibitor  
PD 184352  Axon Medchem, Groningen, NL MEK 1 inhibitor  
PD 98059  Axon Medchem, Groningen, NL MEK inhibitor  
PF-00356231  Axon Medchem, Groningen, NL MMP-12 inhibitor  
PI 103  Axon Medchem, Groningen, NL Class I PI3K inhibitor  
PIK 75  Axon Medchem, Groningen, NL PI3K p110 alpha inhibitor  
PIK 90  Axon Medchem, Groningen, NL PI3K p110 alpha inhibitor  
PLX 4720  Axon Medchem, Groningen, NL B-Raf inhibitor  
Ruboxistaurin (LY333531)  Axon Medchem, Groningen, NL PKC beta inhibitor  
Saracatinib Axon Medchem, Groningen, NL Src and Abl inhibitor  
SB 202190  Axon Medchem, Groningen, NL p38 MAPK inhibitor  
SB 203580  Axon Medchem, Groningen, NL p38 MAPK inhibitor  
SB 216763  Axon Medchem, Groningen, NL GSK-3 inhibitor 
SD 169  Axon Medchem, Groningen, NL p38 alpha MAPK inhibitor  
SD 208  Axon Medchem, Groningen, NL TGF-betaR1 inhibitor  
SL 327  Axon Medchem, Groningen, NL MEK inhibitor  
Sorafenib (BAY 43-9006)  Axon Medchem, Groningen, NL Raf/Mek/Erk inhibitor  
Stobadine  Axon Medchem, Groningen, NL Antioxidant  
SU 6656  Axon Medchem, Groningen, NL Src kinase inhibitor  
Sunitinib - SU 11248  Axon Medchem, Groningen, NL Multiple RTK inhibitor  
Tandutinib  Axon Medchem, Groningen, NL FLT3 inhibitor  
TGX 221  Axon Medchem, Groningen, NL PI3K p110 beta inhibitor  
Tiplaxtinin  Axon Medchem, Groningen, NL PAI-1 inhibitor  
Tyrphostin AG 490  Axon Medchem, Groningen, NL JAK2 inhibitor 
U 73122  Axon Medchem, Groningen, NL Phospholipase C inhibitor  
ZD 6474 (Vandetanib)  Axon Medchem, Groningen, NL VEGFR/EGFR inhibitor  
481407 NF-kB Inhibitor Calbiochem, Zug, Switzerland NF-kB Inhibitor 
Compound C Calbiochem, Zug, Switzerland AMPK inhibitor 
JAK inhibitor I Calbiochem, Zug, Switzerland JAKs inhibitor 
PD150606 Calbiochem, Zug, Switzerland Calpain inhibitor 
Mifepristone Cayman, Ann Arbor, MI, USA Progesterone and glucocorticoid receptor (GR) antagonist 
Piceatannol Cayman, Ann Arbor, MI, USA Syk inhibitor 
Vorinostat/SAHA Cayman, Ann Arbor, MI, USA HDAC inhibitor 
Bortezomib(Velcade) Cilag, Schaffhausen, Switzerland Proteasome inhibitor 
Cyclopamine Enzo Life Sciences, Lausen, Switzerland Hedgehog Pathway Inhibitor 
L-aminoadipic acid Enzo Life Sciences, Lausen, Switzerland Glutamine synthase inhibitor 
Tacrolimus Enzo Life Sciences, Lausen, Switzerland Calcineurin inhibitor 
XL228 Exelixis, San Francisco, CA, USA Multiple Tyr-kinase inhibitor (IGF1-R, Bcr-Abl) 
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Obatoclax GeminX, Montreal, Canada Bcl-2 inhibitor 
2-Deoxy-D-glucose Invitrogen, Basel, Switzerland Glycolysis inhibitor 
NVP-AEW541 Novartis, Basel, Switzerland IGF-1R inhibitor 
NVP-BGJ398 Novartis, Basel, Switzerland FGF-R inhibitor 
NVP-BKM120 Novartis, Basel, Switzerland PI3K inhibitor 
NVP-BSK805 Novartis, Basel, Switzerland JAK2 inhibitor 
NVP-TKI258 Novartis, Basel, Switzerland FGF-R inhibitor 
PKC412 (midostaurin) Novartis, Basel, Switzerland Multi-targeted kinase inhibitor 
[Ala92]-p16 (84-103) Selleck Chemicals, Houston, TX, USA Cdk inhibitor 
AT9283 Selleck Chemicals, Houston, TX, USA Aurora kinases, JAK2, Flt3, and Abl inhibitor 
AZD1152-HQPA Selleck Chemicals, Houston, TX, USA Aurora B inhibitor 
Bax inhibitor peptide P5 Selleck Chemicals, Houston, TX, USA Bcl-2 protein family inhibitor 
Bax inhibitor peptide V5 Selleck Chemicals, Houston, TX, USA Bcl-2 protein family inhibitor 
CP-690550 Selleck Chemicals, Houston, TX, USA JAK3 Inhibitor 
GDC-0449 Selleck Chemicals, Houston, TX, USA Hedgehog Pathway Inhibitor 
Gefitinib Selleck Chemicals, Houston, TX, USA EGFR kinase inhibitor 
JIP-1 (153-163) Selleck Chemicals, Houston, TX, USA JNK inhibitor 
KU-55933 Selleck Chemicals, Houston, TX, USA ATM inhibitor 
MK-2206 Selleck Chemicals, Houston, TX, USA Akt inhibitor 
MLN8237 Selleck Chemicals, Houston, TX, USA Aurora kinase inhibitor 
NVP-AUY922 Selleck Chemicals, Houston, TX, USA HSP90 inhibitor 
PHA-739358(Danusertib) Selleck Chemicals, Houston, TX, USA Aurora kinases, Bcr-Abl and FGFR inhibitor 
Pimecrolimus Selleck Chemicals, Houston, TX, USA Calcineurin inhibitor 
S31-201 Selleck Chemicals, Houston, TX, USA Stat Inhibitor 
SNS-314 Selleck Chemicals, Houston, TX, USA Aurora kinases A, B, and C inhibitor 
SU11274 Selleck Chemicals, Houston, TX, USA c-Met inhibitor 
TG101348/SAR302503 Selleck Chemicals, Houston, TX, USA JAK2 (Flt3) inhibitor 
TW-37 Selleck Chemicals, Houston, TX, USA Bcl-2 protein family inhibitor 
Vandetanib Selleck Chemicals, Houston, TX, USA VEGFR, EGFR Inhibitor 
xav-939  Selleck Chemicals, Houston, TX, USA Wnt/b-catenin signal transduction pathway inhibitor 
Y-27632 Selleck Chemicals, Houston, TX, USA p160 ROCK inhibitor 
3-Bromopyruvate Sigma Aldrich, Buchs, Switzerland Alkylating agent and a potent inhibitor of glycolysis 
3-MA Sigma Aldrich, Buchs, Switzerland Vps34 inhibitor (class III PI3K) 
6-aminonicotinamide Sigma Aldrich, Buchs, Switzerland Pentose phosphate pathway inhibitor 
AMD3100 Sigma Aldrich, Buchs, Switzerland CXCR4 inhibitor 
BAY 61-3606 Sigma Aldrich, Buchs, Switzerland Syk inhibitor 
BMS-345541 Sigma Aldrich, Buchs, Switzerland IκB inhibitor 
Cycloheximide  Sigma Aldrich, Buchs, Switzerland Protein synthesis inhibitor 
Cyclosporine Sigma Aldrich, Buchs, Switzerland Immunosupressant 
Etomoxir Sigma Aldrich, Buchs, Switzerland Inhibitor of fatty acid oxidation 
Honokiol Sigma Aldrich, Buchs, Switzerland pAkt, scr, p44/42 MAPK 
L-685,485 Sigma Aldrich, Buchs, Switzerland Gamma secretase inhibitor 
L-methionine sulfoximide Sigma Aldrich, Buchs, Switzerland Gamma-glutamylcysteine synthetase and glutamine synthetase 
Lonidamine Sigma Aldrich, Buchs, Switzerland Mitochondrial hexokinase inhibitor 
NEC-1 Sigma Aldrich, Buchs, Switzerland Necroptosis/RIPK inhibitor 
Nocodazole  Sigma Aldrich, Buchs, Switzerland Cell cycle G2/M inhibitor 
PP2 Sigma Aldrich, Buchs, Switzerland Src inhibitor 
PU-H71 Sigma Aldrich, Buchs, Switzerland HSP90 inhibitor 
Ranolazine Sigma Aldrich, Buchs, Switzerland Partial inhibitor of fatty acid oxidation 
Roscovitine/Celiciblib Sigma Aldrich, Buchs, Switzerland Cdk inhibitor 
Thapsigargin Sigma Aldrich, Buchs, Switzerland Inhibitor of SERCA and EGFR down-regulator 
VPA Sigma Aldrich, Buchs, Switzerland HDAC inhibitor 
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Identified phospho-peptides *  Rh4 RMS13 Known phospho-sites in PAX3-FOXO1 
ASAPQSDEGSDIDSEPDLPLKR    + + 
Octapeptide: S197, S201, S205, S209; 
Amstutz et al. 2008 
S201, S205; Dietz et al. 2009 and 2011 
HGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQNSIR  + + 
ASLQSGQEGAGDSPGSQFSK  + + 
WPASPGSHSNDDFDNWSTFRPR  + + 
TSSNASTISGR  + 
TSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAK  + + 
LSPIMTEQDDLGEGDVHSMVYPPSAAK  + 
YTYGQSSMSPLPQMPIQTLQDNK  + + 
SSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSR + 
ELLTSDSPPHNDIMTPVDPGVAQPNSR  + + 
NDLMDGDTLDFNFDNVLPNQSFPHSVK  + +  
 
 * coverage after trypsin digestion up to 71%;    
   S430 (Liu et al. 2013) not covered 
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7 Extended	  results	  
7.1 Material	  and	  methods	  
Material	  and	  methods	  are	  mainly	  described	  Manuscript	  I.	  
Drugs	  and	  antibodies	  Rh4	  cells	  have	  been	   treated	  with	  BI	  2536	   (Axon	  Medchem,	  Groningen,	  NL),	  BI	  6727	  (Selleck	   Chemicals,	   Houston	   TX,	   USA),	   KaryoMAX®	   COLCEMID®	   Solution	   (GIBCO,	  Invitrogen,	  Basel,	   Switzerland),	  Vincristin-­‐Teva®	   (Teva	  Pharma,	  Basel,	   Switzerland),	  hesperadin	   (Selleck	   Chemicals,	   Houston,	   TX,	   USA),	   Z-­‐VAD-­‐FMK	   (Selleck	   Chemicals,	  Houston,	  TX,	  USA),	  and	  AEW	  541	  (Novartis,	  Basel,	  Switzerland).	  Western	   blot	   membranes	   were	   incubated	   with	   anti-­‐FOXO1	   (H-­‐128;	   1:1000;	   Santa	  Cruz	   Biotechnology,	   Heidelberg,	   Germany),	   anti-­‐FOXO1A	   phospho	   S322	   +	   S325	  (phospho	  S503	  +	  S506	  in	  PAX3-­‐FOXO1;	  ab60945;	  1:500	  Abcam,	  Cambridge,	  UK),	  anti-­‐FOXO1	  phospho	  S329	  (phospho	  S510	  in	  PAX3-­‐FOXO1;	  ab58519;	  1:500	  Abcam),	  anti-­‐	  phospho-­‐(Ser)	  CDKs	  substrate	   (P-­‐S2-­‐100)	   rabbit	  mAb	  	   (9477;	  1:1000;	  Cell	   Signaling,	  Bioconcept,	  Allschwil,	   Switzerland),	   anti-­‐phospho-­‐PLK	  binding	  motif	   (ST*P)	   (D73F6)	  rabbit	  mAb	  (5243;	   1:1000;	   Cell	   Signaling),	   anti-­‐PARP	   (9542;	   1:1000;	   Cell	   Signaling),	  and	   anti-­‐cyclin	   B1	   (4138;	   1:1000;	   Cell	   Signaling)	   antibodies.	   Anti-­‐β-­‐actin	   (13E5)	  rabbit	  mAb	  (4970;	  1:1000;	  Cell	  Signaling)	  and	  anti-­‐GAPDH	  (D16H11)	  XPTM	  rabbit	  mAb	  (5174;	  1:1000;	  Cell	  Signaling)	  were	  used	  as	  loading	  controls.	  	  	  
Immunofluorescence	  Rh4	  cells	  were	  grown	  on	  chamber	  slides.	  Cells	  were	  fixed	  with	  4%	  paraformaldehyde	  (Carl	  Roth,	  Amsterdam,	  Netherlands)	  in	  PBS	  for	  15	  min,	  quenched	  in	  0.1	  M	  glycine	  in	  PBS	   for	   5	  min,	   and	   permeabilized	  with	   0.5%	  Triton	   X-­‐100	   in	   PBS	   for	   15	  min.	   Upon	  blocking	  in	  3%	  BSA,	  cells	  were	  incubated	  with	  mouse	  anti-­‐α-­‐tubulin	  antibody	  (1:5000;	  clone	  B-­‐5-­‐1-­‐2,	  Sigma-­‐Aldrich,	  Buchs,	  Switzerland)	   for	  1h	  at	  room	  temperature.	  Alexa	  Fluor®	  488	  goat	  anti-­‐mouse	   IgG	  (1:500;	   Invitrogen,	  Basel,	  Switzerland)	  was	  used	  as	  secondary	   antibody.	   VECTASHIELD® mounting media (Vector Labs, USA) 
supplemented with DAPI was applied. Cells	   were	   analyzed	   using	   a	   Nikon	   Eclipse	  TE2000-­‐U	  microscope	  (Nikon,	  Egg,	  Switzerland).	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7.2 Results	  	  
PLK1	  phosphorylates	  PAX3-­‐FOXO1	  at	  multiple	  sites	  in	  vitro	  In	   total,	   PAX3-­‐FOXO1	   contains	   23	   PLK1	   recognition	   motifs	   with	   the	   consensus	  sequences	   [D/E/N]Xp[S/T]	  or	  p[S/T]F,	  as	   they	  have	  been	  reported	  by	  Kettenbach	  et	  al.	   (2012).	   Furthermore,	   GPS-­‐Polo	   1.0	   in	   silico	   analysis	   predicted	   11	   sites	   with	  different	  scores	  to	  be	  phosphorylated	  by	  members	  of	  the	  PLK	  family	  (Liu	  et	  al.,	  2013b)	  (Figs.	   1A	   and	   1B).	   We	   previously	   investigated	   the	   role	   of	   S503	   in	   PAX3-­‐FOXO1	  stabilization	   (Manuscript	   I).	   However,	   remaining	   sites	   should	   be	   considered	   for	  validation	   in	   future	   studies	   as	   at	   least	   some	  of	   them	  might	   also	   contribute	   to	   fusion	  protein	   regulation.	   To	   experimentally	   demonstrate	   their	   direct	   in	   vitro	  phosphorylation	   by	   PLK1,	   we	   transfected	   HEK293T	   cells	   with	   FLAG-­‐PAX3-­‐FOXO1	  encoding	  plasmid	  and	  dephosphorylated	  the	  purified	  protein	  by	  calf	  intestine	  alkaline	  phosphatase	   (CIAP)	   before	   performing	   in	   vitro	   kinase	   assays	   with	   different	  concentrations	  of	  recombinant	  PLK1.	  Results	  are	  schematically	  summarized	  in	  Fig.	  1C	  for	   comparison	   to	   in	   silico	   predicted	   residues.	   Two	   of	   the	   depicted	   phospho-­‐sites,	  S503/S506	  and	  S510,	  were	  identified	  using	  phospho-­‐specific	  antibodies	  for	  detection	  by	   Western	   blotting	   (Fig.	   1D).	   In	   addition,	   samples	   were	   subjected	   to	   mass	  spectrometry	   for	   identification	   of	   phospho-­‐peptides	   and	  phosphorylation	   sites	  were	  mapped	   by	   MASCOT	   analysis.	   A	   summary	   of	   five	   experiments	   is	   illustrated,	   and	  experiment	  details	  and	  MASCOT	  scores	  are	  listed	  in	  Figs.	  1C	  and	  1E.	  We	  applied	  two	  different	  PLK1	  concentrations	  supposing	  higher	  specificity	  of	  phosphorylation	  events	  mediated	  by	  lower	  kinase	  concentrations,	  which	  was	  the	  case	  for	  phosphorylation	  at	  S30,	   S389/S393,	   S399,	   S503,	   and	   S510.	   Nevertheless,	   all	   assays	   and	   all	   identified	  phospho-­‐sites	   should	   be	   considered	   at	   this	   moment	   due	   to	   limiting	   factors	   for	  technical	   implementation	   of	   the	   procedure.	   Varying	   protein	   coverage	   and	   CIAP	  dephosphorylation	   efficiency	   were	   difficult	   to	   standardize,	   leading	   to	   exclusion	   of	  false-­‐negative	   peptides	   in	   individual	   experiments.	   Still,	   software-­‐based	   prediction,	  consensus	  sequence	  comparison,	  detected	  phosphorylation	  in	  aRMS	  cells,	  and	  in	  vitro	  kinase	   assay	   results	   were	   overall	   concordant	   implying	   that	   repetition	   of	   the	   assay	  generated	   reliable	   data	   for	   validation	   in	   future	   studies.	   In	   summary,	   our	   findings	  suggest	   that	   PLK1	   phosphorylates	   PAX3-­‐FOXO1	   at	  multiple	   sites	   in	   vitro,	   indicating	  high	   regulatory	   impact	   on	   PAX3-­‐FOXO1	   activity	   beyond	   the	   previously	   investigated	  function	  in	  protein	  stabilization.	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CDK1	  phosphorylates	  PAX3-­‐FOXO1	  at	  priming	  sites	  for	  PLK	  binding	  in	  vitro	  Binding	   of	   PLK1	   depends	   on	   priming	   events,	   either	   by	   self-­‐priming	   or	   by	   CDK1	  phosphorylation	   of	   PLK1	   substrates	   (Reinhardt	   and	   Yaffe,	   2013).	   Potential	   PLK	  binding	   sites	   in	   PAX3-­‐FOXO1	  were	   predicted	   using	   GPS-­‐Polo	   1.0	   (Liu	   et	   al.,	   2013b).	  Interestingly,	  all	  of	  the	  identified	  sites	  are	  located	  within	  CDK1	  consensus	  sequences	  as	  shown	  by	  phospho-­‐prediction	  using	  GPS	  2.1	  (Xue	  et	  al.,	  2008)	  (Fig.	  2A),	  proposing	  CDK1	  as	  initiator	  of	  PLK1	  -­‐	  PAX3-­‐FOXO1	  axis	  activation.	  To	  confirm	  CDK1	  as	  upstream	  kinase	  of	  the	  fusion	  protein,	  we	  used	  a	  CDK	  substrate	  specific	  antibody	  for	  detection	  of	  phosphorylation	   mediated	   by	   CDK1	   in	   in	   vitro	   kinase	   assays	   (Fig.	   2B).	   To	   further	  demonstrate	   that	   CDK1	   phosphorylation	   initiates	   PLK1	   recruitment,	   we	   applied	   an	  antibody	   detecting	   phosphorylated	   PLK	   binding	  motifs	   (ST*P)	   in	   PAX3-­‐FOXO1	   (Fig.	  2C).	   	   In	  fact,	  Western	  blot	  analysis	  showed	  CDK1	  phosphorylation	  of	  PAX3-­‐FOXO1	   in	  
vitro	  within	  PLK	  binding	  motifs.	  Subsequently,	  we	  performed	  immunoprecipitation	  of	  FLAG-­‐tagged	  PAX3-­‐FOXO1	  expressed	  in	  Rh4	  cells	  to	  demonstrate	  that	  this	  mechanism	  also	  exists	  in	  aRMS	  cells.	  Applying	  antibody	  recognizing	  phosphorylated	  PLK	  binding	  motifs,	  we	  observed	  priming	  of	  PAX3-­‐FOXO1	  and	   increased	   interaction	  of	  PLK1	  and	  the	   fusion	  protein	  under	  conditions	  of	  PLK1	   inhibition	  (Fig.	  2D).	  These	  observations	  indicate	   involvement	   of	   CDK1	   phosphorylation	   rather	   than	   PLK1	   self-­‐priming.	   To	  show	   that	  CDK1	   is	   in	   fact	   active	  under	   these	   conditions,	  we	   applied	  BI	  2536	  and	  BI	  6727	  and	  investigated	  CDK1	  activity	  using	  CDK1	  substrate	  antibody	  on	  Western	  blots	  of	  whole	  cell	  extracts.	  We	  observed	  enhanced	  expression	  of	  CDK1	  co-­‐activator	  cyclin	  B1	  and	  increased	  CDK1	  substrate	  phosphorylation,	  respectively	  CDK1	  activity,	  as	  well	  as	   phosphorylation	   of	   PLK	   binding	   motifs.	   Applying	   the	   CDK1	   inhibitor	   RO-­‐3306,	  CDK1	   phosphorylation	   activity	   as	   well	   as	   phosphorylation	   of	   PLK	   binding	   motifs	  decreased	  (Figs.	  2E	  and	  2F).	  In	  summary,	  these	  findings	  demonstrate	  that	  CDK1	  might	  contribute	   to	   phosphorylation	   and	   regulation	   of	   the	   fusion	  protein.	  We	   suggest	   that	  PLK1	   binding	   depends	   on	   CDK1	   activity	   and	   thus,	   CDK1	   might	   be	   responsible	   for	  recruiting	  PLK1	  to	  PAX3-­‐FOXO1.	  	  
PLK1	   inhibition	   causes	   cell	   cycle	   arrest	   and	   activates	   the	   mitotic	   spindle	  
assembly	  checkpoint	  	  PLK1	   plays	   a	   major	   role	   in	   cell	   cycle	   regulation.	   To	   investigate	   the	   effect	   of	   PLK1	  inhibition	   on	   cell	   cycle	   progression	   in	   aRMS,	   we	   stained	   Rh4	   cells	   with	   propidium	  iodide	  and	  subjected	  them	  to	  FACS	  analysis.	  We	  observed	  a	  strong	  G2/M	  arrest	  after	  PLK1	  silencing	  and	  after	  treatment	  with	  PLK1	  directed	  inhibitors	  (Fig.	  3A).	  Additional	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investigation	   of	   the	   induced	   cell	   cycle	   arrest	   by	   Western	   blot	   analysis	   revealed	  activation	   of	   the	   spindle	   assembly	   checkpoint	   in	   prometaphase	   as	   cyclin	   B1	   was	  accumulated	   in	   PLK1	   depleted	   cells	   (Fig.	   3B).	   To	   verify	   checkpoint	   activation,	   we	  treated	   aRMS	   cells	   with	   PLK1	   inhibitors	   showing	   increased	   cyclin	   B1	   levels,	   while	  simultaneous	  use	  of	  hesperadin,	  a	  drug	  previously	  reported	  to	  override	  mitotic	  arrest	  (Lenart	  et	  al.,	  2007),	  prevented	   this	  accumulation,	   indicating	  checkpoint	   rescue	  (Fig.	  3C).	   Furthermore,	   we	   confirmed	   our	   observations	   at	   single	   cell	   level	   by	  immunofluorescence	  microscopy.	  Untreated	  mitotic	  cells	  showed	  normal	  metaphases	  whereas	   BI	   2536	   treated	   cells	   demonstrated	   a	   phenotype	   of	   aberrant	   mono-­‐polar	  spindles	  circled	  by	  chromosomes	  (Fig.	  3D).	  Thus,	  our	  data	  imply	  that	  PLK1	  inhibition	  in	  aRMS	  cells	  induces	  polo-­‐arrest	  leading	  to	  spindle	  assembly	  checkpoint	  activation.	  	  
Mitotic	  arrest	  leads	  to	  degradation	  of	  PAX3-­‐FOXO1	  	  To	  test	  whether	  cell	  cycle	  arrest	  directly	  affects	  PAX3-­‐FOXO1,	  we	  applied	  the	  mitotic	  inhibitors	   vincristine	   and	   colcemid.	   	   Both	   inhibitors	   cause	   G2/M	   arrest	   as	  demonstrated	  by	  FACS	  analysis	  after	  propidium	  iodide	  staining	  in	  Rh4	  cells	  (Fig.	  4A).	  Analyzing	  the	  fusion	  protein	  by	  Western	  blotting,	  we	  observed	  lower	  levels	  of	  PAX3-­‐FOXO1	  not	   only	   after	  BI	   2536	   and	  BI	   6727	   treatment,	   but	   also	   after	   vincristine	   and	  colcemid	   induced	  G2/M	  cell	   cycle	  arrest	   (Fig.	  4B).	  This	  suggests	  either	  a	  mechanism	  that	   is	   regulating	   PAX3-­‐FOXO1	   in	   a	   cell	   cycle	   dependent	   manner	   or	   specific	  degradation	  of	  PAX3-­‐FOXO1	  during	  mitotic	  checkpoint	  activation.	  	  Importantly,	  this	  degradation	  was	  not	  caused	  by	  apoptosis	  as	  the	  apoptotic	   inhibitor	  Z-­‐VAD-­‐FMK	  that	  completely	  inhibited	  caspase	  3/7	  activity	  (Fig.	  4C)	  was	  not	  sufficient	  to	  rescue	  PAX3-­‐FOXO1	  degradation	  (Fig.	  4B).	  To	  confirm	  that	  the	  degradation	  is	  not	  a	  consequence	   of	   apoptotic	   mechanisms,	   we	   investigated	   PAX3-­‐FOXO1	   protein	   levels	  after	   treatment	  with	   the	   IGF1R	   inhibitor	  AEW	  541.	  Like	  PLK1	   inhibitors,	  vincristine,	  and	   colcemid,	   this	   inhibitor	   induced	   apoptosis	   of	   aRMS	   cells	   as	   demonstrated	   by	  caspase	  3/7	  activity	  assays	  and	  PARP	  cleavage	  (Figs.	  4D	  and	  4F).	  However,	  in	  contrast	  to	   mitotic	   inhibitors,	   AEW	   541	   did	   neither	   cause	   G2/M	   arrest	   (Fig.	   4E)	   nor	   did	   it	  induce	   PAX3-­‐FOXO1	   degradation	   (Fig.	   4F).	   Taken	   together,	   these	   data	   suggest	   that	  PAX3-­‐FOXO1	  degradation	  is	  rather	  the	  consequence	  of	  mitotic	  arrest	  than	  the	  result	  of	  apoptotic	  mechanisms.	  	  
	   88	  
aRMS	  tumors	  relapse	  after	  BI	  2536	  withdrawal	  and	  develop	  resistance	  to	  PLK1	  
inhibition	  	  In	   order	   to	   investigate	  PLK1	   inhibition	   in	  vivo,	  we	   treated	   established	   aRMS	   tumors	  for	   three	   cycles	   and	   achieved	   nearly	   complete	   tumor	   regression	   irrespective	   of	  starting	  volumes	  (Fig.	  5).	  Nevertheless,	  we	  decided	  to	  further	  follow	  tumor	  regrowth	  in	  five	  mice	  after	  discontinuation	  of	  treatment.	  Tumors	  suddenly	  relapsed	  around	  day	  30	  about	  two	  weeks	  after	  the	   last	   injection	   in	   four	  out	  of	   five	  mice	  and	  on	  day	  50	   in	  one	   of	   the	   cases.	  We	   started	   retreatment	   of	   two	   relapsed	   tumors	   and	  were	   able	   to	  achieve	  a	  second	  response	  to	  the	  drug.	  However,	  despite	  a	  reduction	  in	  tumor	  volume	  after	   the	   first	   week	   of	   treatment,	   tumors	   started	   to	   regrow	   after	   the	   second	   week	  during	  treatment	  phases.	  In	  a	  third	  round,	  relapse	  was	  already	  observed	  after	  week	  1,	  indicating	  increasing	  resistance	  to	  PLK1	  inhibition.	  These	  preliminary	  observations	  in	  only	   few	   mice	   urgently	   need	   further	   investigations	   as	   they	   might	   have	   major	  implications	   on	   therapy	   outcome.	   Furthermore,	   careful	   examination	   of	   escape	  mechanisms	  potentially	  supports	  prevention	  of	  resistance	  development.	  
7.3 Figure	  legends	  
Fig.	  1.	  PLK1	  phosphorylates	  PAX3-­‐FOXO1	  at	  multiple	  predicted	  sites	  in	  vitro	  (A	   and	   B)	   In	   silico	   analysis	   of	   PAX3-­‐FOXO1	   phosphorylation	   by	   PLK	   using	   the	  phospho-­‐site	  prediction	  software	  GPS-­‐Polo	  1.0.	  (C-­‐E)	  PLK1	   in	  vitro	  kinase	  assays.	  HEK293T	  cells	  were	  transfected	  with	  FLAG-­‐tagged	  PAX3-­‐FOXO1	   expressing	   plasmid,	   purified,	   dephosphorylated	   by	   CIAP,	   and	   re-­‐phosphorylated	  by	  recombinant	  PLK1.	  	  (C)	  Summary	  of	   in	  vitro	   results	  depicted	  as	  graphic	   illustration	   for	   comparison	   to	   in	  
silico	  results.	  	  	  (D)	  Western	  blot	  analysis	  using	  phospho-­‐S503+S506	  and	  phospho-­‐S510	  antibodies.	  (E)	  Phospho-­‐peptides	  identified	  by	  mass	  spectrometry	  and	  phospho-­‐site	  mapping	  by	  MASCOT	  analysis	  of	  five	  independent	  experiments.	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Fig.	   2.	   CDK1	   phosphorylates	   PAX3-­‐FOXO1	   in	   vitro	   and	   potentially	   primes	   for	  
PLK1	  binding	  (A)	   In	   silico	   analysis	   of	   PAX3-­‐FOXO1	   phosphorylation	   using	   GPS-­‐Polo	   1.0	   for	  prediction	   of	   phosphorylated	   polo-­‐box	   binding	   motifs	   and	   GPS	   2.1	   for	  phosphorylation	  by	  CDK1.	  Prediction	  scores	  are	  listed.	  (B	   and	   C)	   CDK1	   in	   vitro	   kinase	   assays.	   HEK293T	   cells	  were	   transfected	  with	   FLAG-­‐tagged	  PAX3-­‐FOXO1	  expressing	  plasmid,	  purified,	  dephosphorylated	  by	  CIAP,	  and	  re-­‐phosphorylated	  by	  recombinant	  CDK1.	  	  (B)	  Western	  blot	  analysis	  using	  CDK	  substrate	  antibody.	  	  (C)	  Western	  blot	  analysis	  using	  PLK	  binding	  motif	  antibody.	  (D)	  Western	  blot	  analysis	  of	  PLK1	  and	  of	  phosphorylation	  at	  PLK	  binding	  motifs	  after	  FLAG	  immunoprecipitation	  from	  Rh4	  cells	  expressing	  FLAG-­‐tagged	  PAX3-­‐FOXO1.	  Cells	  were	   treated	  with	   DMSO	   or	   15	   nM	  BI	   2536	   for	   16h.	   FLAG-­‐tagged	   GFP	  was	   used	   as	  negative	  control.	  (E	  and	  F)	  Rh4	  cells	  were	  treated	  with	  15	  nM	  BI	  2536	  or	  20	  nM	  BI	  6727	  for	  24h.	  CDK1	  was	  inhibited	  by	  5-­‐10	  μM	  RO-­‐3306.	  	  (E)	  Western	  blot	  analysis	  of	  phosphorylation	  at	  PLK	  binding	  motifs.	  	  (F)	  Western	  blot	  analysis	  of	  CDK1	  activity	  (CDK1	  substrate	  antibody).	  	  
Fig.	   3.	   PLK1	   inhibition	   induces	   G2/M	   arrest	   and	   activation	   of	   the	   spindle	  
assembly	  checkpoint	  (A)	  Rh4	  cells	  were	  treated	  with	  25	  nM	  PLK1	  directed	  siRNA	  (S449)	  and	  with	  15	  nM	  BI	  2536	  or	  20	  nM	  BI	  6727	  for	  48h.	  Cell	  cycle	  distribution	  was	  measured	  by	  FACS	  analysis	  after	  PI-­‐staining.	  (B)	  Western	   blot	   analysis	   after	   silencing	   of	   PLK1	   in	   Rh4	   cells	   for	   48h	   using	   25	   nM	  siRNA	  (S449).	  (C)	  Western	  blot	  analysis	  after	  treatment	  of	  Rh4	  cells	  with	  15	  nM	  BI	  2536	  +/-­‐	  100	  nM	  hesperadin	  and	  20	  nM	  BI	  6727+/-­‐	  100	  nM	  hesperadin	  for	  24h.	  (D)	   Immunofluorescence	   microscopy	   of	   Rh4	   cells	   treated	   with	   DMSO	   or	   15	   nM	   BI	  2536	  for	  2h.	  DAPI	  (blue)	  and	  α-­‐tubulin	  (green)	  staining.	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Fig.	  4.	  Mitotic	  arrest	  induces	  degradation	  of	  PAX3-­‐FOXO1	  	  (A)	  Rh4	  cells	  were	  treated	  with	  10	  nM	  vincristine	  and	  135	  nM	  colcemid	  for	  48h.	  Cell	  cycle	  distribution	  was	  measured	  by	  FACS	  analysis	  after	  PI-­‐staining.	  (B)	  Western	  blot	  analysis	  of	  Rh4	  cells	  treated	  with	  15	  nM	  BI	  2536,	  20	  nM	  BI	  6727,	  10	  nM	  vincristine,	  and	  135	  nM	  colcemid	  +/-­‐	  50	  μM	  Z-­‐VAD-­‐FMK	  for	  48h.	  (C)	  Relative	  caspase	  3/7	  activity	  of	  Rh4	  cells	   treated	  with	  15	  nM	  BI	  2536,	  20	  nM	  BI	  6727,	   10	   nM	   vincristine,	   and	   135	   nM	   colcemid	   +/-­‐	   50	   μM	   Z-­‐VAD-­‐FMK	   for	   48h;	  
Columns,	  mean	  of	  technical	  replicates;	  bars,	  SD;	  ***	  p	  ≤	  0.0005,	  **	  p	  =	  0.0017.	  (D)	  Relative	  caspase	  3/7	  activity	  of	  Rh4	  cells	  treated	  with	  increasing	  concentrations	  of	  BI	  2536	  and	  1	  μM	  AEW	  541	   for	  24h	  and	  48h.	  Columns,	  mean	  of	   technical	  replicates;	  
bars,	  SD;	  ***	  p	  <	  0.0001,	  **	  p	  =	  0.0025.	  (E)	   Rh4	   cells	  were	   treated	  with	   1	   μM	  AEW	  541	   for	   48h.	   Cell	   cycle	   distribution	  was	  measured	  by	  FACS	  analysis	  after	  PI-­‐staining.	  (F)	  Western	  blot	  analysis	  of	  Rh4	  cells	  treated	  with	  1	  μM	  AEW	  541	  for	  24h	  and	  48h.	  	  
Fig.	  5.	  aRMS	  tumors	  relapse	  after	  BI	  2536	  withdrawal	  and	  develop	  resistance	  to	  
PLK1	  inhibition	  
In	   vivo	   drug	   treatment	   of	   NOD/Scid	   il2rg-­‐/-­‐	   mice	   engrafted	   with	   Rh4	   (n=5).	   Mice	  bearing	  established	  tumors	  were	  treated	  intravenously	  with	  either	  vehicle	  control	  or	  BI	  2536	  at	   a	  dose	  of	  40	  mg/kg	   twice	  weekly	  on	   two	   consecutive	  days	   (indicated	  by	  triangles).	  Absolute	  tumor	  volume	  was	  measured	  by	  caliper.	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PLK$
phosphoryla-on Pep-de Score Cutoﬀ 
180$ ERKEAEESEKKAKHS$ 3.243$ 2.590$
187$ SEKKAKHSIDGILSE$ 3.091$ 2.590$
205$ APQSDEGSDIDSEPD$ 3.312$ 2.590$
311$ TYQLSETSYQPTSIP$ 3.112$ 2.590$
325$ PQAVSDPSSTVHRPQ$ 2.855$ 2.590$
399$ NSIRHNLSLHSKFIR$ 2.764$ 2.590$
442$ AASMDNNSKFAKSRS$ 3.069$ 2.590$
457$ RAAKKKASLQSGQEG$ 3.942$ 2.590$
503$ PRTSSNASTISGRLS$ 3.844$ 2.590$
611$ KYTYGQSSMSPLPQM$ 2.707$ 2.590$
701$ HNKMMNPSSHTHPGH$ 2.826$ 2.590$










Probability relative to other possible residues within the 
relevant phospho-peptide (MASCOT analysis) 
 
 

























  2x 1x S8 no score S8 42.90%; T9 57.08% S8 67.89%   S30   yes   
YQETGSIRPGAIGGSKPK 
  1x   T4 90.80%   T93       
AKHSIDGILSER 
  1x     S4 100%   S187       











S1 46.60; T3,T4 17.80%   S222/T224/T225 yes 
  
  
HGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQNSIR   1x S29,S33 38.83%   S389/S393     yes 
HNLSLHSK 
  2x 1x S4 99.69% S4 99.49% S4 80.72%   S399 yes yes   
AASMDNNSKFAK 
  2x   S8 98.85% S8 98.86%   S442 yes yes   
ASLQSGQEGAGDSPGSQFSK 1x    S13 99.58%   S468     yes 
TSSNASTISGR 
  1x 2x *   S6, T7 49.14% 
S6,T7 39.92% 
S6 95.73%* yes S503 yes yes yes 
Ser 510 
        yes S510     yes 
YTYGQSSMSPLPQMPIQTLQDNK 1x   S6, S7 48.88%   S610/S611 yes   yes 
SSYGGMSQYNCAPGLLK 
  2x   S7 77.55% S7 73.87%    S634   yes   
LDCDMESIIR 
 2x   S7 100% S7 100%   S797       
TTTHSWVSG 
  1x   S5 67.97%   S832       
* First identification: phospho-peptide only found after PLK1 assay 










































PLK binding motif 
CDK1 
phosphorylation Peptide Score Cutoff 
PLK 
binding Score Cutoff 
31 GFPLEVSTPLGQGRV 4.043 2.300 PLK-binding 10.268 5.268 
104 RPGAIGGSKPKQVTT 2.367 2.300 
111 SKPKQVTTPDVEKKI 5.892 2.300 PLK-binding 6.196 5.268 
326 QAVSDPSSTVHRPQP 2.921 2.300 
327 AVSDPSSTVHRPQPL 2.583 2.300 
389 PTIGNGLSPQNSIRH 3.388 2.300 
430 EGGKSGKSPRRRAAS 6.410 2.300 
468 GQEGAGDSPGSQFSK 3.986 2.300 
479 QFSKWPASPGSHSND 2.396 2.300 PLK-binding 5.500 5.268 
510 STISGRLSPIMTEQD 3.295 2.300 
564 DNLNLLSSPTSLTVS 5.986 2.300 PLK-binding 8.232 5.268 
575 LTVSTQSSPGTMMQQ 3.360 2.300 PLK-binding 6.500 5.268 
583 PGTMMQQTPCYSFAP 6.158 2.300 PLK-binding 6.661 5.268 
597 PPNTSLNSPSPNYQK 4.187 2.300 
599 NTSLNSPSPNYQKYT 3.439 2.300 
613 TYGQSSMSPLPQMPI 4.396 2.300 PLK-binding 5.714 5.268 
651 KELLTSDSPPHNDIM 4.014 2.300 
659 PPHNDIMTPVDPGVA 5.655 2.300 PLK-binding 6.232 5.268 
737 TSGMNRLTQVKTPVQ 2.741 2.300 
741 NRLTQVKTPVQVPLP 7.899 2.300 PLK-binding 7.679 5.268 
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   2:	   CK1α	   cooperates	   with	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8.1 Abstract	  
The	   oncogenic	   transcription	   factor	   PAX3-­‐FOXO1	   is	   the	   major	   driver	   of	   alveolar	  rhabdomyosarcoma.	   Therefore,	   targeting	   PAX3-­‐FOXO1	   function	   might	   improve	  treatment	  of	  this	  highly	  aggressive	  tumor.	  The	  oncogenic	  potential	  of	  PAX3-­‐FOXO1	  is	  the	   results	   of	   a	   chromosomal	   translocation	   that	   is	   further	   activated	   by	  posttranslational	  modifications.	  In	   the	   present	   study,	   we	   identified	   specific	   phospho-­‐sites	   by	   mass	   spectrometric	  analysis	   showing	   that	   the	   fusion	   protein	   is	   highly	   phosphorylated.	   Combining	   these	  data	  with	  the	  results	  of	  a	  kinome-­‐wide	  siRNA	  reporter	  activity	  screen,	  we	  were	  able	  to	  match	  specific	  serine	  residues	  with	  kinases	   that	  mediate	   their	  phosphorylation.	  This	  approach	   highlighted	   CK1α	   and	   PLK1	   as	   potential	   upstream	   regulators	   of	   PAX3-­‐FOXO1.	  Having	  described	   the	  role	  of	  PLK1	   in	   fusion	  protein	  regulation	   in	  a	  previous	  study,	  we	   aimed	  at	   focusing	  on	  CK1α	  and	   interestingly	   then	  discovered	  overlapping	  functions	  with	  PLK1.	  We	  demonstrated	  in	  vitro	  phosphorylation	  of	  the	  fusion	  protein	  at	   different	   residues	   within	   its	   octapeptide	   domain	   as	   well	   as	   at	   the	   position	  S503/S506.	   	   By	   site-­‐specific	   mutagenesis	   of	   PAX3-­‐FOXO1	   and	   its	   heterologous	  expression	  as	  well	  as	  by	  CK1α	  silencing	   in	  aRMS	  cells,	  we	   investigated	   two	  different	  mechanisms	   leading	   to	   enhanced	   PAX3-­‐FOXO1	   activity.	   On	   the	   one	   hand,	  phosphorylation	   stabilized	   the	   fusion	   protein	   through	   its	   FOXO1	   part,	   and	   on	   the	  other	  hand,	  it	  enhanced	  its	  transcriptional	  activity	  through	  the	  octapeptide	  in	  its	  PAX3	  part.	   These	   new	   insights	   in	   PAX3-­‐FOXO1	   regulation	   might	   help	   to	   improve	   PAX3-­‐FOXO1	  targeting	  by	  rationally	  designed	  combination	  therapy,	  taking	  advantage	  of	  the	  complementary	  functions	  of	  CK1α	  and	  PLK1.	  
8.2 Introduction	  
Transcription	   factors	   play	   a	   major	   role	   in	   tumorigenesis,	   as	   well	   as	   in	   tumor	  maintenance.	  However,	  direct	   targeting	  of	  oncogenic	   transcription	   factors	   is	  difficult	  as	  they	  are	  characterized	  by	  nuclear	  expression	  and	  by	  large	  surface	  areas	  rather	  than	  by	  deep	  binding	  pockets,	  which	  both	  limits	  the	  accessibility	  for	  small	  molecules	  (Yeh	  et	   al.,	   2013).	   Activities	   of	   oncogenic	   transcription	   factors	   can	   be	   modulated	   by	  multiple	   mechanisms	   including	   epigenetic	   regulation,	   protein	   synthesis,	   protein	  stability,	   posttranslational	   modifications,	   protein-­‐protein	   interactions,	   and	   DNA	  binding	  restricted	  by	  chromatin	  configuration.	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Alveolar	   rhabdomyosarcoma	   represents	   an	   ideal	   model	   for	   studying	   oncogenic	  transcription	   factors,	  as	  expression	  of	   the	  chimeric	   transcription	   factor	  PAX3-­‐FOXO1	  is	  the	  only	  major	  recurrent	  genomic	  alteration	  that	  could	  be	  detected	  in	  this	  tumor	  by	  whole-­‐genome	  sequencing	  (Chen	  et	  al.,	  2013;	  Shern	  et	  al.,	  2014).	  Moreover,	  we	  were	  able	  to	  show	  in	  the	  preceding	  study	  that	  PAX3-­‐FOXO1	  stability	  and	  its	  transcriptional	  activity	   depend	   on	   phosphorylation	   events.	   Its	   stability	   is	   regulated	   by	   PLK1	  phosphorylation	   within	   the	   FOXO1	   part	   of	   the	   protein	   (Manuscript	   I),	   whereas	  phosphorylation	   of	   the	   octapeptide	   located	   in	   between	   the	   paired	   domain	   and	   the	  homeodomain	  of	  PAX3	  regulates	  its	  DNA	  binding	  ability	  (Amstutz	  et	  al.,	  2008).	  	  The	  human	   casein	   kinase	  1	   (CK1)	   family	   consists	   of	   seven	   serine/threonine	  protein	  kinases	  harboring	  a	  highly	  conserved	  kinase	  domain	  with	  redundant	  and	  also	  distinct	  functions.	   Next	   to	   its	   role	   in	   circadian	   rhythm,	   CK1	   is	   implicated	   in	   cancer	   by	  regulation	  of	  cell	  growth	  and	  survival	  (Cheong	  and	  Virshup,	  2011).	  CK1α	  was	  shown	  to	  form	  a	  complex	  with	  MDM2,	  which	  impedes	  p53	  while	  it	  positively	  regulates	  E2F1	  (Huart	  et	  al.,	  2009).	  Furthermore,	  CK1	  is	  an	  important	  regulator	  of	  the	  Wnt/β-­‐catenin	  signaling	   pathway.	   CK1γ,	   CK1δ	   and	   CK1ε	   activate	   the	   pathway,	   whereas	   CK1α	  contributes	   to	   the	   degradation	   of	   β-­‐catenin.	   In	   addition,	   CK1δ	   and	   CK1ε	   were	  demonstrated	   to	   suppress	   apoptosis	   and	   regulate	   mitotic	   function	   causing	  progression	   of	   colon,	   pancreatic	   and	   breast	   cancer	   (Cheong	   and	   Virshup,	   2011).	  However,	  a	  specific	  function	  of	  CK1	  in	  aRMS	  has	  not	  been	  described	  so	  far.	  Applying	   a	   kinome-­‐wide	   siRNA	   library,	   we	   identified	   PLK1	   and	   CK1α	   to	   regulate	  PAX3-­‐FOXO1	   activity	   with	   the	   strongest	   effects	   on	   cell	   viability	   compared	   to	   45	  further	   candidate	   kinases.	   	   Here	   we	   show	   that,	   besides	   PLK1,	   CK1α	   was	   the	   only	  candidate	   predicted	   to	   directly	   phosphorylate	   the	   fusion	   protein.	   Thus,	   we	  demonstrate	   regulation	   of	   PAX3-­‐FOXO1	   activity	   by	   phosphorylation	   involving	   two	  complementary	   functions	   of	   CK1α	   and	   PLK1.	   These	   activities	   suggest	   an	   actionable,	  rational	  treatment	  combination	  for	  this	  rare	  pediatric	  sarcoma.	  
8.3 Material	  and	  methods	  
Cell	  lines,	  plasmids	  and	  transfection	  methods	  Rh4	  aRMS	  cells,	  RD	  eRMS	  cells	  (kindly	  provided	  by	  Peter	  Houghton,	  St.	  Jude	  Children's	  Hospital,	  Memphis,	  TN,	  USA),	  HEK293T	  cells	  (American	  Type	  Culture	  Collection	  ATCC,	  LGC	   Promochem,	   Molsheim	   Cedex,	   France)	   and	   293	   GPG	   cells	   (kindly	   provided	   by	  Richard	  C.	  Mulligan,	  Children's	  Hospital,	  Boston,	  MA,	  USA)	  were	  cultured	  in	  Dulbecco's	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modified	   Eagle's	   medium	   (Sigma-­‐Aldrich,	   Buchs,	   Switzerland),	   supplemented	   with	  100	   U/ml	   penicillin/streptomycin,	   2	   mM	   L-­‐glutamine	   and	   10%	   FBS	   (Life	  Technologies,	  Zug,	  Switzerland)	  in	  5%	  CO2	  at	  37°C.	  Culture	  medium	  for	  293	  GPG	  cells	  was	  additionally	  supplemented	  with	  1	  μg/ml	  tetracycline,	  except	  for	  periods	  of	  virus	  production.	  PAX3-­‐FOXO1	   was	   cloned	   into	   a	   pCMV-­‐SC-­‐NF	   vector	   (N-­‐terminal	   FLAG,	   Stratagene,	  Agilent	   Technologies,	   Basel,	   Switzerland)	   and	   into	   a	   pMSCV-­‐IRES-­‐GFP	   vector	  (Addgene,	  no.	  33336,	  Cambridge,	  MA,	  USA).	  Site-­‐directed	   mutagenesis	   was	   performed	   using	   QuikChange	   recommendations	  (Stratagene,	   Agilent	   Technologies,	   Basel,	   Switzerland).	   Parental	   DNA	   template	   was	  digested	  with	  DpnI	  (Thermo	  Scientific,	  Reinach,	  Switzerland).	  Rh4,	  RD	  and	  293	  GPG	  cells	  were	  transfected	  using	  JetPrimeTM	  (Polyplus-­‐Transfections,	  Illkirch,	  France),	  HEK293T	  cells	  by	  CaPO4.	  	  
Purification	  of	  FLAG-­‐PAX3-­‐FOXO1	  from	  Rh4	  and	  HEK293T	  cells	  Rh4	   or	   HEK293T	   cells	   were	   transfected	   with	   pCMV-­‐FLAG-­‐PAX3-­‐FOXO1	   in	   15	   cm	  plates,	   lysed	   40	   hours	   post	   transfection	   and	   FLAG-­‐PAX3-­‐FOXO1	   was	  immunoprecipitated	   using	   75	   μl	   Dynabeads	   (Novex	   by	   Life	   Technologies,	   Zug,	  Switzerland)	  per	  plate	  coupled	  to	  8	  μg	  monoclonal	  ANTI-­‐FLAG®	  M2	  antibody	  (F1804,	  Sigma-­‐Aldrich,	   Buchs,	   Switzerland).	   After	   washing,	   bead-­‐bound	   FLAG-­‐PAX3-­‐FOXO1	  was	  either	  used	  for	  in	  vitro	  kinase	  assays	  or	  the	  protein	  was	  eluted	  by	  1x	  NuPage	  LDS	  buffer	   (Life	   Technologies,	   Zug,	   Switzerland)	   and	   directly	   subjected	   to	   mass	  spectrometry.	  	  
In	  vitro	  kinase	  assay	  Bead-­‐bound	   protein	   was	   dephosphorylated	   using	   300	   units	   CIAP	   enzyme	   (alkaline	  phosphatase,	  calf	  intestinal	  HC,	  Promega,	  Dübendorf,	  Switzerland)	  for	  90	  min	  at	  37°C	  (50	   mM	   Tris	   HCl	   pH	   7.5,	   1	   mM	   MgCl2,	   0.1	   mM	   ZnCl2).	   FLAG-­‐PAX3-­‐FOXO1	   was	  phosphorylated	   after	   washing	   using	   2.5	   μg	   of	   recombinant	   CK1α	   or	   PLK1	   (PV3850	  and	  PV3501;	  Life	  Technologies,	  Zug,	  Switzerland)	  for	  30	  min	  at	  30°C	  (250	  mM	  HEPES	  pH	  7.5,	   50	  mM	  MgCl2,	   12.5	  mM	  DTT,	   0.05%	  Triton	  X-­‐100,	   200	  μM	  ATP).	   4x	  NuPage	  LDS	  buffer	   (Life	  Technologies,	  Zug,	   Switzerland)	  was	  added	   for	  elution	  and	  proteins	  were	  separated	  by	  gel	  electrophoresis.	  After	  staining	  with	  colloidal	  coomassie	  (Instant	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blue,	   Expedeon,	   Harston,	   UK),	   the	   band	   corresponding	   to	   PAX3-­‐FOXO1	  was	   excised	  and	  prepared	  for	  mass	  spectrometry.	  	  
Mass	  spectrometry	  Sample	  preparation	  and	  mass	  spectrometry	  procedures	  are	  described	  in	  Manuscript	  I.	  	  
siRNA	  kinome	  library	  screen	  and	  data	  analysis	  siRNA	  kinome	  screen	  and	  data	  analysis	  are	  described	  in	  Manuscript	  I.	  	  
Silencing	  Knockdown	   of	   CK1α	  was	   achieved	   by	   reverse	   transfection	   of	   1.9x105	  cells	   in	   6-­‐well	  plates	  using	  8	  nM	  scrambled	  (scrambled	  #2	  Silencer®	  Select	  siRNA,	  4390846)	  or	  8	  nM	  CK1α-­‐directed	  siRNAs	  (Silencer®	  Select	  siRNA	  S3625,	  S3626	  and	  S3624,	  Ambion,	  Life	  Technologies,	  Zug,	  Switzerland)	  with	   INTERFERinTM	  according	   to	   the	  manufacturer’s	  protocol	   (Polyplus-­‐Transfections,	   Illkirch,	   France).	   Cells	   were	   lysed	   48h	   post	  transfection.	  	  
Immunoblotting	  Total	   cell	   extracts	   were	   separated	   using	   4-­‐12%	   Bis-­‐Tris	   SDS-­‐PAGE	   gels	   (Life	  Technologies,	   Zug,	   Switzerland)	   and	   transferred	   to	   nitrocellulose	   membranes	  (PROTAN,	   Schleicher	   &	   Schuell,	   Kassel,	   Germany).	   After	   blocking	   with	   5%	   milk	  powder	   in	   TBS/0.1%	   Tween,	   the	   membrane	   was	   incubated	   with	   the	   primary	  antibodies	   anti-­‐FOXO1	   (H-­‐128;	   1:1000;	   Santa	   Cruz	   Biotechnology,	   Heidelberg,	  Germany),	   anti-­‐phospho-­‐FOXO1A	   (phospho	   S322	  +	   S325	  =	   phospho	   S503	  +	   S506	   in	  PAX3-­‐FOXO1;	  ab60945;	  1:500;	  Abcam,	  Cambridge,	  UK)	  overnight	  at	  4°C.	  	  Anti-­‐β-­‐actin	  (13E5)	  rabbit	  mAb	  (4970;	  1:1000;	  Cell	  Signaling,	  Bioconcept,	  Allschwil,	  Switzerland)	  and	  anti-­‐GAPDH	  (D16H11)	  XPTM	  rabbit	  mAb	  (5174;	  1:1000;	  Cell	  Signaling)	  were	  used	  as	  loading	  controls.	  The	  membrane	  was	  washed	  three	  times	  in	  TBS/0.1%	  Tween	  and	  incubated	  with	  anti-­‐rabbit	  IgG	  HRP-­‐linked	  antibody	  (7074;	  1:2000;	  Cell	  Signaling)	  for	  1h	  at	  room	  temperature.	  Proteins	  were	  detected	  using	  ECL	  detection	  reagent	  (Fisher	  Scientific,	  Wohlen,	  Switzerland)	  after	  three	  washings	  in	  TBS/0.1%	  Tween.	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Stability	  assay	  2x105	  RD	  cells	  were	  seeded	  per	  6-­‐well	  the	  day	  before	  transfection	  with	  1	  μg	  pMSCV-­‐PAX3-­‐FOXO1-­‐IRES-­‐GFP	   or	   pMSCV-­‐PAX3-­‐FOXO1-­‐S503A-­‐IRES-­‐GFP.	   Cells	   were	   treated	  with	  35	  μM	  cycloheximide	  (Sigma-­‐Aldrich,	  Buchs,	  Switzerland)	  or	  DMSO	  for	  6h	  before	  cell	  lysis	  and	  protein	  extraction.	  Protein	  levels	  were	  analyzed	  by	  Western	  blotting.	  	  
qRT-­‐PCR	  Total	  RNA	  was	  extracted	  using	  the	  Qiagen	  RNeasy	  Kit	  (Qiagen,	  Basel,	  Switzerland)	  and	  reverse-­‐transcribed	   using	   oligo	   (dT)	   primers	   and	   Omniscript	   reverse	   transcriptase	  (Qiagen,	   Basel,	   Switzerland).	   qRT-­‐PCR	   was	   performed	   for	   PLK1	   (Hs00153444_m1),	  PAX3-­‐FOXO1	   (Hs03024825_ft),	   AP2β	   (Hs00231468_m1),	   FGFR4	   (Hs01106908_m1),	  CDH3	  (Hs00999918_m1),	  PIPOX	  (Hs04188864_m1),	  MYL1	  (Hs00984899_m1),	  MYCN	  (Hs02330075_m1),	   MYOD1	   (Hs02330075_g1),	   PRKAR2B	   (Hs00176966_m1)	   and	  POU4F1	   (Hs00366711_m1)	   using	   TaqMan	   gene	   expression	   master	   mix	   (Life	  Technologies,	   Zug,	   Switzerland).	   Cycle	   threshold	   (CT)	   values	   were	   normalized	   to	  GAPDH	  (Hs02758991_g1).	  Relative	  expression	   levels	  were	  calculated	  using	   the	  ΔΔCT	  method.	  	  	  
Cell	  viability	  assay	  Reverse	   transfection	  was	   carried	   out	   using	   1x104	   cells	   per	   96-­‐well.	   Cell	   viability	   of	  Rh4	   and	   RMS13	   cells	   was	  measured	   by	  WST-­‐1	   assay	   (Roche	   Diagnostics,	   Rotkreuz,	  Switzerland)	  72h	  post	   transfection	  of	  50	  nM	  CK1α-­‐directed	  siRNAs	  (Silencer®	  Select	  siRNA	   S3625,	   S3626	   and	   S3624,	   Ambion,	   Life	   Technologies,	   Zug,	   Switzerland)	   and	  PLK1-­‐directed	   siRNAs	   (Silencer®	   Select	   siRNA	   S450,	   S448	   and	   S449,	   Ambion,	   Life	  Technologies,	  Zug,	  Switzerland)	  with	  N-­‐TER	  nanoparticle	  transfection	  reagent	  (Sigma-­‐Aldrich,	  Buchs,	  Switzerland).	  Values	  were	  calculated	  relative	  to	  scrambled	  knockdown	  based	  on	  three	  biological	  replicates	  of	  technical	  triplicates.	  	  
	   	  
	   104	  
Retroviral	  infections	  293	   GPG	   cells	   have	   been	   stably	   transfected	  with	   packaging	   plasmids	   containing	   the	  Gag	  and	  Pol	  genes	  of	  moloney	  murine	  leukemia	  virus	  and	  the	  VSV-­‐G	  gene	  of	  vesicular	  stomatitis	  virus.	  Cells	  were	  cultured	  in	  DMEM	  containing	  1	  μg/ml	  tetracycline,	  except	  for	  periods	  of	  virus	  production	  to	  repress	  expression	  of	  VSV-­‐G	  coat	  protein	  regulated	  by	   a	   TET	   repressor.	   2.5x106	   cells	  were	   seeded	   per	   10	   cm	  dish	  without	   tetracycline.	  	  Medium	  was	   changed	   after	   24h	   and	   cells	  were	   transfected	  with	   retroviral	   plasmids	  containing	   wild	   type	   or	   mutant	   PAX3-­‐FOXO1	   using	   JetPrimeTM	   (Polyplus-­‐Transfections,	   Illkirch,	   France).	   The	   virus	   supernatant	   was	   collected	   72h	   post	  transfection,	  centrifuged	  for	  4	  min	  at	  1200	  rpm,	  and	  filtered	  using	  a	  0.45	  nm	  cellulose	  acetate	   membrane	   filter	   tip.	   1.5x105	   RD	   cells	   were	   plated	   per	   6-­‐well	   24h	   before	  infection	  with	  virus	  supernatant.	  Polybrene	  was	  added	  to	  a	   final	  concentration	  of	  10	  μg/ml.	   Infection	   rates	  were	   increased	   by	   centrifugation	   for	   1h	   at	   800	   x	   g	   and	   32°C.	  Virus	  supernatant	  was	  removed	  and	  cells	  were	  washed	  by	  PBS.	  Cells	  were	  harvested	  120h	  post	  infection.	  
8.4 Results	  
Phosphorylation	  of	  PAX3-­‐FOXO1	  in	  aRMS	  cells	  In	   order	   to	   investigate	   the	   phosphorylation	   status	   of	   PAX3-­‐FOXO1	   in	   aRMS,	   we	  transfected	   plasmids	   encoding	   FLAG-­‐tagged	   PAX3-­‐FOXO1	   into	   Rh4	   cells.	   After	  purification	   using	   anti-­‐FLAG	   antibody,	   we	   digested	   the	   protein	   by	   trypsin	   or	  chymotrypsin	   and	   performed	   mass	   spectrometry	   for	   identification	   of	   phospho-­‐peptides.	   Achieving	   92%	   protein	   coverage,	   we	   were	   able	   to	   interrogate	   90%	   of	   all	  potential	   serine,	   threonine	   and	   tyrosine	   phosphorylation	   sites	   (Fig.	   1A).	   Peptides	  found	   to	  be	  phosphorylated	  by	  mass	   spectrometric	  analysis	  are	   indicated	   in	  Fig.	  1B.	  Furthermore,	  we	  carried	  out	  MASCOT	  analysis	  to	  narrow	  our	  search	  down	  to	  residues	  with	   the	   highest	   probability	   relative	   to	   other	   possible	   sites	   within	   the	   relevant	  phospho-­‐peptides.	  Like	  this,	  we	  found	  10	  phosphorylated	  residues	  and	  one	  additional	  phospho-­‐peptide	   (TSSNASTISGR)	   in	   which	   the	   modified	   site	   could	   not	   be	   located	  precisely	   by	  MASCOT	   analysis	   (Fig.	   1C).	   In	   addition,	   all	   the	   phospho-­‐peptides	   were	  also	   identified	   when	   PAX3-­‐FOXO1	   was	   purified	   from	   RMS13	   cells	   (Manuscript	   I).	  These	   results	  demonstrate	   that	  PAX3-­‐FOXO1	   is	  heavily	  phosphorylated	  and	   indicate	  that	  the	  transcription	  factor	  is	  regulated	  by	  posttranslational	  modifications.	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siRNA	  screen	  identifies	  CK1α	  and	  PLK1	  as	  potential	  upstream	  kinases	  of	  PAX3-­‐
FOXO1	  To	   identify	   potential	   upstream	   kinases	   responsible	   for	   phosphorylation	   of	   the	  identified	   sites,	  we	   first	  performed	  a	  kinome-­‐wide	   siRNA	  screen.	   For	   the	   screen,	  we	  employed	   a	   reporter	   cell	   line	   expressing	   luciferase	   under	   the	   control	   of	   the	   PAX3-­‐FOXO1	  responsive	  AP2β	  promoter.	  To	  measure	  significant	  reduction	  of	  PAX3-­‐FOXO1	  activity,	  the	  ratio	  of	  luciferase	  activity	  to	  cell	  viability	  from	  averaged	  triplicate	  values	  was	  determined	  for	  each	  targeting	  sequence.	  We	  thereby	  identified	  CK1α	  (CSNK1A1)	  and	  PLK1	  among	  47	   candidates	   that	   contributed	   to	   transcriptional	   activity	  of	  PAX3-­‐FOXO1	  (Fig.	  2	  and	  Manuscript	   I)	   suggesting	  modulation	  of	   fusion	  protein	  activity	  by	  direct	  phosphorylation.	  	  
CK1α	  and	  PLK1	  are	  predicted	  to	  phosphorylate	  PAX3-­‐FOXO1	  at	  identified	  sites	  In	  a	  second	  step	  we	  combined	  the	  phosphorylation	  data	  with	  the	  results	  of	  our	  whole-­‐kinome	   siRNA	   screen	   (Manuscript	   I)	   to	   scan	   for	   putative	   direct	   upstream	   kinases.	  Towards	   this	  end,	  in	  silico	   analysis	  was	  conducted	  using	   the	  phospho-­‐site	  prediction	  software	   GPS	   2.1	   (Xue	   et	   al.,	   2008).	   Five	   out	   of	   the	   47	   candidate	   kinases	   were	  predicted	   to	   phosphorylate	   PAX3-­‐FOXO1	   (CSNK1A1,	   PLK1,	   NEK2,	   PKCA,	   and	   YES1).	  Interestingly,	  the	  predicted	  sites	  for	  CSNK1A1	  (CK1α)	  and	  PLK1	  overlapped	  with	  the	  phospho-­‐residues	   found	   in	   PAX3-­‐FOXO1	   purified	   from	   Rh4	   cells.	   However,	   it	   is	  important	   to	   realize	   that	   the	   prediction	   tool	   includes	   only	   408	   kinases	   for	   analysis.	  Predicted	  sites	  for	  PLK	  (all	   isoforms)	  according	  to	  the	  PLK	  specific	  tool	  GPS-­‐Polo	  1.0	  (Liu	  et	  al.,	  2013b),	  and	   for	  CK1α	  are	  depicted	   in	  Fig.	  3A	   including	  a	   list	  of	   individual	  scores.	  In	  conclusion,	  four	  of	  the	  phospho-­‐residues	  mapped	  in	  Fig.	  1	  (S201,	  S205,	  S503	  and	   S506)	   could	  be	   categorized	   as	  potential	   CK1α	  or	  PLK1	   substrates	   implying	   that	  these	   two	   kinases	  might	   play	   a	  major	   role	   in	   the	   regulation	   of	   the	   oncogenic	   fusion	  protein.	   Subsequently,	   in	  vitro	   phosphorylations	   of	   PAX3-­‐FOXO1	  by	   CK1α	   and	   PLK1	  were	  performed.	  	  
CK1α	   and	   PLK1	   phosphorylate	   PAX3-­‐FOXO1	   in	   vitro	   at	   S503/S506	   and	   at	  
multiple	  sites	  within	  the	  octapeptide	  To	   demonstrate	   direct	   phosphorylation	   of	   PAX3-­‐FOXO1	   by	   CK1α	   and	   PLK1,	   we	  transfected	   HEK293T	   cells	   with	   FLAG-­‐PAX3-­‐FOXO1	   expressing	   plasmids,	  dephosphorylated	  the	  purified	  proteins	  by	  calf	  intestine	  alkaline	  phosphatase	  (CIAP),	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and	   subsequently	   carried	   out	   in	   vitro	   kinase	   assays.	   Having	   identified	   phospho-­‐peptides	  by	  comparing	  mass	  spectrometric	  data	  of	  dephosphorylated	  PAX3-­‐FOXO1	  to	  CK1α-­‐,	   respectively	   PLK1-­‐treated	   PAX3-­‐FOXO1,	   we	   exactly	   mapped	   localizations	   of	  phospho-­‐sites	  by	  MASCOT	  analysis.	  Within	  the	  octapeptide,	  three	  serines	  (S197,	  S205	  and	  S209)	  have	  been	  phosphorylated	  by	  CK1α	  and	   two	   serines	   (S187	  and	  S205)	  by	  PLK1	   (Fig.	   3B).	   As	   predicted,	   additional	   Western	   blot	   analysis	   revealed	   further	  phosphorylation	   at	   S503/S506	   (Fig.	   3C).	   Interestingly,	   S205	   as	  well	   as	   S503	   can	   be	  phosphorylated	  by	  either	  of	  the	  two	  enzymes.	  Polo-­‐like	  kinases	  and	  casein	  kinases	  in	  fact	  both	  belong	  to	  the	  rare	  group	  of	  acidophilic	  kinases	  (Cheong	  and	  Virshup,	  2011;	  Salvi	   et	   al.,	   2012),	   suggesting	   homologous	   substrate	   sequences.	   The	   result	   is	   also	   in	  agreement	  with	   in	  silico	  predicted	  sites	  as	  well	  as	  with	  consensus	  recognition	  motifs	  for	   CK1	   (D/E-­‐X-­‐X-­‐S/T)	   and	   for	   PLK1	   (D/E/N-­‐X-­‐S/T)	   (Cheong	   and	   Virshup,	   2011;	  Kettenbach	  et	   al.,	   2012).	   Importantly,	   these	   sites	  were	  also	  phosphorylated	   in	  aRMS	  cells	  (Fig.	  3D).	  Thus,	  both,	  CK1α	  and	  PLK1	  are	  supposed	  to	  be	  able	  to	  phosphorylate	  the	   fusion	   protein	   at	   multiple	   sites	   within	   the	   octapeptide	   and	   at	   S503/S506	  indicating	  complementary	  roles	  in	  the	  regulation	  of	  PAX3-­‐FOXO1.	  	  
CK1α	  and	  PLK1	  stabilize	  PAX3-­‐FOXO1	  by	  phosphorylation	  of	  S503	  	  In	   a	   next	   step,	   we	   assessed	   the	   biological	   function	   of	   individual	   phospho-­‐sites.	   We	  previously	   demonstrated	   by	   site-­‐specific	   mutagenesis	   and	   cycloheximide	   treatment	  studies	   in	   RD	   cells	   that	   phosphorylation	   of	   S503	  mediates	   enhanced	   fusion	   protein	  stability	   (Fig.	   4A	   and	   Manuscript	   I).	   Verifying	   these	   finding,	   we	   investigated	   PAX3-­‐FOXO1	   protein	   levels	   after	   CK1α	   silencing	   in	   Rh4	   cells.	   As	   expected,	   we	   observed	  degradation	  of	  the	  fusion	  protein	  by	  Western	  blot	  analysis	  using	  three	  different	  siRNA	  sequences	   (Fig.	   4B).	   However,	   knockdown	   efficiencies	   remain	   to	   be	   tested.	  Furthermore,	   densitometric	   quantification	   revealed	   a	   mean	   significant	   reduction	   of	  protein	   amount	   by	   50%	   relative	   to	   scrambled	   knockdown	   suggesting	   that	   CK1α	  stabilizes	  the	  fusion	  protein	  by	  phosphorylation	  at	  S503	  as	  it	  has	  previously	  also	  been	  shown	  for	  PLK1	  (Fig.	  4C	  and	  Manuscript	  I).	  	  	  
CK1α	  and	  PLK1	  activate	  PAX3-­‐FOXO1	  by	  multiple	  phosphorylation	  events	  in	  the	  
octapeptide	  region	  	  The	  impact	  of	  phosphorylation	  of	  the	  octapeptide	  on	  DNA	  binding	  and	  transcriptional	  activation	  of	  PAX3-­‐FOXO1	  has	  previously	  been	  demonstrated	  in	  transactivation	  assays	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using	  a	  6xCD19	  reporter	  plasmid	  in	  HEK293T	  cells	  (Amstutz	  et	  al.,	  2008).	  In	  order	  to	  test	   PAX3-­‐FOXO1	   mutants,	   we	   developed	   a	   read-­‐out	   system	   in	   the	   embryonal	  rhabdomyosarcoma	   cell	   line	   RD.	   We	   chose	   the	   PAX3-­‐FOXO1	   target	   genes	   MYCN,	  PIPOX,	   MYOD1,	   PRKAR2B	   and	   POU4F1,	   which	   were	   upregulated	   after	   retroviral	  infection	  of	  the	  fusion	  protein	  (Davicioni	  et	  al.,	  2006).	  Relative	  transactivation	  of	  these	  genes	   was	   measured	   by	   qRT-­‐PCR	   comparing	   wild	   type	   to	   mutant	   PAX3-­‐FOXO1.	  Relative	  basal	   expression	   in	  RD	   cells	   is	   indicated	  by	   transduction	  of	  GFP	   expressing	  retroviral	  plasmids.	  In	  addition,	  we	  used	  DNA	  binding	  mutants	  PAX3-­‐FOXO1-­‐G48S	  and	  PAX3-­‐FOXO1-­‐N269A	   as	   positive	   controls.	   In	   order	   to	   assess	   the	   role	   of	   octapeptide	  phosphorylation,	  we	  transduced	  PAX3-­‐FOXO1	  with	  loss	  of	  function	  mutations	  at	  all	  six	  octapeptide	  serines,	  including	  the	  four	  identified	  CK1α	  and	  PLK1	  sites.	  In	  preliminary	  experiments,	   we	   found	   reduced	   transactivation	   by	   the	   octapeptide	   mutant	   for	   all	  tested	   target	   genes	   after	   120	   hours.	   As	   expression	   of	   wild	   type	   PAX3-­‐FOXO1	   and	  PAX3-­‐FOXO1-­‐6xA	   was	   almost	   identical,	   phosphorylation	   of	   the	   octapeptide	   might	  indeed	  impact	  PAX3-­‐FOXO1	  activity	  in	  rhabdomyosarcoma	  cells	  (Figs.	  5A	  and	  5B).	  	  To	  further	  investigate	  the	  biological	  function	  of	  CK1α	  in	  aRMS	  cells	  and	  to	  validate	  it	  as	   upstream	   regulator	   of	   PAX3-­‐FOXO1,	   we	   silenced	   the	   kinase	   and	   again	  measured	  PAX3-­‐FOXO1	   target	   gene	   expression.	   Endogenous	   mRNA	   levels	   of	   the	   target	   genes	  AP2β,	  FGFR4	  and	  CDH3	  (Cao	  et	  al.,	  2010;	  Davicioni	  et	  al.,	  2006;	  Khan	  et	  al.,	  2001;	  Lae	  et	  al.,	  2007;	  Marshall	  et	  al.,	  2012;	  Taylor	  et	  al.,	  2009;	  Thuault	  et	  al.,	  2013;	  Wachtel	  et	  al.,	  2004;	  Wachtel	  et	  al.,	  2006)	  were	  analyzed	  by	  qRT-­‐PCR	  after	  48	  hours	  of	  silencing.	  	  In	   addition,	   transcription	   of	  MYL1,	   a	  muscle	   differentiation	  marker	   that	   is	   normally	  repressed	  by	  PAX3-­‐FOXO1	  (De	  Pitta	  et	  al.,	  2006)	  was	  assessed.	  Three	  different	  CK1α	  targeting	   siRNAs	   individually	   resulted	   in	   reduction	   of	   FGFR4	   and	   CDH3	   expression	  with	  minor	   effects	   on	   AP2β,	   while	   MYL1	  mRNA	  was	   upregulated	   except	   for	   one	   of	  three	  targeting	  sequences	  (Fig.	  5C).	  PAX3-­‐FOXO1	  mRNA	  levels	  were	  not	  decreased	  by	  CK1α	   silencing,	   implying	   regulation	   of	   PAX3-­‐FOXO1	   by	   posttranslational	  modifications.	  	  Taken	   together,	   silencing	   of	   CK1α	   modulated	   PAX3-­‐FOXO1	   transcriptional	   activity	  similar	  to	  PLK1	  knockdown	  (Manuscript	  I).	  This	  suggests	  an	  essential	  contribution	  of	  CK1α	  and	  PLK1	  to	  fusion	  protein	  regulation.	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CK1α	  and	  PLK1	  depletion	  reduce	  cell	  viability	  of	  aRMS	  cells	  We	   furthermore	   tested	  whether	  CK1α	   could	  be	   an	  appropriate	   therapeutic	   target	   in	  aRMS	  cells	   like	   it	  has	  been	  previously	  proposed	   for	  PLK1.	  Therefore,	  we	  determined	  cell	   viability	   upon	   CK1α	   and	   PLK1	   depletion	   relative	   to	   scrambled	   treatment	   of	   the	  two	  aRMS	  cell	  lines	  Rh4	  and	  RMS13.	  We	  applied	  three	  different	  sequences	  per	  kinase	  target	  for	  72	  hours	  and	  observed	  significant	  reduction	  of	  cell	  viability	  for	  both	  targets	  in	  both	  cell	   lines.	  The	  maximum	  reduction	  of	  Rh4	  cell	  viability	  was	  42%	  upon	  CK1α	  knockdown	  and	  61%	  upon	  PLK1	  knockdown	  (Fig.	  6A).	  In	  RMS13	  cells,	  CK1α	  depletion	  resulted	  in	  a	  maximum	  reduction	  of	  cell	  viability	  by	  51%	  and	  PLK1	  silencing	  by	  60%	  (Fig.	   6B).	   If	   double	   knockdowns	   can	   induce	   synergism	   in	   cytotoxicity	   remains	   to	   be	  investigated.	   Nevertheless,	   these	   data	   demonstrate	   that	   CK1α	   and	   PLK1	   are	   both	  essential	   for	   the	   survival	   of	   aRMS	   tumors,	   likely	   based	   on	   their	   capability	   to	  phosphorylate	  PAX3-­‐FOXO1.	  	  
CK1α	   expression	   negatively	   correlates	   with	   the	   expression	   of	   PLK1	   in	   aRMS	  
tumor	  biopsies	  To	   finally	   show	   that	   CK1α	   expression	   is	   also	   relevant	   in	   patient-­‐derived	   tumor	  biopsies,	  we	  conducted	  microarray	  expression	  analysis	  of	  translocation	  positive	  aRMS	  tumors	  (Davicioni	  et	  al.,	  2006)	  and	  found	  relevant	  expression	  across	  all	  these	  tumors.	  Interestingly,	  we	   also	   observed	   a	   significant	   negative	   correlation	   of	   CK1α	   and	  PLK1	  expression	   in	   these	   tumor	   samples,	   indicating	   that	   both	   kinases	   might	   not	   just	  complement,	  but	  also	  compensate	  for	  each	  other	  (Fig.	  7).	  
8.5 Discussion	  
In	   this	  study,	  we	  show	  that	  CK1α	  regulates	  PAX3-­‐FOXO1,	  as	   it	  has	  been	  predicted	   in	  our	  kinome-­‐wide	  siRNA	  screen.	  Its	  impact	  on	  fusion	  protein	  activity	  is	  verified	  by	  the	  identification	   of	   five	   in	   vitro	   phospho-­‐sites	   of	   which	   at	   least	   two	   (S205	   and	  S503/S506)	   also	   exist	   in	   vivo	   with	   demonstrated	   effects	   on	   PAX3-­‐FOXO1	   function.	  Moreover,	   we	   reveal	   complementary	   biological	   functions	   of	   CK1α	   and	   PLK1	   in	  phosphorylation	  of	  these	  sites.	  First,	   we	   showed	   phosphorylation	   of	   S503/S506.	   Previous	   studies	   already	   reported	  phosphorylation	   of	   S322	   and	   S325	   by	   CK1	   in	   wild	   type	   FOXO1,	   which	   are	  corresponding	   to	   S503	   and	   S506	   in	   the	   fusion	   protein	   (Rena	   et	   al.,	   2002).	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Interestingly,	   phosphorylation	   of	   S503	   can	   be	  mediated	   either	   by	   CK1α	   or	   by	   PLK1	  resulting	   in	   stabilization	   of	   the	   fusion	   protein	   as	   already	   discussed	   in	  Manuscript	   I.	  However,	  the	  role	  of	  phosphorylated	  S506	  as	  well	  as	  double	  phosphorylation	  needs	  to	  be	  examined	  in	  future	  studies.	  Second,	  CK1α	  phosphorylated	  the	  octapeptide	  region	  of	  PAX3-­‐FOXO1	  in	  vitro	  at	  three	  different	  serines	  (S197,	  S205	  and	  S209),	  and	  PLK1	  phosphorylated	  it	  at	  two	  different	  serines	  (S187	  and	  S205).	  Interestingly,	  several	  studies	  have	  described	  the	  relevance	  of	  this	  domain	  and	  we	  previously	  found	  that	  this	  region	  is	  phosphorylated	  at	  least	  at	  four	  out	  of	  six	  different	  residues	  (S187,	  S193,	  S197,	  S201,	  S205,	  and	  S209)	  regulating	  DNA	  binding	   and	   thus	   transcriptional	   activity	   of	   the	   fusion	   protein	   in	   HEK293T	   cells	  (Amstutz	  et	  al.,	  2008).	  Here,	  we	  detected	  phosphorylation	  at	  S201	  and	  S205	  but	  not	  at	  S209	   in	  PAX3-­‐FOXO1	  purified	   from	  Rh4	  cells,	  which	   is	   line	  with	   the	  observations	  of	  Dietz	  et	  al.	   (2011).	  However,	  Amstutz	  et	  al.	   (2008)	   found	  that	  single	   loss	  of	   function	  mutation	  at	  S205	  did	  not	  affect	  transactivation,	  whereas	  double	  mutation	  of	  S205	  and	  S209	  did	  reduce	  fusion	  protein	  activity,	  which	  even	  further	  decreased	  when	  also	  S197	  and	  S187	  were	  mutated	  indicating	  that	  also	  phosphorylation	  at	  S187,	  S197	  and	  S209	  might	  be	  relevant	  for	  PAX3-­‐FOXO1	  activation.	  	  We	  established	  a	  system	  to	  investigate	  the	  function	  of	  the	  octapeptide,	  utilizing	  fusion	  negative	   embryonal	   RMS	   cells	   to	   express	   mutant	   PAX3-­‐FOXO1.	   Mutation	   of	   all	   six	  serines	  within	  the	  octapeptide	  resulted	   in	  reduction	  of	   fusion	  protein	  activity.	  Single	  site	  mutations	  as	  well	  as	  different	  combinations	  remain	  to	  be	  tested.	  Dietz	  et	  al.	  (2011)	  demonstrated	  that	  phosphorylation	  of	  S201	  in	  Pax3	  is	  mediated	  by	  Gsk3β,	  whereas	   both	   S205	   in	   Pax3	   and	   PAX3-­‐FOXO1	   as	  well	   as	   S209	   in	   Pax3,	  were	  proposed	  to	  be	  phosphorylated	  by	  casein	  kinase	  2	  (Ck2)	  (Dietz	  et	  al.,	  2009;	  Iyengar	  et	  al.,	  2012).	  Of	  notice,	  all	  the	  in	  vitro	  kinase	  assays	  in	  these	  studies	  were	  performed	  with	  cell	   extracts	   from	   mouse	   myoblasts	   but	   not	   with	   cell	   extracts	   from	   aRMS	   cells.	  	  Identification	  was	  performed	  based	  on	  the	  kinase’s	  ability	  to	  utilize	  GTP	  as	  substrate	  instead	   of	   ATP,	   which	   suggests	   Ck2	   as	   upstream	   kinase	   instead	   of	   Ck1,	   at	   least	   in	  mouse	   myoblasts.	   However,	   no	   genetic	   loss-­‐of-­‐function	   experiments	   have	   been	  carried	   out	   in	   these	   studies.	   And	   the	   employed	   and	   rather	   unspecific	   drugs	   heparin	  and	  DRB	  are	  expected	  to	  also	  inhibit	  CK1	  (Meggio	  et	  al.,	  1990).	  In	  our	  kinome	  screen	  we	  identified	  CK1α	  but	  not	  CK2	  to	  regulate	  PAX3-­‐FOXO1	  activity	  in	  aRMS	  cells.	  Furthermore,	  we	  demonstrated	  that	  CK1α	  is	  capable	  of	  phosphorylating	  S205	   and	   S209	   in	   vitro	   like	   it	   has	   been	   shown	   for	   Ck2	   before	   (Dietz	   et	   al.,	   2009;	  Iyengar	  et	  al.,	  2012).	  	  This	  can	  be	  explained	  by	  overlapping	  recognition	  motifs	  of	  CK1	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and	   CK2	   at	   these	   positions	   (CK1:	   D/E-­‐X-­‐X-­‐S/T;	   CK2:	   S/T-­‐X-­‐X-­‐D/E;	   PAX3-­‐FOXO1	  sequence: DEGS205DIDS209EPD),	   rather	   than	   by	   close	   relationship	   (Venerando	   et	   al.,	  2014).	   CK1	   and	   CK2	   actually	   belong	   to	   different	   branches	   of	   the	   kinome	   and	   share	  only	  weak	   structural	   similarities.	   Importantly,	   knockdown	  of	   CK1α	  was	   sufficient	   to	  reduce	   target	   gene	   expression,	   concluding	   that	  CK1α	   likely	   represents	   the	  phospho-­‐mediating	   kinase	   in	   aRMS	   cells,	   although	   a	   role	   for	   CK2	   cannot	   be	   excluded	   at	   the	  moment.	  Additional	  knockdown	  experiments	  will	  have	  to	  be	  carried	  out	  to	  clarify	  this	  issue.	  	  Nevertheless,	   the	  most	   important	   finding	  of	   this	  study	   is	   the	  cooperating	   function	  of	  CK1α	   and	   PLK1	   in	   PAX3-­‐FOXO1	   regulation.	   Both	   kinases	   phosphorylated	   the	   fusion	  protein	   at	   S205	   and	   S503,	   at	   least	   in	   vitro.	   The	   impact	   of	   this	   observation	   becomes	  apparent	  considering	  that	  tumors	  often	  develop	  resistances	  to	  kinase	  inhibitors.	  In	  the	  case	  of	   aRMS,	  we	  previously	  observed	  escape	   from	  PLK1	   inhibition	   (Chapter	  7)	   and	  now	   actually	   found	   a	   negative	   correlation	   of	   CK1α	   and	   PLK1	   expression	   in	   tumor	  biopsies	   indicating	  not	  only	  cooperating	  but	  also	  compensating	  capacities	  of	   the	  two	  kinases.	  In	  a	  next	  step,	  we	  will	  investigate	  if	  double	  depletion	  of	  CK1α	  and	  PLK1	  could	  attain	   synergistic	   effects	   and	   if	   CK1α	   plays	   a	   superordinate	   role	   in	   resistant	   cells,	  which	  would	  demand	  for	  development	  of	  potential	  combination	  therapies.	  	  In	   summary,	  our	   results	  highlight	   the	  particular	   importance	   to	  consider	  mechanistic	  biological	  interactions	  for	  therapeutic	  targeting	  as	  shown	  here	  for	  the	  cooperation	  of	  CK1α	  and	  PLK1	  in	  PAX3-­‐FOXO1	  regulation.	  
8.6 Figure	  legends	  
Fig.	  1.	  Mass	  spectrometric	  analyses	  detect	  phosphorylation	  sites	  of	  PAX3-­‐FOXO1	  
purified	  from	  Rh4	  cells	  (A)	  Protein	  coverage	  achieved	  after	  trypsin	  and	  chymotrypsin	  digestions.	  (B)	  Phospho-­‐peptides	  identified	  by	  mass	  spectrometry.	  (C)	   Summary	   of	   phospho-­‐sites	   achieving	   the	   highest	   probability	   values	   within	   the	  according	  peptide	  based	  on	  MASCOT	  analyses.	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Fig.	   2.	   Kinome-­‐wide	   siRNA	   screen	   identifies	   CK1α	   and	   PLK1	   as	   regulators	   of	  
PAX3-­‐FOXO1	  RNA	   silencing	   was	   carried	   out	   for	   48h	   using	   50	   nM	   siRNA	   (Ambion	   Silencer®	   V3	  Kinase	  siRNA	  Library).	  The	  luciferase	  readout	  (LF)	  was	  normalized	  to	  cell	  viability	  (V)	  measured	   by	   WST-­‐1	   assay.	   siRNAs	   targeting	   luciferase	   (pGL4)	   and	   PAX3-­‐FOXO1	  served	  as	  positive	  controls	  for	  reduced	  activity/cell	  viability	  ratio	  (LF/V),	  and	  siKIF11	  for	   reduced	   cell	   viability.	   Reduced	   LF/V	   ratios	   upon	   CK1α	   silencing	   and	   PLK1	  silencing	  are	  marked.	  Data	  points,	  mean	  of	  three	  independent	  experiments	  performed	  in	  triplicates;	  threshold,	  1.5	  SDs	  of	  mean	  of	  luciferase	  knockdown.	  	  
Fig.	  3.	  CK1α	  and	  PLK1	  phosphorylate	  PAX3-­‐FOXO1	  in	  vitro	  (A)	   In	   silico	   analysis	   of	   PAX3-­‐FOXO1	   phosphorylation	   using	   the	   phospho-­‐site	  prediction	  software	  GPS	  2.1	  for	  CK1α	  and	  GPS-­‐Polo	  1.0	  for	  PLK	  (all	  isoforms).	  (B	   and	   C)	   In	  vitro	   kinase	   assays.	   HEK293T	   cells	  were	   transfected	  with	   FLAG-­‐tagged	  PAX3-­‐FOXO1	   expressing	   plasmid,	   purified,	   dephosphorylated	   by	   CIAP,	   and	   re-­‐phosphorylated	  by	  recombinant	  CK1α	  and	  PLK1.	  	  (B)	  Western	  blot	  analysis	  using	  anti	  phospho-­‐S503+S506	  antibody.	  	  (C)	   Phospho-­‐peptides	   identified	   by	  mass	   spectrometric	   analyses	   and	  most	   probable	  residues	  based	  on	  MASCOT	  analyses.	  	  
Fig.	  4.	  CK1α	  stabilizes	  PAX3-­‐FOXO1	  (A)	   Quantification	   of	   exogenous	   PAX3-­‐FOXO1	   degradation	   by	   densitometry.	  Degradation	  of	  exogenous,	  wild	  type	  or	  phospho-­‐mutant	  PAX3-­‐FOXO1.	  RD	  cells	  were	  transfected	  with	  PAX3-­‐FOXO1	  wild	  type	  or	  PAX3-­‐FOXO1-­‐S503A	  expressing	  constructs	  and	  treated	  for	  6h	  with	  DMSO	  or	  35	  μM	  cycloheximide	  (CHX).	  Levels	  were	  normalized	  to	  GAPDH.	  Columns,	  mean	  of	  three	  independent	  experiments;	  bars,	  SD	  Student’s	  t-­‐test	  **	  p=	  0.0052.	  (B)	   Western	   blot	   analysis	   of	   endogenous	   PAX3-­‐FOXO1	   degradation	   after	   CK1α	  silencing.	   Rh4	   cells	   were	   transfected	   with	   8	   nM	   of	   siRNA	   using	   three	   different	  sequences	  for	  48h.	  	  (C)	   Quantification	   of	   endogenous	   PAX3-­‐FOXO1	   degradation	   by	   densitometry	   upon	  CK1α	  silencing.	  Bars,	  SD;	  Student’s	  t-­‐test	  *	  p=	  0.0257.	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Fig.	  5.	  CK1α	  activates	  PAX3-­‐FOXO1	  	  	  (A+B)	  RD	  cells	  were	  transduced	  with	  wild	  type	  PAX3-­‐FOXO1	  or	  mutant	  PAX3-­‐FOXO1-­‐6xA	  for	  120h.	  	  (A)	  Relative	  mRNA	  expression	  of	  PAX3-­‐FOXO1	  and	  target	  genes	  in	  RD	  cells.	  CT	  values	  relative	   to	   wild	   type	   PAX3-­‐FOXO1	   were	   measured	   by	   qRT-­‐PCR	   and	   normalized	   to	  GAPDH	   expression.	   Columns,	   two	   biological	   experiments	   performed	   in	   technical	  triplicates;	  bars,	  SD;	  no	  statistics	  due	  to	  lack	  of	  biological	  replicates.	  	  (B)	  Western	  blot	  analysis	  of	  PAX3-­‐FOXO1	  expression.	  (C)	   Relative	   mRNA	   expression	   of	   PAX3-­‐FOXO1	   and	   target	   genes	   in	   Rh4	   cells	   after	  CK1α	  knockdown	  using	  three	  individual	  sequences	  at	  a	  concentration	  of	  8	  nM	  for	  48h.	  CT	   values	   relative	   to	   scrambled	   knockdown	   were	   measured	   by	   qRT-­‐PCR	   and	  normalized	   to	   GAPDH	   expression.	   Columns,	   experiments	   performed	   with	   three	  independent	   siRNAs	   in	   technical	   triplicates;	   no	   statistics	   due	   to	   lack	   of	   biological	  replicates	  per	  siRNA.	  	  
Fig.	  6.	  CK1α	  and	  PLK1	  depletion	  reduce	  cell	  viability	  of	  aRMS	  cells	  RNA	   silencing	   was	   carried	   out	   for	   72h	   using	   50	   nM	   siRNA	   and	   three	   different	  sequences	  per	  target.	  Cell	  viability	  was	  measured	  by	  WST-­‐1	  assay	  and	  set	  relative	  to	  scrambled	  knockdown.	  Columns,	  mean	  of	   three	   independent	  experiments	  performed	  in	  triplicates;	  bars,	  SD;	  Student’s	  t-­‐test	  ***	  p	  <	  0.001,	  **	  p	  <	  0.01,	  *	  p	  <	  0.025.	  (A)	  Cell	  viability	  of	  Rh4	  cells.	  (B)	  Cell	  viability	  of	  RMS13	  cells.	  	  
Fig.	   7.	   CK1α	   expression	   negatively	   correlates	   with	   the	   expression	   of	   PLK1	   in	  
aRMS	  tumor	  biopsies	  CK1α	   and	   PLK1	   gene	   expression	   in	   translocation	   positive	   aRMS	   patient-­‐derived	  biopsies	  (n=54)	  measured	  by	  microarray	  (Affymetrix	  HG-­‐U133A).	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   651 SPPHNDIMTP VDPGVAQPNS RVLGQNVMMG PNSVMSTYGS QASHNKMMNP 
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   751 MQMSALGGYS SVSSCNGYGR MGLLHQEKLP SDLDGMFIER LDCDMESIIR  
 
   801 NDLMDGDTLD FNFDNVLPNQ SFPHSVKTTT HSWVSG 
Phospho-peptide found after trypsin 
digestion 
 
Phospho-peptide found after 
chymotrypsin digestion 
 
Phospho-peptide found only after 
purification from  RMS13 
 
Residue with the highest probability 
 
Definite mapping of phospho-site not 




Coverage after trypsin digestion 
 




PAX3-FOXO1 purified from Rh4 cells 
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   601 NYQKYTYGQS SMSPLPQMPI QTLQDNKSSY GGMSQYNCAP GLLKELLTSD 
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   701 SSHTHPGHAQ QTSAVNGRPL PHTVSTMPHT SGMNRLTQVK TPVQVPLPHP 
  
   751 MQMSALGGYS SVSSCNGYGR MGLLHQEKLP SDLDGMFIER LDCDMESIIR  
 
   801 NDLMDGDTLD FNFDNVLPNQ SFPHSVKTTT HSWVSG 
* The same phospho-peptides were identified after PAX3-
FOXO1 purification from RMS13 cells (data not shown) 
* 
Phospho-site Probability relative to other possible 
residues within the relevant 
phospho-peptide (MASCOT analysis) 
S201 + S205 97.21% (T; for double phosphorylation) 
S389 84.06% (T); 
alternative S393: 10.78% 
S468 98.21% (T); 98,54% (C) 
S479 95.36% (T); 76.41% (C) 
S500/503/506 all sites possible 
S510 92.72% (T, short peptide);  
96.00% (T, long peptide) 
S599 96.51% (C) 
S613 87.96% (T); 64.16% (C);  
alternative S611: 8.05% (T); 12.48% (C) 
S651 91.12% (T) 
T807 100% (T) 
(T) percentage after trypsin digestion; ( C) percentage after chymotrypsin digestion 
8.7 Figures	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Kinase  Phospho-peptide 
Probability relative to other possible 
residues within the relevant phospho-
peptide (MASCOT analysis) 






CK1α HSIDGILSER S8 100% S197 yes 
CK1α ASAPQSDEGSDIDSEPDLPLKR S10 + S14 double  99.77% S205 + S209 yes yes (S205) 
PLK1 AKHSIDGILSER S4 100% S187 yes   















CK1α site Peptide Score Cutoff 
197 GILSERASAPQSDEG 1.706 1.235 
201 ERASAPQSDEGSDID 2.294 1.235 
205 APQSDEGSDIDSEPD 1.941 1.235 
209 DEGSDIDSEPDLPLK 1.235 1.235 
399 NSIRHNLSLHSKFIR  1.353 1.235 
449 SKFAKSRSRAAKKKA! 1.412 1.235 
503 PRTSSNASTISGRLS 7.824 1.235 
506 SSNASTISGRLSPIM 7.824 1.235 
538 PSAAKMASTLPSLSE  1.235 1.235 
566 LNLLSSPTSLTVSTQ  2.000 1.235 
690 SVMSTYGSQASHNKM  1.235 1.235 
713 PGHAQQTSAVNGRPL  1.765 1.235 
835 TTTHSWVSG****** 2.059 1.235 
PLK site Peptide Score Cutoff 
180 ERKEAEESEKKAKHS 3.243 2.590 
187 SEKKAKHSIDGILSE 3.091 2.590 
205 APQSDEGSDIDSEPD 3.312 2.590 
311 TYQLSETSYQPTSIP 3.112 2.590 
325 PQAVSDPSSTVHRPQ 2.855 2.590 
399 NSIRHNLSLHSKFIR 2.764 2.590 
442 AASMDNNSKFAKSRS 3.069 2.590 
457 RAAKKKASLQSGQEG 3.942 2.590 
503 PRTSSNASTISGRLS 3.844 2.590 
611 KYTYGQSSMSPLPQM 2.707 2.590 
701 HNKMMNPSSHTHPGH 2.826 2.590 
Phospho-sites 




In vitro kinase 
assay  
S201 CK1α 
S205 PLK, CK1α PLK1, CK1α 
S389 PLK1 (Chapter 7) 
S468 PLK1 (Chapter 7) 
S479 
S500/503/506 PLK, CK1α PLK1, CK1α 
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9 Discussion	  
Performing	  a	  kinome-­‐wide	  siRNA	  screen	   in	  an	  aRMS	  based	  reporter	  assay	   led	  to	  the	  identification	  of	  47	  upstream	  kinases	  of	  PAX3-­‐FOXO1	  with	  PLK1	  and	  CK1α	  emerging	  as	  the	  most	  promising	  targets	  in	  terms	  of	  aRMS	  cytotoxicity.	  Grouping	  of	  the	  candidate	  kinases	   delineates	   a	   picture	   of	   the	   regulatory	   environment	   of	   PAX3-­‐FOXO1	   with	   a	  dominant	   influence	   of	   cell	   cycle	   regulators.	   Integration	   of	   our	   mechanistic	   data	  suggests	   a	  model	   of	   PAX3-­‐FOXO1	   regulation	   during	   cell	   cycle	   progression	   (Fig.	   17).	  These	   novel	   findings	   allow	   targeting	   the	   fusion	   protein	   on	   top	   of	   the	   oncogenic	  machinery.	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With	  very	  potent	  PLK1	  inhibitors	  currently	  investigated	  in	  clinical	  trials	  for	  treatment	  of	   different	   adult	   cancers,	  we	   first	   focused	   on	  mechanistic	   characterization	   of	   PLK1	  inhibition	   in	   aRMS	   and	   successfully	   collected	   compelling	   and	   promising	   preclinical	  data	  suggesting	  PLK1	  as	  a	  therapeutic	  target	  and	  prognostic	  marker	  in	  fusion	  positive	  RMS.	  	  Although	  we	  have	  not	  yet	  identified	  CK1α	  specific	  inhibitors	  for	  in	  vivo	  treatment,	  we	  could	   actually	   demonstrate	   cooperation	   of	   CK1α	   and	   PLK1	   in	   regard	   of	  phosphorylation	   of	   the	   fusion	   protein.	   This	   might	   be	   of	   special	   interest	   for	   future	  studies	  investigating	  escape	  mechanisms	  that	  have	  been	  indicated	  by	  our	  preliminary	  experiments.	  Here,	  we	  discuss	  our	  strategy	  of	  transcription	  factor	  targeting,	  emerging	  challenges	  as	  well	  as	  future	  approaches.	  Our	  strategic	  but	  also	  novel	  mechanistic	  insights	  might	  be	  transferred	   to	   a	   variety	   of	   different	   tumors	   addicted	   to	   oncogenic	   transcription	  factors.	  As	  our	  strategy	  led	  to	  the	  successful	  identification	  and	  validation	  of	  PLK1	  as	  a	  target	   in	   aRMS,	   we	   furthermore	   provide	   rationales	   for	   translating	   our	   results	   into	  clinical	  studies	  and	  discuss	  potential	  risks	  of	  PLK1	  inhibitors	  and	  their	  application	  in	  aRMS	  therapy.	  
9.1 Strategies	  of	  transcription	  factor	  targeting	  	  
Many	  of	  the	  characterized	  PAX3-­‐FOXO1	  target	  genes	  contribute	  to	  tumor	  progression	  or	   maintenance,	   meaning	   that	   they	   are	   essential	   parts	   of	   the	   same	   oncogenic	  machinery.	   Therefore,	   most	   of	   them	   may	   be	   qualified	   as	   putative	   targets	   in	   aRMS	  therapy.	  However,	  involvement	  of	  several	  different	  target	  genes	  in	  tumorigenesis	  also	  suggests	   that	   single	   inhibition	   of	   any	   of	   these	   pathways	  might	   not	   be	   a	   sufficiently	  effective	   targeting	   strategy.	   Antagonizing	   single	   signaling	   cascades	   could	   moreover	  lead	   to	   activation	   of	   alternative	   pathways	   to	   overtake	   essential	   functions	   and	   could	  even	  exacerbate	  the	  disease	  by	  causing	  resistances	  (Kovar,	  2014).	  In	  aRMS,	  preclinical	  activity	  was	  reported	  for	  several	  inhibitors	  targeting	  pathways	  downstream	  of	  PAX3-­‐FOXO1.	   The	  most	   intensively	   studied	   target	   gene	   is	   IGF1R	   and	   its	   inhibition	   by	   the	  monoclonal	   antibody	   cixutumumab	   (IMC-­‐A12)	   demonstrated	   significant	   in	   vivo	  activity	  in	  rhabdomyosarcoma	  xenografts	  (Houghton	  et	  al.,	  2010).	  However,	  in	  recent	  clinical	   phase	   2	   trials,	   monotherapies	   with	   cixutumumab	   did	   not	   meet	   the	   efficacy	  criteria	   for	   rhabdomyosarcoma	   treatments	   in	   a	   first	   study	   and	   showed	   only	   partial	  response	   in	   1	   out	   20	   RMS	   patients	   in	   a	   second	   investigation	   (Schoffski	   et	   al.,	   2013;	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Weigel	  et	  al.,	  2014).	  This	  might	  be	  due	  to	  different	  resistance	  mechanisms	  acquired	  by	  IGF1R	   inhibition,	   including	   overexpression	   of	   PDGFRα,	   MAPK	   reactivation,	   HER2	  overexpression,	   and	  downregulation	   of	   the	   IGF1R	   inhibitor	   IGFBP2	   (Abraham	  et	   al.,	  2011;	  Huang	  et	  al.,	  2010;	  Kang	  et	  al.,	  2013).	  	  Consequently,	   a	   more	   elegant	   strategy	   of	   choice	   implies	   direct	   targeting	   of	   PAX3-­‐FOXO1	   aiming	   at	   complete	   and	   definite	   elimination	   of	   the	   tumor.	   Therefore,	   we	  decided	   to	   exploit	   mechanisms	   of	   upstream	   PAX3-­‐FOXO1	   regulation.	   PAX3-­‐FOXO1	  function	   is	   the	  product	  of	   upstream	  enzymatic	   activities	  mediating	  posttranslational	  modifications	   and	   protein	   stability,	   protein-­‐protein	   interactions,	   transcriptional	   as	  well	  as	  translational	  activities,	  and	  finally,	  epigenetic	  regulation.	  Based	  on	  studies	  that	  previously	  showed	  phosphorylation	  of	  PAX3-­‐FOXO1	  (see	  Introduction),	  our	  approach	  focused	  on	  kinase	  targeting.	  	  
9.1.1 Establishment	  of	  a	  functional	  screening	  system	  for	  upstream	  regulators	  
The	   first	   crucial	   step	   for	   identification	   of	   upstream	   regulators	   is	   the	   design	   and	  establishment	  of	  a	  screening	  system.	  We	  conducted	  a	  luciferase	  reporter	  assay	  and	  the	  resulting	   siRNA	   screening	   data	   suggest	   that	   this	   system	   recapitulates	   transcription	  factor	  activity	  and	  mirrors	  the	  function	  of	  the	  identified	  candidate	  kinases	  in	  primary	  aRMS	  tumors.	  Actually,	  eleven	  of	  the	  identified	  kinases	  showed	  an	  expression	  profile	  with	   significantly	   higher	   expression	   values	   in	   alveolar	   than	   in	   embryonal	   RMS,	  revealing	   a	   potential	   contribution	   to	   aRMS	   tumorigenesis	   (Hecker,	   2010).	   A	   further	  group	   of	   seven	   candidates	   was	   represented	   within	   the	   target	   profile	   of	   the	   broad-­‐spectrum	  kinase	  inhibitor	  PKC412,	  which	  represses	  PAX3-­‐FOXO1	  activity	  (Amstutz	  et	  al.,	   2008).	   Finally,	   five	   of	   the	   47	   candidates	   have	   been	   predicted	   to	   directly	  phosphorylate	  PAX3-­‐FOXO1,	  indicating	  their	  impact	  on	  fusion	  protein	  activity.	  Hence,	  we	   think	   that	   the	   design	   of	   our	   screening	   system	   meets	   the	   requirements	   for	   the	  identification	   of	   upstream	   regulators	   of	   PAX3-­‐FOXO1.	   However,	   limitations	   of	   such	  reporter	   assays	   are	   based	   on	   restriction	   to	   solely	   one	   target	   gene	   promoter	   in	   a	  context	   that	   does	   not	   recapitulate	   endogenous	   epigenetic	   landmarks	   and	   chromatin	  structure	   (Kovar,	   2014).	   These	   technical	   limitations	   demand	   for	   substantial	  endogenous	   validation	   and	   request	   consequent	   expression	   analysis	   of	   various	  different	  endogenous	  target	  genes	  as	  we	  performed	  by	  qRT-­‐PCR	  after	  PLK1	  and	  CK1α	  depletion.	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9.1.2 Complexity	  of	  posttranslational	  regulation	  	  
PAX3-­‐FOXO1	   was	   demonstrated	   to	   be	   highly	   phosphorylated	   indicating	   that	   its	  regulation	  might	   be	   orchestrated	   by	  multiple	   different	   phosphorylation	   events.	   Our	  mass	   spectrometry	   data	   showed	   at	   least	   eleven	   different	   phospho-­‐sites	   in	   PAX3-­‐FOXO1	  purified	  from	  aRMS	  cells.	  Although	  we	  observed	  effects	  on	  protein	  stability	  by	  mutating	   S503,	   we	   predict	   that	   simultaneous	   site-­‐specific	   mutagenesis	   of	   several	  residues	   might	   lead	   to	   an	   even	   more	   pronounced	   multilayered	   phenotypic	   change.	  This	   prediction	   is	   supported	   by	   the	   findings	   of	   Amstutz	   et	   al.	   (2008),	   who	  demonstrated	   that	   loss	  of	   function	  of	   six	  phospho-­‐sites	  within	   the	  octapeptide	  has	  a	  greater	   impact	   on	   transactivation	   potency	   of	   PAX3-­‐FOXO1	   than	   single	   mutations.	  Thus,	   systematic	   site-­‐specific	   mutagenesis	   might	   uncover	   the	   interplay	   of	   different	  phosphorylation	  sites	  in	  future	  studies.	  Moreover,	   the	   overlapping	   functions	   of	   different	   kinases	   in	   phosphorylation	   of	  identical	   or	   additional	   sites	   in	   transcription	   factors	   as	   observed	   in	   PAX3-­‐FOXO1	   for	  PLK1	   and	   CK1α,	   and	   potentially	   PLK1	   and	   PLK4,	   might	   bear	   the	   risk	   of	   escape	  mechanisms	   induced	   by	   single	   agent	   targeting.	   Whether	   upregulation	   of	   CK1α	   and	  PLK4	   activity	   after	   PLK1	   inhibition	   occurs,	   remains	   to	   be	   investigated	   in	   future	  studies.	   Nevertheless,	   this	   illustrates	   that	   targeting	   posttranslational	   modifiers	   of	  oncogenic	   transcription	   factors	   might	   be	   compensated	   by	   alternative	   pathways,	  demanding	  awareness	  of	  escape	  mechanisms	  and	  undesired	  side	  effects.	  	  
9.1.3 Analysis	  of	  phospho-­‐mutant	  transcription	  factors	  
We	  examined	  the	  S503	  mutant	  and	  the	  6xA	  octapeptide	  mutant	  by	  introducing	  them	  into	   fusion	  negative	  RD	  cells.	  Performing	   transient	   transfection,	  we	  were	  not	  able	   to	  modulate	   the	   expression	   signature	   of	   these	   cells	   (data	   not	   shown).	   Even	   viral	  transduction	   only	   resulted	   in	   partial	   upregulation	   of	   selected	   target	   genes.	   Using	   a	  proper	  cellular	  context,	  meaning	  in	  the	  case	  of	  aRMS	  either	  fusion	  positive	  cells	  after	  depletion	   of	   wild	   type	   PAX3-­‐FOXO1	   or	   cells	   resembling	   the	   cells	   of	   origin,	   might	  facilitate	   studies	   of	   mutant	   PAX3-­‐FOXO1,	   as	   cellular	   context	   and	   chromatin	  accessibility	  determine	  transcription	  factor	  function.	  In	  fact,	  preliminary	  experiments	  demonstrated	  more	  efficient	  upregulation	  of	   several	   target	   genes	   in	  primary	  human	  MSC	  cells	  than	  in	  RD	  cells	  (data	  not	  shown),	  which	  might	  be	  a	  better	  approximation	  to	  the	  actual	  cell	  of	  origin	  and	  could	  be	  incorporated	  into	  future	  studies	  of	  PAX3-­‐FOXO1	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mutants.	   Taking	   together,	   this	   indicates	   that	   a	   careful	   choice	   of	   cell	   context	   is	  important	  for	  studying	  mutants	  of	  oncogenic	  transcription	  factors.	  
9.1.4 Cooperation	  of	  cell	  cycle	  arrest	  and	  impaired	  transcription	  factor	  activity	  
The	   identification	   of	   compounds	   specifically	   antagonizing	   PAX3-­‐FOXO1	   might	   be	  difficult	  because	  PAX3-­‐FOXO1	  activity	  and	  expression	  has	  been	  shown	  to	  be	  dynamic	  during	  cell	   cycle	  progression	   (Kikuchi	  et	  al.,	  2014).	  This	   is	  probably	  also	   the	  reason,	  why	   we	   identified	   many	   kinases	   involved	   in	   cell	   cycle	   regulation.	   Therefore,	  potentially	  any	  cell	  cycle	  arrest	  could	  affect	  PAX3-­‐FOXO1	  target	  gene	  expression.	  Also	  in	   the	  case	  of	  PLK1	   inhibition,	  we	  did	  not	   fully	  succeed	   to	  distinguish	   fusion	  protein	  specific	   effects	   from	   those	   caused	   by	   mitotic	   arrest.	   In	   fact,	   we	   believe	   that	   drug	  induced	   apoptosis	   is	   the	   result	   of	   a	   combinational	   inhibition	   of	   several	   PLK1	  dependent	   mechanisms	   including	   PAX3-­‐FOXO1	   regulation	   and	   cell	   cycle	   regulation.	  This	   interrelationship	  may	  not	  be	   surprising	  when	   considering	   the	  various	  different	  functions	  of	  PLK1	   in	  cell	  division	  and	   in	   tumorigenesis	   (see	   Introduction).	  However,	  from	   a	   therapeutic	   point	   of	   view,	   targeting	   multiple	   tumor	   killing	   mechanism	  represents	   an	  advantage.	   Involving	   inhibition	  of	  multiple	  mechanisms	  does	  not	  only	  reach	  different	  compartments	  within	  a	  heterogeneous	  tumor,	  but	  also	  targets	  possible	  alternative	  pathways.	  Last	  but	  not	  least,	  a	  multiple	  approach	  enables	  the	  generation	  of	  a	  therapeutic	  window	  by	  reducing	  drug	  concentrations	  to	  protect	  healthy	  cells.	  Summing	  up,	   the	  posttranslational	   regulation	  of	   the	   fusion	  protein	   is	  probably	  more	  complex	  than	  expected.	  Nevertheless,	  we	  were	  able	  to	  shed	  light	  on	  posttranslational	  regulation	   and	   cell	   cycle	   dependent	   dynamics	   of	   PAX3-­‐FOXO1	   function.	   Although	  strategies	   to	   directly	   target	   the	   oncogenic	   driver	   of	   aRMS	   are	   still	   impeded	   by	  insufficient	  knowledge	  about	  cell	  of	  origin	  and	  epigenetic	  regulation	  of	  PAX3-­‐FOXO1,	  we	  successfully	  identified	  crucial	  upstream	  regulators	  of	  the	  fusion	  protein.	  
9.1.5 Future	  goals	  in	  transcription	  factor	  targeting	  
Studies	   investigating	   epigenetics	   of	   aRMS	   are	   still	   rare,	   but	   the	   low	   frequency	   of	  genetic	   alterations	   in	   aRMS	   indicates	   deregulation	   of	   epigenetic	   control,	   similar	   to	  other	  pediatric	  tumors	  (Huether	  et	  al.,	  2014).	  Mutations	  found	  in	  BCOR,	  encoding	  for	  a	  transcriptional	  repressor	  that	  interacts	  with	  histone	  deacetylases,	  support	  this	  notion	  (Shern	  et	  al.,	  2014).	  In	  addition,	  misbalance	  of	  different	  epigenetic	  modifiers	  has	  been	  reported	  for	  aRMS	  (Ciesla	  et	  al.,	  2014).	  For	  example,	  the	  overexpressed	  fusion	  target	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gene	   and	   epigenetic	   regulator	   JARID2	  maintains	   an	   undifferentiated	   state	   of	   fusion	  positive	   RMS	   (Walters	   et	   al.,	   2014).	   Also,	   the	   histone	   methyltransferase	   KMT1A	  arrests	   aRMS	   cells	   in	  myogenic	   differentiation	   (Lee	   et	   al.,	   2011).	   Last	   but	   not	   least,	  EZH2,	   a	   member	   of	   the	   polycomb	   group,	   is	   aberrantly	   expressed	   in	   aRMS.	   And	  importantly,	   EZH2	  depletion	   resulted	   in	   apoptosis	   and	   its	  pharmacologic	   inhibitions	  prevented	   aRMS	   in	   vivo	   tumor	   growth	   (Ciarapica	   et	   al.,	   2014).	   Interestingly,	   it	   has	  furthermore	  been	  shown	  that	  histone	  deacetylase	   inhibitors	  potentiate	   the	  effects	  of	  PKC412	  by	  p21	  reactivation	  in	  aRMS	  (Hecker	  et	  al.,	  2010).	  To	  what	  extend	  epigenetic	  mechanisms	   also	   affect	   the	   expression	   of	   PAX3-­‐FOXO1	   itself	   and	   regulate	   its	  accessibility	   to	   chromatin,	   remains	   unresolved	   so	   far,	   although	   particular	  investigation	   of	   epigenetic	   mechanisms	   in	   relation	   to	   PAX3-­‐FOXO1	   expression	   will	  eventually	  lead	  to	  novel	  strategies	  of	  fusion	  protein	  targeting	  by	  epigenetic	  inhibition.	  	  Surprisingly,	  two	  independent	  studies	  recently	  showed	  that	  BI	  2536	  and	  BI	  6727	  act	  as	  dual	  inhibitors	  against	  PLK1	  kinase	  and	  against	  the	  bromodomain	  of	  BRD4	  (Ciceri	  et	   al.,	   2014;	   Ember	   et	   al.,	   2014).	   Bromodomain	   and	   extra	   terminal	   (BET)	   family	  proteins	   are	   epigenetic	   readers	   that	   recruit	   transcriptional	   regulators,	   chromatin	  modulators	   and	  modifiers.	  Notably,	   in	   activity	   and	  binding	   studies	   against	  BRD4,	  BI	  2536	  was	  as	  potent	  as	   the	  prototypic	  BET	   inhibitor	   JQ1	  (Ember	  et	  al.,	  2014).	   	  As	  we	  rather	   observed	   upregulation	   of	   PAX3-­‐FOXO1	   mRNA	   after	   BI	   2536	   treatment	   than	  repression	   of	   transcription,	  we	   could	   not	   identify	   inhibitory	   effects	   on	   PAX3-­‐FOXO1	  itself.	   However,	   different	   target	   genes	   such	   as	   NMYC	   might	   be	   affected	   by	   BRD4	  inhibition	   as	   it	   has	   previously	   also	   been	   shown	   in	   neuroblastoma	   (Puissant	   et	   al.,	  2013).	  In	  this	  regard,	  we	  observed	  downregulation	  of	  NMYC	  after	  PLK1	  inhibition,	  but	  we	  have	  not	   yet	   investigated	   the	   underlying	  mechanisms.	   In	   conclusion,	  we	   assume	  benefits	   for	   aRMS	   therapy	   by	   combining	   PLK1	   inhibitors	   with	   epigenetic	   inhibitors	  and	   suggest	   future	   consideration	   of	   epigenetics	   for	   targeting	   of	   oncogenic	  transcription	  factors.	  
9.2 Rationales	  for	  clinical	  studies	  of	  PLK1	  inhibitors	  in	  aRMS	  
9.2.1 Preclinical	  success	  of	  PLK1	  inhibition	  in	  aRMS	  	  
We	  demonstrated	   a	   nearly	   complete	   tumor	   regression	   of	   aRMS	   xenografts	   by	   PLK1	  inhibition,	  which	  has	   recently	  been	   confirmed	  by	   studies	   of	   the	  Pediatric	  Preclinical	  Testing	  Program	  investigating	  the	  second-­‐generation	  PLK1	  inhibitor	  BI	  6727	  (Gorlick	  et	  al.,	  2014).	  The	  authors	  did	  not	  provide	  any	  mechanistic	  model,	  but	  BI	  6727	  showed	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potent	  activity	  against	  a	  panel	  of	  pediatric	  cancer	  cell	   lines	  in	  vitro.	  Two	  of	   the	  most	  responding	  cell	   lines	  included	  the	  aRMS	  lines	  Rh41	  and	  Rh30	  with	  a	  median	  relative	  IC50	  of	  6.9	  nM	  and	  8.2	  nM	  after	  96	  hours.	  Across	  different	  pediatric	  tumor	  xenografts,	  objective	   in	   vivo	   responses	   were	   demonstrated	   for	   4	   out	   of	   32	   solid	   tumors	   (two	  neuroblastoma,	  one	  glioblastoma	  and	  one	  rhabdomyosarcoma	  model)	  and	  1	  out	  of	  4	  ALL	  xenografts	   (Gorlick	  et	  al.,	  2014).	  Concluding,	   the	   two	   independent	  studies	  proof	  that	  aRMS	  cells	  are	  highly	  prone	  to	  PLK1	  inhibition	  in	  comparison	  to	  less	  responsive	  pediatric	  cell	  lines.	  Besides	   the	   formation	   of	   mono-­‐polar	   spindles,	   activation	   of	   the	   spindle	   assembly	  checkpoint,	   and	   mitotic	   arrest,	   additional	   factors	   might	   contribute	   to	   aRMS	   cell	  toxicity	  induced	  by	  PLK1	  inhibitors.	  
9.2.1.1 Sensitization	  to	  PLK1	  inhibition	  by	  PAX3-­‐FOXO1	  expression	  Central	   to	   our	   study	   was	   the	   regulation	   of	   PAX3-­‐FOXO1	   by	   PLK1.	   Comparing	   drug	  induced	   cytotoxicity	   in	   different	   fusion	   positive	   and	   fusion	   negative	  rhabdomyosarcoma	   cell	   lines,	   we	   demonstrated	   PAX3-­‐FOXO1	   to	   sensitize	   to	   PLK1	  inhibition.	   In	   agreement	  with	   investigations	   of	   BI	   6727	   by	   Gorlick	   et	   al.	   (2014),	  we	  measured	  lower	  IC50	  values	  for	  BI	  2536	  in	  aRMS	  than	  in	  eRMS	  cells.	  Furthermore,	  we	  demonstrated	  that	  PLK1	  expression	  significantly	  correlated	  with	  AP2β	  expression	   in	  human	   aRMS	   biopsies.	   This	   latter	   finding	   reveals	   that	   in	   aRMS	   PLK1	   function	   is	  strongly	  reflected	  in	  PAX3-­‐FOXO1	  activity.	  
9.2.1.2 Sensitization	  to	  PLK1	  inhibition	  by	  NMYC	  expression	  Expression	  of	  the	  oncogenic	  transcription	  factor	  NMYC	  is	  common	  to	  the	  solid	  tumors	  that	   showed	   objective	   responses	   to	   BI	   6727	   in	   the	   study	   of	   Gorlick	   et	   al.	   (2014),	  suggesting	   a	   correlation	   of	   PLK1	   function	   and	   NMYC	   levels.	   	   In	   accordance	   to	   this	  finding,	  our	  study	  provided	  the	  first	  evidence	  for	  reduced	  NMYC	  protein	  after	  BI	  2536	  and	   BI	   6727	   treatment.	   	   This	   reduction	  might	   be	   caused	   either	   by	   impaired	   PAX3-­‐FOXO1	  activity,	  by	  destabilization	  and	  active	  degradation	  of	  NMYC	  due	  to	  lack	  of	  PLK1	  phosphorylation,	   or	   by	   a	   mechanism	   that	   also	   involves	   BI	   2536/BI	   6727	   induced	  BRD4	   inhibition.	   In	  any	  case,	  NMYC	  reduction	   is	  potentially	  contributing	   to	   the	  anti-­‐tumor	  activity	  of	  PLK1	  inhibitors	  in	  NMYC	  addicted	  tumors.	  
9.2.1.3 Sensitization	  to	  PLK1	  inhibition	  by	  p53	  repression	  Various	  studies	  investigated	  whether	  non-­‐functional	  p53	  might	  influence	  cytotoxicity	  of	  PLK1	   inhibition,	  obtaining	  different	  results	   that	  are	  still	  under	  debate.	  On	  the	  one	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hand,	   treatment	   efficiencies	   in	   p53-­‐/-­‐	   in	   comparison	   to	   p53+/+	   cell	   lines	   including	  HCT116	   colorectal	   cancer,	   MCF7	   breast	   cancer	   and	   A549	   non-­‐small	   lung	   cancer,	  showed	  no	  dependency	  on	  p53	  status	  upon	  treatment	  with	  different	  PLK1	  inhibitors	  (Sanhaji	  et	  al.,	  2012;	  Sanhaji	  et	  al.,	  2013).	  On	  the	  other	  hand,	  several	  studies	  reported	  that	  mutant	  p53	  is	  a	  marker	  of	  sensitivity	  (Craig	  et	  al.,	  2014).	  Based	  on	  the	  notion	  that	  mutant	   p53	   cannot	   repress	   PLK1	   expression,	   studies	   in	   pairs	   of	   isogenic	   cell	   lines	  showed	  that	  cells	  without	   functional	  p53	  are	  more	  susceptible	   to	  PLK1	   inhibition	  as	  they	   are	   addicted	   to	   overexpressed	   PLK1	   (King	   et	   al.,	   2012;	   Sur	   et	   al.,	   2009).	  Sensitivity	   of	   Rh4	   and	   RMS13	   cells	   might	   also	   partially	   be	   the	   result	   of	   their	   p53	  status.	  Our	  STR	  analysis	  demonstrated	  that	  the	  Rh4	  cell	  line	  is	  derived	  from	  the	  same	  patient	   as	   Rh41	   cells,	   and	   the	   RMS13	   cell	   line	   from	   the	   same	   patient	   as	   Rh30	   cells.	  Both	   Rh41	   and	   Rh30	   cells	   harbor	   mutations	   in	   the	   p53	   gene	   (Hinson	   et	   al.,	   2013)	  implying	   that	   also	   Rh4	   and	   RMS13	   cells	   express	   non-­‐functional	   p53.	   In	   general,	  mutant	  p53	  is	  often	  found	  in	  aRMS	  cell	  lines	  but	  has	  not	  been	  detected	  by	  sequencing	  of	  primary	  aRMS	  biopsies.	  However,	  p53	   loss	  of	  heterozygosity,	  copy	  number	  gain	  of	  
MDM2,	  and	  INK4/ARF	  loss	  resulting	  in	  degradation	  of	  p53	  are	  very	  common	  in	  aRMS	  tumors	  (Shern	  et	  al.,	  2014).	  	  Summing	   up,	   the	   combination	   of	   these	   tumor-­‐specific	   factors	   sensitizes	   to	   PLK1	  inhibition.	   Nevertheless,	   it	   is	   important	   to	   conduct	   and	   evaluate	   toxicity	   in	   healthy	  cells	  before	  introducing	  PLK1	  inhibitors	  into	  clinical	  trials.	  
9.2.2 Investigation	   and	   circumvention	   of	   PLK1	   inhibitor	   toxicities	   in	   healthy	  
cells	  
Despite	  great	  efficacy	  in	  preclinical	   in	  vivo	  studies,	  the	  clinical	  use	  of	  PLK1	  inhibitors	  might	   be	   limited	   by	   undesired	   toxicities	   due	   to	   disturbance	   of	   pleiotropic	   PLK1	  functions	  in	  mitosis.	  To	  exclude	  adverse	  effects	  on	  healthy	  cells,	  Plk1	  depletion	  in	  non-­‐cancer	   cell	   lines	   and	   primary	   cells	   has	   been	   performed	   in	   vitro	   and	   in	   vivo.	   Plk1	  depletion	   in	   the	   mouse	   myoblast	   cell	   line	   C2C12	   did	   neither	   cause	   any	   growth	  reduction	  nor	  any	  induction	  of	  apoptosis	  (Hu	  et	  al.,	  2009),	  whereas	  minor	  impact	  on	  proliferative	  activity	  was	  found	  in	  inducible	  knockdown	  mouse	  embryonic	  fibroblasts	  (MEFs)	  compared	  to	  wild	  type	  MEFs	  (Raab	  et	  al.,	  2011).	  Lentiviral	  targeting	  of	  PLK1	  in	  retinal	   epithelial	   cells	   expressing	   human	   telomerase	   reverse	   transcriptase	   (hTERT-­‐RPE1)	  and	  non-­‐transformed	  breast	  epithelial	  cells	  	  (MCF10A)	  showed	  also	  only	  minor,	  respectively	  no	  impact	  on	  proliferation	  and	  kinetics	  as	  well	  as	  no	  effects	  on	  cell	  cycle	  profiles.	  Interestingly,	  p53	  depletion	  sensitized	  MCF10A	  cells	  and	  resulted	  in	  cell	  cycle	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arrest	   and	   induction	   of	   apoptosis	   (Liu	   et	   al.,	   2006).	   Also,	   PLK1	   directed	   siRNA	   has	  been	  applied	  to	  test	  effects	  of	  PLK1	  depletion	  in	  further	  human	  cells	  including	  human	  umbilical	  vein	  endothelial	  cells	   (HUVEC),	   fibroblasts	  and	  keratinocytes	  resulting	   in	  a	  non-­‐significant	   growth	   inhibition	   below	   5%.	   Cell	   cycle	   analysis	   of	   primary	   cells	  revealed	  only	  a	  moderate	  increase	  of	  cells	  in	  G2/M	  upon	  siRNA	  mediated	  knockdown	  of	  PLK1,	  which	  was,	  at	  least	  in	  keratinocytes,	  reflected	  by	  spindle	  assembly	  defects	  at	  a	  much	  lower	  frequencies	  than	  in	  cancer	  cell	  lines.	  Furthermore,	  a	  lack	  of	  activation	  of	  the	   spindle	   assembly	   checkpoint	   has	   been	   suggested	   in	   keratinocytes.	   In	   summary,	  induction	  of	  apoptosis	  was	  barely	  observed	   in	  primary	  cells,	  and	   in	   this	   latter	  study,	  not	  even	  upon	  silencing	  of	  p53	  in	  contrast	  to	  the	  previously	  mentioned	  MCF10A	  cells	  (Raab	  et	  al.,	  2011).	  Overall,	  PLK1	  depletion	  induced	  only	  minor	  effects	  in	  non-­‐cancer	  cells.	  However,	   it	   is	   indispensable	   to	   point	   out	   that	   treatment	   of	   MEFs	   with	   the	   PLK1	  inhibitor	  BI	  2536	  showed	  different	  effects	  than	  Plk1	  depletion.	  Growth	  inhibition	  was	  observed	  after	  24	  hours	  at	  elevated	  levels	  and	  was	  accompanied	  by	  altered	  cell	  cycle	  distribution	   at	   50	   nM	   as	   well	   as	   an	   induction	   of	   considerable	   apoptosis	   at	   100	   nM	  indicating	   the	   need	   for	   careful	   dose-­‐finding	   studies	   (Raab	   et	   al.,	   2011).	   	   A	   further	  investigation	   compared	   fibroblasts	   to	   fully	   differentiated	   cells.	   Although	   BI	   2536	  treatment	  of	  primary	  neonatal	   rat	   cardiac	   fibroblasts	   for	  24	  hours	  either	  mitotically	  arrested	   cells	  with	   an	   IC50	   of	   43	   nM	   leading	   to	   apoptosis	   or	   resulted	   in	   aneuploidy,	  treatment	  with	  100	  nM	  BI	  2536	  for	  24	  hours	  did	  not	  affect	  cardiomyocytes	  and	  their	  function.	   Importantly,	   this	   reveals	   that	   there	   is	   no	   impact	   of	   PLK1	   inhibition	   on	  terminally	  differentiated	  cells	  (Lu	  et	  al.,	  2010).	  The	   difference	   in	   apoptotic	   response	   to	   Plk1	   depletion	   and	   BI	   2536	   treatment	  observed	  in	  MEFs	  might	  be	  due	  to	  unspecific	   inhibition	  of	  all	  Plk	  family	  members	  by	  the	   pharmaceutical	   compound.	   Plk1	   depletion	   did	   not	   change	   Plk3	   levels	   in	   MEFs.	  However,	   Plk2	   and	   Plk4	   levels	   have	   not	   been	   reported.	   It	   is	   likely	   that	   these	   PLK	  family	   members,	   in	   addition	   to	   other	   unrelated	   kinases,	   compensate	   PLK1	   specific	  depletion	  in	  healthy	  cells,	  whereas	  this	  is	  not	  the	  case	  for	  BI	  2536	  treatment	  (Raab	  et	  al.,	   2011).	  While	   simultaneous	   inhibition	   of	   the	   oncogenes	   Plk1	   and	   PLk4	   in	   cancer	  cells,	   especially	   in	   aRMS,	   could	   be	   a	   therapeutic	   advantage,	   antagonizing	   the	   tumor	  suppressors	  PLK2	  and	  PLK3	  might	  be	  contra-­‐productive	  for	  killing	  tumor	  cells	  and	  for	  persevering	   healthy	   cells.	   Thus,	   the	   development	   of	   more	   specific	   inhibitors	   is	  warranted.	  A	  first	  step	  has	  been	  made	  by	  the	  generation	  of	  polo-­‐box	  binding	  domain	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inhibitors	  such	  as	  poloxin,	  which	   leave	  kinases	  outside	   the	  PLK	  family	  unaffected	  by	  inhibition	  (Craig	  et	  al.,	  2014).	  In	  addition	  to	  inhibitor	  specificity,	  also	  the	  p53	  status	  might	  play	  a	  role	  in	  protecting	  healthy	   cells	   from	   apoptosis.	   The	   study	   of	   Sur	   et	   al.	   (2009)	   directly	   addressed	  reduction	   of	   side	   effects	   by	   combining	   BI	   2536	   with	   nutlin-­‐3	   in	   BALB/c	   xenograft	  models	  of	  HCT116	  p53-­‐/-­‐	  cells,	  whereby	  nutlin-­‐3	  is	  supposed	  to	  stabilize	  p53	  in	  healthy	  cells.	  While	  anti-­‐tumor	  activity	  did	  not	  change,	  an	  immense	  reduction	  of	  neutropenia	  was	  observed	  because	  normal	  cells	  were	  protected	   from	  toxicity,	  a	   finding	   that	   is	  of	  high	  clinical	  relevance	  (Sur	  et	  al.,	  2009).	  To	  also	  investigate	  in	  vivo	  functions	  of	  PLK1,	  an	  inducible	  knockdown	  of	  Plk1	  in	  adult	  mice	   has	   been	   established	   receiving	   efficient	   but	   not	   complete	   Plk1	   depletion.	  Mice	  underwent	   detailed	   phenotypic	   analysis.	   Neither	   histological,	   nor	   metabolic	  differences	  to	  wild	  type	  mice	  have	  been	  observed	  despite	  increased	  body	  weight	  and	  enhanced	  rectal	  temperature	  in	  males.	  In	  contrast	  to	  structural	  anti-­‐mitotic	  drugs	  that	  interfere	  with	  spermatogenesis,	  no	  testis	  disorders	  have	  been	  reported	  for	  transgenic	  mice.	  Only	   a	   reduced	  proliferation	   index	  was	  detected	   in	  mucosal	   folds	   and	  ovarian	  follicles.	   Additionally,	   no	   significant	   induction	   of	   apoptosis	   was	   registered	   in	   any	  murine	  tissue.	  Despite	  reduced	  ferritin	  levels	  that	  could	  cause	  hematologic	  alterations,	  there	  was	  no	  evidence	  for	  disturbance	  in	  hematopoiesis	  without	  any	  abnormalities	  in	  white	   blood	   count,	   indication	   of	   neutropenia,	   or	   myelosuppression	   as	   it	   is	   often	  observed	   for	   anti-­‐mitotic	   inhibition	   (Raab	   et	   al.,	   2011).	   With	   regard	   to	   our	  investigations	   and	   the	   evaluation	   of	   PLK1	   inhibitors	   in	   pediatric	   malignancies,	  additional	   early	   stage	   induction	   of	   PLK1	   inhibition	   during	   development	   and	   in	   very	  young	  mice	  might	  be	  important.	  	  In	   summary,	   these	  data	  provide	  evidence	   that	  PLK1	   inhibitors	   could	  succeed	  also	   in	  clinical	   trials	  without	   causing	   severe	   side	   effects.	   Genetic	   studies	   revealed	   only	   low	  dependency	  of	  primary	  non-­‐transformed	  cells	  on	  Plk1	  regarding	  proliferation,	  spindle	  assembly	  and	  apoptosis,	  whereas	  cancer	  cells	  were	  suggested	  to	  be	  addicted	  to	  Plk1.	  However,	  PLK1	  inhibitors	  warrant	  further	  improvements	  in	  terms	  of	  specificity	  and	  it	  also	   needs	   to	   be	   considered	   for	   clinical	   studies	   that	   mice	   can	   tolerate	   higher	   drug	  concentrations	   than	   humans,	   a	   fact	   that	   demands	   an	   even	   more	   careful	   dosage	  evaluation	  (Gorlick	  et	  al.,	  2014).	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9.2.3 Identification	  of	  escape	  mechanisms	  
Translation	   of	   preclinical	   results	   into	   clinical	   practice	   can	   fail	   due	   to	   evolving	  mechanisms	   of	   resistance	   often	   observed	   with	   kinase	   inhibitors.	   This	   effect	   might	  challenge	  kinase	  inhibitors	  more	  than	  other	  drugs,	  because	  they	  are	  main	  executers	  in	  cell	  metabolism,	   cellular	   function,	   and	   survival	   and	   therefore	   are	   opposed	   to	   strong	  selection	   pressure.	   Thus,	   cells	   mediate	   quick	   and	   efficient	   upregulation	   of	  compensatory	   pathways	   or	   counteracting	  mechanisms	   as	   logical	   reaction	   on	   kinase	  inhibition.	   Furthermore,	   their	   multiple	   interference	   points,	   which	   mediate	  interactions	  and	  structural	  dynamics	  for	  activation,	  are	  prone	  to	  mutations	  (Barouch-­‐Bentov	   and	   Sauer,	   2011).	   This	   can	   lead	   to	   clinical	   complications	   as	   for	   example	  observed	   in	   7-­‐15%	   of	   imatinib-­‐treated	   CML	   patients	   that	   develop	   secondary	  resistance	   (Barouch-­‐Bentov	   and	   Sauer,	   2011).	   Besides	   few	   other	   studies	   that	   have	  already	  described	  escape	   from	  PLK1	   inhibition,	  our	  preliminary	  results	  also	   indicate	  that	  aRMS	  tumors	  might	  be	  able	  to	  acquire	  resistance	  to	  BI	  2536.	  One	   common	   phenomenon	   observed	   in	   tumor	   resistance	   is	   overexpression	   of	   ATP-­‐binding	   cassette	   (ABC)	   transporters,	   which	   mediate	   the	   efflux	   of	   many	   different	  compounds.	  Wu	  et	  al.	  (2013)	  provided	  first	  evidences	  that	  resistance	  towards	  BI	  2536	  might	  be	  mediated	  by	  drug	  efflux	  through	  ABCB1	  and	  ABCG2.	  BI	  2536	  treatment	  per	  se	   did	   not	   lead	   to	   altered	   expression,	   but	   it	   was	   capable	   of	   enhancing	   the	   ATPase	  activity	  of	  these	  transporters.	  Recently,	   the	   C67V	   mutation	   in	   the	   active	   site	   of	   PLK1	   has	   been	   described	   to	  potentially	  cause	  drug	  insensitivity.	  In	  contrast	  to	  the	  gatekeeper	  mutation	  L130G,	  the	  C67V	   mutation	   did	   not	   interfere	   with	   function,	   but	   was	   able	   to	   occlude	   the	   PLK1	  inhibitors	   BI	   2536,	   BI	   6727,	   GSK461364,	   and	   ZK-­‐thiazolidone	   (TAL)	   from	   the	   ATP-­‐binding	   pocket	   by	   steric	   hindrance	   resulting	   in	   drug	   resistance	   after	   PLK1-­‐C67V	  compared	  to	  PLK1	  wild	  type	  complementation	  of	  PLK1-­‐/-­‐	  cells	  (Burkard	  et	  al.,	  2012).	  	  In	   aRMS,	   also	   mutations	   at	   PLK1	   dependent	   phosphorylation	   sites	   within	   PAX3-­‐FOXO1	  might	  occur,	  leading	  to	  stabilization	  or	  constitutive	  activation	  of	  the	  fusion	  and	  thus	  to	  a	   less	  pronounced	  effect	  of	  PLK1	  inhibition.	  Also,	  considering	  PLK1	  crosstalk	  and	   feedback	   signaling	   might	   be	   of	   great	   value	   for	   further	   preclinical	   and	   clinical	  studies	  of	  aRMS	  and	  careful	  validation	  of	  resistance	  mechanisms	  could	  help	  to	  prevent	  disillusions.	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9.2.4 Suggestion	  of	  reasonable	  data-­‐based	  combination	  therapies	  in	  aRMS	  
Having	   identified	   crucial	   kinases,	   pathways	   and	   regulatory	   mechanisms	   in	   alveolar	  rhabdomyosarcoma,	  a	  first	  step	  and	  widely	  accepted	  strategy	  to	  circumvent	  resistance	  mechanisms	   is	   the	   combination	   of	   drugs	   targeting	   these	   different	   interconnected	  candidate	  networks.	  Based	  on	  our	  screening	  results,	   several	   candidate	   targets	  might	  be	  suitable	  for	  simultaneous	  inhibition	  with	  PLK1	  in	  order	  to	  approach	  this	  challenge.	  	  We	   observed	   overlapping	   functions	   of	   PLK1,	   PLK4	   and	   CK1α,	   suggesting	   potential	  activation	   or	   upregulation	   of	   compensatory	   kinases	   and	   pathways	   upon	   PLK1	  inhibition.	  Due	   to	  non-­‐specific	   targeting	  within	   the	  PLK	   family,	  BI	  2536	  and	  BI	  6727	  probably	  simultaneously	  inhibit	  PLK1	  and	  PLK4.	  Therefore,	   it	  could	  be	  interesting	  to	  also	  investigate	  anti-­‐tumor	  activity	  of	  newly	  available	  PLK4	  specific	  inhibitors	  such	  as	  CFI-­‐400945	  (Mason	  et	  al.,	  2014).	  Regarding	  specific	  CK1α	  targeting,	  we	  unfortunately	  could	  not	  identify	  suitable	  CK1α	  specific	  inhibitors	  so	  far.	  	  In	   addition,	   our	   siRNA	   screening	   revealed	   phosphatidylinositol	   signaling	   and	  MAPK	  signaling	  as	  well	  as	  cell	  cycle	  regulation	  as	  essential	  pathways	  in	  fusion	  positive	  RMS.	  Importantly,	   all	   three	   pathways	   have	   already	   been	   suggested	   for	   treatment	   of	  rhabdomyosarcoma	  in	  previous	  studies.	  Activation	  of	  the	  PI3K/AKT/mTOR	  as	  well	  as	  the	  RAS/RAF/MEK/ERK	  pathway	  has	  been	  reported	  in	  rhabdomyosarcoma	  and	  high	  levels	  of	  AKT	  phosphorylation	  were	  associated	  with	  poor	  diagnosis	  (Cen	  et	  al.,	  2007;	  Petricoin	  et	  al.,	  2007).	  A	  further	  study	  even	  revealed	  co-­‐activation	  of	  AKT	  and	  ERK	  in	  36%	  of	  primary	  aRMS	  tumors	  (Renshaw	  et	  al.,	  2013).	  Finally,	  based	  on	  the	  linkage	  of	  the	  two	  signaling	  cascades	  and	  their	  ability	  to	  compensate	  for	  each	  other,	  Renshaw	  et	  al.	  (2013)	  proposed	  a	  combination	  therapy	  using	  an	  mTORC1/2	  inhibitor	  (AZD8055)	  and	   a	   MEK	   inhibitor	   (AZD6244),	   while	   we	   propose	   additional	   co-­‐administration	   of	  PLK1	  directed	  compounds.	  Involvement	   of	   cell	   cycle	   in	   the	   regulation	   of	   PAX3-­‐FOXO1,	   as	   well	   as	   the	   fusion	  protein’s	   own	   function	   in	   checkpoint	   adaptation,	   suggest	   combination	   of	   PLK1	  targeting	  with	   further	   cell	   cycle	   inhibitors.	   Probably	   the	  most	  obvious	   combinations	  include	   standard	   chemotherapeutic	   regimens	   like	   vincristine.	   Moreover,	   the	  alternative	  mitotic	  inhibitor	  eribulin,	  which	  binds	  and	  inhibits	  microtubule	  plus	  ends,	  has	   recently	   been	   reported	   to	   achieve	   complete	   responses	   in	   five	   out	   of	   five	   aRMS	  xenografts	  demonstrating	  even	  superior	  activity	  to	  vincristine	  (Kolb	  et	  al.,	  2013).	  Also	  recent	   preclinical	   studies	   with	   nab-­‐paclitaxel	   (abraxane),	   an	   albumin-­‐stabilized	  nanoparticle	   formulation	   of	   paclitaxel,	   which	   stabilizes	   microtubules	   and	   induces	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mitotic	   arrest,	   showed	   complete	   tumor	   regression	   in	   aRMS	   xenografts	   (Zhang	   et	   al.,	  2013).	   In	   terms	   of	   cell	   cycle	   kinase	   inhibition,	   the	   proposed	   PAX3-­‐FOXO1	   upstream	  regulators	   CDK1	   and	   CDK4	   (Liu	   et	   al.,	   2013a)	   may	   potentiate	   direct	   effects	   on	   the	  fusion	   protein.	   However,	   CDK4/6	   inhibitors	   induce	   a	   G1	   arrest,	   which	   might	  antagonize	  favorable	  effects	  of	  PLK1	  inhibitor	  induced	  mitotic	  arrest,	  as	  it	  was	  already	  observed	  in	  pancreatic	  cancer	  by	  Franco	  et	  al.	  (2014).	  Further	  candidate	  compounds	  for	  co-­‐administration	  have	  been	  identified	  in	  our	  drug	  screen	   and	   importantly,	   some	   of	   the	   pathways	   and	   targets	   have	   already	   been	  proposed	  for	  therapeutic	  approaches	  in	  aRMS.	  These	  compounds	  include	  AKT	  (Cen	  et	  al.,	  2007),	  HSP90	  (Lesko	  et	  al.,	  2007;	  Smith	  et	  al.,	  2008),	  FGFR	  (Crose	  et	  al.,	  2012;	  Li	  et	  al.,	  2013;	  Taylor	  et	  al.,	  2009),	  and	  SRC	  (Shor	  et	  al.,	  2007).	  	  To	   round	   up,	   an	   additional	   targeting-­‐layer	   of	   these	   oncogenic	   transcription	   factors	  that	  still	  requires	  validation	  might	  be	  realized	  by	  epigenetic	  inhibition.	  	  
9.2.5 Clinical	  studies	  of	  BI	  2536	  and	  BI	  6727	  
The	  first	  clinical	  phase	  1	  trial	  of	  BI	  2536	  in	  adult	  patients	  with	  advanced	  solid	  tumors	  showed	   favorable	   efficacy	   and	   manageable	   toxicity	   (Mross	   et	   al.,	   2008),	   whereas	  respond	  rates	  could	  not	  be	  confirmed	  in	  a	  second	  part	  of	  the	  study	  (Frost	  et	  al.,	  2012).	  Also,	  phase	  2	  studies	  of	  relapsed	  or	  refractory	  solid	  tumors,	  non-­‐small	  cell	  lung	  cancer,	  small	   cell	   lung	   cancer,	   chemotherapy-­‐naive	   pancreatic	   cancer,	   and	   relapsed	   or	  refractory	  AML	   showed	   only	  modest	   to	   no	   activity	   of	   BI	   2536,	   probably	   due	   to	   low	  intratumoral	  exposure	  and	  short	  half-­‐life	   (Gjertsen	  and	  Schoffski,	  2014).	  Thereupon,	  monotherapy	  with	  BI	  2536	  in	  clinical	  trials	  was	  terminated	  (Yim,	  2013).	  	  Nevertheless,	   the	   current	   focus	   of	   clinical	   development	   lies	   on	   the	   most	   advanced,	  second-­‐generation	  PLK1	  inhibitor	  volasertib	  (BI	  6727)	  next	  to	  compounds	  from	  other	  companies	   like	  GSK461364	  or	  NMS-­‐P937	  (Strebhardt	  et	  al.,	  2014).	  Volasertib	  has	  an	  improved	  pharmacokinetic	  profile	  and	  higher	  efficacy,	  which	  has	  been	  determined	  in	  a	   phase	   1	   trial	   in	   adults	   with	   advanced	   or	   metastatic	   solid	   tumors.	   In	   this	   study,	  reversible	  hematologic	  toxicity	  was	  the	  main	  side	  effect.	  Clinical	  phase	  2	  monotherapy	  and	   combination	   trials	   in	   advanced	   solid	   tumors,	   advanced	   or	  metastatic	   urothelial	  cancer,	   advanced	   ovarian	   cancer,	   advanced	   NSCLC,	   and	   AML	   have	   recently	   been	  completed	   or	   are	   currently	   ongoing	   (Gjertsen	   and	   Schoffski,	   2014;	   Rudolph	   et	   al.,	  2009;	  Schoffski	  et	  al.,	  2012).	  Response	  rates	   in	  patients	  with	  solid	  tumors	  have	  been	  moderate,	  while	  monotherapy	   in	  AML	  patients	  resulted	   in	  a	  response	  rate	  of	  13.3%,	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and	  combination	  with	  low-­‐dose	  cytarabine	  yielded	  a	  response	  rate	  of	  31%	  (complete	  remission	  and	  complete	  remission	  with	  incomplete	  blood	  count	  recovery),	  leading	  to	  significant	  clinical	  benefits	  (Dohner	  et	  al.,	  2014;	  Gjertsen	  and	  Schoffski,	  2014).	  Due	  to	  its	   impact	  on	   significantly	   improved	   survival	   rates,	  BI	  6727	  has	   also	  been	  granted	  a	  Breakthrough	  Therapy	  designation	  for	  treatment	  of	  AML	  by	  the	  FDA	  (Strebhardt	  et	  al.,	  2014).	  Based	  on	  these	  encouraging	  data	  in	  adult	  cancers,	  we	  believe	  that	  also	  children	  could	  benefit	  from	  volasertib	  therapy.	  
9.3 Conclusions	  and	  outlook	  
Despite	  a	  complex	  phosphorylation	  pattern	  and	  crosstalk	  between	  different	  signaling	  pathways,	   we	   were	   able	   to	   target	   PAX3-­‐FOXO1	   and	   NMYC	   by	   PLK1	   inhibition.	  Validation	   of	   further	   candidate	   kinases	   might	   provide	   additional	   opportunities	   for	  PAX3-­‐FOXO1	   targeting,	   thus	   reduce	   drug	   dosing	   of	   PLK1	   inhibitors	   and	   prevent	  compensatory	  mechanisms.	  Based	  on	  our	  studies,	  identification	  of	  compounds	  against	  CK1α	  and	  application	  of	  PLK4	  and	  mitotic	  inhibitors	  would	  allow	  first	  combinational	  trials	   along	   these	   lines.	   In	   addition,	   we	   suggest	   investigations	   of	   PAX3-­‐FOXO1	  epigenetic	  regulation.	  In	   general,	   our	   strategy	   can	   be	   easily	   transferred	   to	   other	   tumors	   addicted	   to	  oncogenic	   transcription	   factors,	   such	   as	   Ewing	   sarcoma.	   According	   to	   our	   proposed	  mechanism,	  NMYC/MYC	  expressing	  tumors	  like	  neuroblastoma	  might	  be	  sensitized	  to	  PLK1	   inhibition,	   and	   possibly	   also	   PAX3	   expressing	   cancers	   like	   melanoma	   might	  respond	  to	  PLK1	  and/or	  CK1α	  inhibition.	  We	  believe	  that	  transcription	  factor	  targeting	  is	  superior	  to	  inhibition	  of	  downstream	  pathways.	  Based	  on	  our	  data,	  PLK1	  inhibitors	  might	  be	  able	  to	  confirm	  this	  for	  fusion	  positive	   RMS	   in	   clinical	   studies.	   Our	   preclinical	   studies	   of	   PLK1	   inhibition	   in	   aRMS	  highly	   suggest	   clinical	   translation	   and	   promise	   encouraging	   prospects	   for	   improved	  therapy	  of	  alveolar	  rhabdomyosarcoma.	  Next	   to	   induction	  of	  mitotic	  arrest	  observed	  in	   different	   tumors	   treated	  with	   PLK1	   inhibitors,	   expression	   of	   PAX3-­‐FOXO1,	  NMYC	  and	   repressed	   p53	   especially	   sensitize	   aRMS	   tumors.	   	   Referring	   to	   studies	   showing	  that	  healthy	  and	  terminally	  differentiated	  cells	  are	  not	  addicted	  to	  PLK1,	  risks	  of	  PLK1	  inhibition	   for	   dividing	   cells	   persist	   but	   remain	   manageable	   as	   long	   as	   favorable	  therapeutic	  windows	  can	  be	  defined.	  Nevertheless,	  it	  is	  crucial	  to	  investigate	  potential	  resistance	  mechanisms	  in	  future	  studies.	  Prevention	  of	  escape	  of	  aRMS	  cells	  might	  be	  accomplished	   by	   proposed	   combination	   therapies,	   which	   needs	   to	   be	   proven	   by	   in	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vitro	   and	   in	   vivo	   approaches.	   Importantly,	   anti-­‐tumor	   activity	   and	   manageable	   side	  effects	  of	  volasertib	  observed	  in	  adult	  patients	  provide	  a	  good	  basis	  for	  future	  clinical	  studies	   in	   pediatric	   tumors	   like	   aRMS.	   Furthermore,	   we	   suggest	   prognostic	   value	  validation	  of	  PLK1	  expression	  in	  a	  large-­‐scale	  study	  to	  introduce	  routine	  PLK1	  tissue	  staining	  for	  risk	  stratification	  of	  fusion	  positive	  RMS	  in	  clinical	  protocols.	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